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ABSTRACT 
GHADEER N. THALJI: Genome wide assessment of early osseointegration in implant-adherent cells 
(Under the direction of Professor Lyndon F. Cooper) 
 
Objectives: To determine the molecular processes involved in osseointegration. 
Materials and methods:  A structured literature review concerning in vitro and in vivo molecular 
assessment of osseointegration was performed. A rat and a human model were then used to identify 
the early molecular processes involved in osseointegration associated with a micro roughened and 
nanosurface superimposed featured implants. In the rat model, 32 titanium implants with surface 
topographies exhibiting a micro roughened (AT-II) and nanosurface superimposed featured implants 
(AT-I) were placed in the tibiae of 8 rats and subsequently harvested at 2 and 4 days after placement. 
Whereas in the human model, four titanium mini-implants with either a moderately roughened 
surface (TiOblast) or super-imposed nanoscale topography (Osseospeed) were placed in edentulous 
sites of eleven systemically healthy subjects and subsequently removed after 3 and 7 days.  Total 
RNA was isolated from cells adherent to retrieved implants. A whole genome microarray using the 
Affymetrix 1.1 ST Array platform was used to describe the gene expression profiles that were 
differentially regulated by the implant surfaces. 
Results: The literature review provided evidence that particular topographic cues can be specifically 
integrated among the many extracellular signals received by the cell in its signal transduction 
network. In the rat model, functionally relevant categories related to ossification, skeletal system 
development, osteoblast differentiation, bone development and biomineral tissue development were 
upregulated and more prominent at AT-I compared to AT-II. In the human model, there were no 
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significant differences when comparing the two-implant surfaces at each time point. However, the 
microarray identified several genes that were differentially regulated at day 7 vs. day 3 for both 
implant surfaces. Functionally relevant categories related to the extracellular matrix, collagen fibril 
organization and angiogenesis were upregulated at both surfaces. Abundant upregulation of several 
differential markers of alternative activated macrophages was also observed. The biological processes 
involved with the inflammatory/immune response gene expression were concomitantly 
downregulated. 
Conclusions: The presence of micro-roughened and nanosurface features modulated in vivo bone 
response. This work confirms previous evaluations and further implicates modulation of the 
inflammatory/immune responses as a factor affecting the accrual of bone mass shortly after implant 
placement. 
 
 
 
 
 
 
	   v	  
 
ACKNOWLEDGEMENTS 
I would like to express my deepest gratitude to my advisor, Dr. Lyndon Cooper, for his excellent 
guidance, caring and encouragement. I feel I was very fortunate to be mentored by him throughout 
my prosthodontics residency training, as well as my PhD education. 
 
I would like to thank my committee members, Dr. Salvador Nares, Dr. Eric T. Everett,                     
Dr. Clark M. Stanford and Dr. Gustavo Mendonça for their valuable and constructive criticism that 
have contributed to my completion of my dissertation. 
 
I would like to thank Mrs. Lisa Cooper for her kindness and making me feel like one of her family in 
a foreign country. Her thoughtfulness will long be remembered. 
 
I would also like to thank my parents, my sisters; Abeer, Nour, Huda and Hala and my brothers; 
Bader and Musa for all their love, understanding and support all along. 
 
Last, but by no means least, I thank my friends at UNC School of Dentistry for their friendship and 
encouragement throughout. 
 
 
 
 
	   vi	  
 
TABLE OF CONTENTS 
I. List of tables…………………………………………………………………………………………………viii 
II. List of figures………………………………………………………………………………………………..…x 
III. List of abbreviations and symbols ………………………………………………………………………….viii 
VI. Introduction……………………………………………………………………………………………………1 
V. Chapter 1: Molecular Assessment of Osseointegration In Vitro; A review of current literature………………5 
A. Abstract………………………………………………………………………………………………...…..5 
B. Introduction…………………………………………………………………………………………...……6 
C. Materials and Methods…………………………………………………………………………………..…7 
D. Results…………………………………………………………………………………………………...…8 
E. Conclusions……………………………………………………………………………………………..…16 
F. References………………………………………………………………………………………………....39 
VI. Chapter 2: Molecular Assessment of Osseointegration In Vivo; A review of current literature………….....61 
A. Abstract…………………………………………………………………………………………………...61 
B. Introduction……………………………………………………………………………………………….62 
C. Materials and Methods……………………………………………………………………………………64 
D. Results…………………………………………………………………………………………………….65 
	   vii	  
E. Discussion………………………………………………………………………………………………....66 
F. Conclusions………………………………………………………………………………………………..73 
G. References………………………………………………………………………………………………...82 
VII. Chapter 3: Comparative Molecular Assessment of Early Osseointegration in Implant-Adherent Cells. Rat   
model……………………………………………………………………………………………………………..89 
 
A. Abstract…………………………………………………………………………………………………...89 
B. Introduction……………………………………………………………………………………………….91 
C. Materials and Methods……………………………………………………………………………………92 
D. Results…………………………………………………………………………………………………….95 
E. Discussion…………………………………………………………………………………………………98 
F. Conclusions………………………………………………………………………………………………101 
G. References……………………………………………………………………………………………….116 
VIII. Chapter 4: Early molecular assessment of osseointegration in humans………………………………….120 
A. Abstract………………………………………………………………………………………………….120 
B. Introduction……………………………………………………………………………………………...122 
C. Materials and Methods…………………………………………………………………………………..124 
D. Results…………………………………………………………………………………………………...126 
E. Discussion………………………………………………………………………………………………..128 
F. Conclusions………………………………………………………………………………………………133 
G. References……………………………………………………………………………………………….147 
 
	   viii	  
LIST OF TABLES 
 
Table 1.1 Surface modification and coatings examined in the in-vitro studies………………………………….17 
Table 1.2 Cell culture models used at different implant surfaces………………………………………………..22 
 
Table 1.3 Genes examined in in-vitro culture models with different implant surfaces along with their functional 
gene ontology annotation………………………………………………………………………………………...24 
 
Table 1.4 Technique used in in-vitro culture models for molecular assessment of osseointegration with different 
implant surfaces………………………………………………………………………………………………….34 
 
Table 1.5 Genome wide expression profiling in in-vitro culture models for molecular assessment of 
osseointegration………………………………………………………………………………………………….36 
 
Table 2.1 In vivo models used for molecular assessment of osseointegration…………………………………..76 
 
Table 2.2 Methods used to assess gene expression adjacent to different implant surfaces in in-vivo models…..76 
Table 2.3 Molecular assessment of osseointegration in in-vivo models along with Gene Ontology 
classification……………………………………………………………………………………………………..77 
Table 2.4 Wide genome expression profiling studies in vivo……………………………………………………81 
Table 3.1 Surface roughness values as determined by optical interferometry.………………………………...102 
Table 3.2 Quantitative chemical surface composition …………………………………………………………103 
Table 3.3 Number of genes differentially expressed at AT-I, AT-II (Day 4 vs. Day 2)……………………….103 
Table 3.4 List of the top 35 differentially regulated genes at AT-I (Day4 vs. Day2)…………………………..104 
Table 3.5 List of the top 35 differentially regulated genes at AT-II (day4 vs. day2)…………………………..105 
Table 3.6 List of top 25 differentially expressed genes at AT-I (Day 4 vs. day2) with their fold regulation in AT-
I, AT-II. ………………………………………………………………………………………………………...106 
Table 3.7 Top 25 downregulated genes at AT-I. ………………………………………………………………107 
Table 3.8 Top 25 downregulated genes at AT-II. ……………………………………………………………...108 
Table 3.9 The validation of the array data was carried out by qRT-PCR of select number of transcripts for equal 
number of AT-I and AT-II samples ……………………………………………………………………………109 
Table 3.10 Top 60 GO terms for differentially regulated genes at AT-I (Day 4 vs Day2) ……………………110 
Table 3.11 Top 6o GO terms for the differentially regulated genes at AT-II satisfying the criteria of fold 
upregulation >2 and p-value <0.05. ……………………………………………………………………………112 
Table 3.12 Top 25 GO terms for downregulated genes at AT-I (Day 4 vs Day 2). …………………………...114 
Table 3.13 GO terms related to downregulated genes at AT-II. 21 terms satisfied p < 0.05 and fold 
dowregulation >2……………………………………………………………………………………………….115 
Table 4.1 Number of genes differentially expressed (Day 7 vs. Day 3) ……………………………………….135 
	   ix	  
Table 4.2 List of top 35 differentially upregulated genes at OS (Day 7 vs. day3) with their fold regulation and p-
value in OS and TiO. …………………………………………………………………………………………..136 
Table 4.3 List of top 35 differentially downregulated genes at OS (Day 7 vs. day3) with their fold regulation 
and p-value in OS and TiO. ……………………………………………………………………………………138 
Table 4.4 Top 30 GO terms for differentially upregulated genes at both surfaces (Day 7 vs. Day3)………….140 
 
Table 4.5 List of differentially expressed genes in the functional categories related to ECM and collagen fibril 
organization, blood vessel development, ossification and osteoclastogenesis. ………………………………..142 
Table 4.6 List of genes differentially expressed relevant to alternative activation of macrophages pathway…145 
Table 4.7 Top 30 downregulated genes at both surfaces. ……………………………………………………...146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   x	  
 
LIST OF FIGURES 
 
Figure1.1 Topography-dependent signaling and phenotype…………………………………………………….38 
Figure 2.1 Histological result of osseointegration and the process(es) that lead to it…………………………...74 
 
Figure 2.2 An in-vivo evaluation model of implant adherent cells……………………………………………...75 
 
Figure 3.1 Scanning electron microscopic  (SEM) evaluation of tested implant surfaces……………………..102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   xi	  
LIST OF ABBREVIATIONS AND SYMBOLS 
 
 
ANOVA          analysis of variance 
 
BMP                bone morphogenic proteins 
 
Ca                    calcium 
 
Cr                     chromium 
 
Co                    cobalt 
 
cDNA              complimentary deoxyribonucleic acid 
 
COX                cyclooxygenase 
 
Cp Ti               commercially pure 
 
ELISA             enzyme-linked immunosorbent assay 
 
ECM                extracellular matrix 
 
FC                   fold change 
 
GO                  gene ontology 
 
GAPDH          glyceraldehyde 3-phosphate dehydrogenase 
 
GAG                glycosaminoglycans  
 
hMSC              human mesenchymal cells 
 
HUVEC           human umbilical vein endothelial cells 
 
HCL                 hydrocluoric acid 
 
HF                    hydrofluoric acid 
 
H2O2               hydrogen peroxide 
 
HA                   hydroxyapatite  
 
ID                     identification 
 
ISQ                   implant stability quotient 
 
IL                      interleukin 
 
Fe                      iron 
 
Mg                    magnesium 
 
Mn                    manganese 
 
mRNA              messenger ribonucleic acid 
	   xii	  
 
Mod                  modified 
 
Mo                    Molybdenum 
 
MAO                monoamine oxidation 
 
Ni                      nickel 
 
Nb                     niobium 
 
NS                     not significant 
 
OS                     osseospeed 
 
P                        phosphate 
 
PMMA              polymethylmethacrylate 
 
qRT-PCR          quantitative real-time polymerase chain reaction 
 
RhoA                 Ras homolog gene family, member A 
 
RBM                  rat bone marrow cells 
 
RT-PCR             real-time polymerase chain reaction 
 
RANKL             receptor activator of nuclear factor kappa-B ligand 
 
SEM                   scanning electron microscopy 
 
SBF                    serum blood fluid 
 
Si                        silicon 
 
Ag                       silver 
 
SMO                   smooth 
 
Sst                       stainless steel 
 
Sa                        surface roughness 
 
TRAP                 tartrate resistant acid phosphatse 
 
Sn                       tin 
 
Ti                        titanium 
 
TiO                     TiOBlast 
 
TiO2                    titanium oxide 
 
TNF                    tumor necrosis factor 
 
UNC                   University of North Carolina at Chapel Hill 
	   xiii	  
UV                     ultraviolet 
 
Wt                      weight 
 
XPS                   X-ray photoelectron spectroscopy 
 
Zn                      zinc 
 
Zr                       zirconium 
 
α                        alpha 
 
β                        beta 
 
γ                         gamma 
 
µ                        micro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   1	  
Introduction 
      Current tooth replacement strategies typically consider the alloplastic integrated replacement of missing 
teeth using endosseous dental implants as a primary choice among available modes of therapy. The success of 
contemporary dental implants is largely attributed to the process of osseointegration. Osseointegration is 
defined as a direct structural and functional connection between ordered living bone and the surface of a load-
carrying implant [1]. Despite the high success rates achieved, implant failures that mandate implant removal do 
occur. Factors attributing to implant failures include local and systemic conditions such as reduced bone 
volume, reduced bone density, periodontitis, and impaired wound healing (e.g., diabetes, smoking, osteoporosis, 
radiation therapy, chemotherapy) [2-6]. Efforts to enhance osseointegration of dental implants allowing for 
faster prosthetic rehabilitation and improved success rates in clinically challenging situations, included 
modifications to the physical and chemical properties of the implants surfaces.  
      It is well demonstrated that implants with moderately rough surfaces (average height deviation of 1-2µm) 
enhance the rate and quality of osseointegration with greater bone-to-implant contact and higher resistance to 
torque removal [7-11]. Human clinical investigations have provided histomorphometric data indicating the 
importance of surface topography for improvement of osseointegration.   At the histological level, pair-wise 
comparisons of machined implant surfaces with etched or grit-blasted surfaces revealed marked increases in 
bone-to-implant contact for the rough surface implants.  The majority of the studies focusing on this comparison 
involved implants placed in the posterior regions of the maxilla and mandible (presumed type III or IV bone) 
and represented healing periods of greater than 3 months duration [12-15].  
      In contrast to micron-features of alloplastic materials, bone is composed of constituent nanofeatures [16]. 
Nanostructured materials are those with features less than 100nm in at least one dimension [17]. In the dynamic 
research field of implants, a multitude of biomaterial modification approaches with nanoscale features have 
been pursued. Typically applied techniques include lithography, ionic implantation, anodization, acid etching, 
alkali treatment, peroxidation and sol-gel deposition [18]. Various reports support that embellishment of the 
micron-rough surface with nanoscale features further enhances osteoblast differentiation [19-21], which could 
also promote stability and increase interfacial biomechanical locking with bone [22-24].  
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      Precisely how this is achieved has not been clearly delineated. Only recently has the molecular basis of 
osseointegration been considered. A comprehensive understanding of the molecular and cellular processes 
relevant to peri-implant healing is critical for achieving therapeutically relevant targets to positively influence 
implant osseointegration. 
      The scope of work presented in this dissertation included a comprehensive structured literature review of 
current molecular data in vitro and in vivo and genome-wide evaluation of nanoscale topography influences on 
osseointegration in a rodent model and in man. 
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Chapter 1 
Molecular Assessment of Osseointegration In Vitro; A review of current literature 
 
Abstract: 
This paper represents the results of a structured review of the literature concerning in vitro molecular 
assessment of osseointegration at the level of cell – surface topography interactions.  A search of the electronic 
databases was performed up to and including November, 2010.  320 articles met the inclusion criteria. 
Characteristics of the included in-vitro reports were model systems used, genes examined, techniques used for 
molecular assessment of the osseointegration process, and wide gene expression profiling studies.  There exists 
a growing body of in vitro evidence to support a role for surface topography in the direct influence of cellular 
phenotypes as related to the process of osseointegration.  Most recently, functional or mechanistic studies have 
provided evidence that particular topographic cues can be specifically integrated among the many extracellular 
signals received by the cell in its signal transduction network.  Such investigations begin to define linkages 
between the character of the implant surface and adherent cellular responses, including cells from extravasated 
blood (e.g., platelets) and of the immune system (e.g., monocytes).  In vitro studies involving cell culture on 
endosseous implant related biomaterials offer important and beneficial insight into the clinical control of the 
implant/bone interface. 
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Introduction: 
      The dental implant surface represents one of the key factors affecting osseointegration success.  Earliest 
studies indicated that implant surfaces could dramatically influence the possible formation of a direct bone to 
implant contact [1], despite the recognized influence of surgical technique and loading conditions [2].  In the 
influential report of Buser et al (1991), comparison of experimental implant surfaces bearing different surface 
topography ranging from electropolished to electropolished and plasma sprayed hydroxyapatite-coated surfaces 
revealed that increasing surface roughness resulted in increased bone-to implant contact [3].  The efforts of 
Wennerberg and co-workers also systematically revealed that compared to machined cpTitanium surfaces, 
increasing surface roughness improved both bone-to-implant contact and physical interaction with bone 
(removal torque) [4-8].  In summary reviews, it was concluded that numerous investigations demonstrated that 
smooth (S(a) <0.5 micron) and minimally rough (S(a) 0.5 – 1.0 micron)surfaces showed less strong bone 
responses than rougher surfaces [7,9].    
      The current literature involving in vivo studies of surface topography effects on osseointegration at the 
molecular level further supports both histomorphometric and biomechanical data of improved osseointegration 
[8,10].  These studies demonstrate that surface topography is, in part, responsible for changes in the interfacial 
tissue responses to the endosseous implant that lead to greater bone to implant contact.   These changes are 
manifest by a) greater bone-to-implant contact and b) increased biomechanical interlocking with bone in animal 
and human studies.   
      Human clinical investigations have provided histomorphometric data indicating the importance of surface 
topography for improvement of osseointegration.   At the histological level, pair-wise comparisons of machined 
implant surfaces with etched or grit-blasted surfaces revealed marked increases in bone-to-implant contact for 
the rough surface implants.  The majority of the studies focusing on this comparison involved implants placed 
in the posterior regions of the maxilla and mandible (presumed type III or IV bone) and represented healing 
periods of greater than 3 months duration [11-14].  Implants with altered topography, indicated partly by 
increased S(a) values, supported greater bone accumulation at the interface.  It is assumed that the surface 
topographic changes of the surface represent alloplastic cues that promote tissue changes leading to increased 
bone accrual at the implant surface.   
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      Several in vivo studies at the molecular level indicate that surface topography influences adjacent cellular 
functions including the process of bone matrix biosynthesis and mineralization [15].   Most recent investigations 
focusing on mRNA expression profiles within cells adjacent to tissue at implants or cells adherent on implant 
surfaces.   The findings include increased expression of mRNAs involved in the regulation of cell proliferation, 
angiogenesis, osteoinduction and osteogenesis [16]. 
      The complexity of wound healing is self evident in the many changes in gene expression observed in gene 
profiling studies such as those recently published regarding osseointegration.  For example, examination of gene 
expression events at 4, 7 and 14 days in tissues surrounding SLActive surface implants in the retromolar area of 
9 human volunteers revealed thousands of differentially significant genes that increased and decreased with 
time [17].   The biological processes identified at day 4 prominently involved the cell cycle, the immune 
response and inflammatory gene regulation, phagocytosis and macrophage activation.   These prominent 
changes suggested the induction of fundamental wound healing events.  At day 14, gene expression events 
representing skeletal development, ossification and cellular differentiation were prominently revealed.   The 
complexity of these processes requires detailed analysis and model systems that permit the testing of hypotheses 
to confirm what descriptive analyses have suggested. 
      In vitro studies that pursue aspects of osseointegration, particularly cellular responses to implant surface 
topography, provide insight into the role that the implant surface plays in modulating cellular responses during 
the complex process of osseointegration.  It is the aim of this review to assess the knowledge that has been 
gained to date from molecular biological evaluations of cellular responses to endosseous dental implant surface 
topography.  
Materials and methods: 
      For the literature to be included in this review, the following eligibility criteria were used: in vitro reports 
assessing the molecular process of osseointegration, and articles published only in English.  Studies related to 
wear particles, letters to the editor and reviews were excluded. Articles limited to assessment of Alkaline 
phosphatase activity were excluded. Articles limited to biological coatings were excluded in this review. 
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      Search Strategy: A thorough search was performed up to and including November, 2010 through the 
following databases: PubMed (1948 to November, 2010), using the following terms: (titanium[tw] OR 
zirconium[tw] OR dental implant*[tw]) AND (gene expression[MeSH Terms] OR gene expression[tw] OR 
differentiation[tw] OR rna[MeSH Terms] OR rna[tw] OR messenger rna[tw] OR mrna[tw]),  EMBASE via 
OVID (1947 to November, 2010) using: (Titanium.mp. or zirconium.mp. or tooth implantation/ or dental 
implant*.mp. and gene expression.mp. or exp gene expression/ or exp DIFFERENTIATION/ or 
differentiation.mp. or ena.mp. or exp RNA/ or messenger rna.mp.[mp=title, abstract, subject headings, heading 
words, drug trade name, original title, device manufacturer, drug manufacturer] or mrna.mp.[mp=title, abstract, 
subject headings, heading words, drug trade name, original title, device manufacturer, drug manufacturer], and 
BIOSIS Previews via ISI Web of Science (1969 to November, 2010), ISI Citation via ISI Web of Science (1955 
to November, 2010 ) using the following words: Topic=((titanium OR zirconium OR "dental implant*") AND 
("gene expression" OR differentiation OR rna OR rna OR "messenger rna" OR mrna)). Titles and abstracts were 
screened for possible inclusion in the review. The full text of the articles judged to be relevant by the title and 
abstract was read and independently evaluated against the eligibility criteria. In addition, a hand search of the 
reference lists of original studies that were found to be relevant was conducted. 
Results: 
      320 articles met the inclusion criteria. Characteristics of the included in-vitro reports including surfaces 
examined, model systems used, genes examined, techniques used for molecular assessment of the 
osseointegration process, and wide gene expression profiling studies are presented in Tables 1, 2, 3, 4 and 5 
respectively.  
      The spectrum of surfaces investigated in in vitro studies of cellular aspects of the osseointegration process is 
widely represented by metallic and ceramic materials (Table 1).  It is apparent that, when limited to critical 
appraisal of studies involving osteoblast-like or osteoblastic cell performance in relationship to endosseous 
implant material influences, studies performed in cell culture are possible and provide information regarding 
cytotoxicity, cell adhesion, proliferation and differentiation.  The vast majority of these studies have been 
conducted using typical cell culture conditions that include the use of 5 – 15% serum, typically bovine derived.  
It is acknowledged that adhesion – related phenomena involved the interaction of cellular receptors with serum 
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derived proteins such as Fibronectin.  The study of direct cell (or cell-derived protein) - surface interaction has 
not been widely pursued.  
      Interestingly, despite many preliminary studies of cell function with regard to bulk endosseous implant 
material, the majority have focused on osteoblastic or osteoblast-like cell behavior without regard to the key 
cellular components of the immune system.    More recent interest in the role of immunomodulation of 
osteogenesis in general [18] suggests the importance of other cell types in the process of osseointegration.   The 
more recent investigations of monocyte/macrophage function, platelet function and inflammatory gene 
regulation in vitro demonstrate that surface topography influences cellular processes beyond osteoblast 
functions and these processes may be evaluated in cell culture [19,20]. 
      While the obvious variable in studies of topography-dependent modulation of osseointegration is the 
implant surface, the previous statement indicates that in vitro studies are highly dependent on the model system 
and particularly upon the cell line selected for investigation.   Comprehensive review revealed approximately 50 
different types of cells, the majority representing the osteoblastic lineage, has been used to study implant 
surface-cell interactions in culture (Table 3).  The majority of studies employed one or another osteoblastic cell 
model able to differentiated under culture stimulation.  Such models have included primary cultured bone 
marrow-derived stem cells (e.g., hMSCs), stem cell-like cell lines (e.g., C3H10T1/2) or C2C12), bone-derived 
osteoprogenitors (e.g., RBM cells), transformed osteoblastic cells (e.g. FOB), osteoblastic cell lines (e.g., 
MC3T3-E1), and osteosarcoma derived cell lines (e.g., MG63).  Cells of human, mouse and rat origin dominate 
these models, however, canine, chick and bovine cell models have also been utilized.  Each model system offers 
select advantages and disadvantages [21], despite the generalized ability to adhere to and proliferate on the 
alloplastic substrates.  Differences in phenotypes such as the relative expression of integrin receptors, matrix 
proteins or signal transduction molecules must be understood for proper deployment and interpretation of 
results.   Irrespective of important distinctions that must be made for the different models deployed to 
investigate “osteoblast” – implant surface interactions, it may be generally concluded that osteoblastic cell 
adhesion and culture on titanium (or Zirconia) surfaces with enhanced surface topography in the micron-scale 
range results in increased osteoblastic differentiation as evidenced by a) increased osteoinductive transcription 
factor mRNA expression (RUNX-2 and Osterix), b) elevated type 1 collagen expression, c) increased bone 
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specific matrix protein expression including alkaline phosphatase,  osteopontin, osteocalcin and bone 
sialoprotein, and d) cell matrix layer mineralization.   
      The array of surface topographies investigated to date spans the range of applicable technologies 
represented by clinical dentistry and orthopedics.  They include grit blasting, acid etching, anodizing, laser 
ablating, micromachining, and photolithography methods among them.  While most investigations have 
examined one or two surfaces representing the result of a modification process, a select few investigations have 
attempted to systematically interrogate the role of a specific surface modification parameter on adherent cell 
behavior.  For example, Sjotstrom et al. (2009) [22] utilized titania nanopillar structures of 15 – 100 nm to 
examine hMSC osteoblastic differentiation as a function of nanoscale topography.   In this instance, diameter 
and spacing parameters were not controlled.  In this particular review, the biological activation of metallic and 
ceramic implant surfaces by linking of receptor targets (e.g., matrix proteins, growth factors, or cytokines) was 
not considered. [23] 
      Cell Adhesion – A general appreciation for cell adhesion phenomena at endosseous implant surfaces 
includes specific roles for adherent extracellular matrix proteins (ECM, e.g., fibronectin, osteopontin) and 
related transmembrane receptors (e.g., integrins) present on the adherent cells [24].  Adherent osteoprogenitors 
produce ECM proteins in a manner that is influenced by the nature of the titanium surface, suggesting that 
surface topography provides environmental cues that change cell signaling at the most fundamental levels [25].  
Surface topography does influence the expression of integrins important in osteoblastic cell adhesion and 
differentiation [26].  The systematic knockdown of alpha 2 integrins in MG63 osteosarcoma cells revealed the 
requirement of alpha 2-beta1 integrin signaling of titanium topographic cues affecting osteoblastic 
differentiation [27].  The role of integrins in cell adhesion involves many different integrins and common 
integrin subunits (e.g., b1) appear to mediate binding to many different surfaces in cell culture [28], leaving 
open the question of precisely how specificity of adhesion is controlled at the cellular level.   One other 
mechanistic evaluation of topographic cue-based signaling has focused on b-Catenin activation involving the 
cytoskeleton, RhoA, as well as WNT pathway mediators.  Using reporter gene tools to study the activity of b-
Catenin (a known mediator of osteoinduction), Macaluso and colleagues have provided among the few 
investigations probing the mechanisms by which surface topographic cues influence adherent cell function [29]. 
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      The surface cues imposed through adhesion –based signaling leads to functionally and structurally 
significant changes in the cultured cell layer, suggesting that similar influences are imposed at the implant bone 
interface in vivo.   Ogawa and colleagues’ comparison of rat BMC cultured on titanium and tissue culture 
polystyrene (TCPS) revealed a collagen rich, calcium phosphate layer at the titanium but not TCPS interface.  
The titanium interfacial tissue demonstrated greater hardness, elastic modulus and interfacial strength [30].  
Changes of the titanium surface in fact alter abundance of key signaling proteins such as the small GTPase RAS 
and the MAP kinase pathway within adherent osteoblastic cells [31].   When considering the influence of 
topography, the stimulation of matrix formation can influence a range of cellular processes including migration, 
matrix organization, cytoskeletal organization and intracellular signaling [32]. An elegant investigation of 
hMSC adhesion to nanoporous TiO2 surfaces measured displacement of adherent cells using atomic force 
microscopy methods which led to hypothesize that initial adsorption is a function of proteins adsorbed from 
serum (e.g., fibronectin; [33]).  Additional studies have revealed that particular signals area mediated from 
topographically modified titanium substrates to cells via integrins including the a2b1 integrin [27] .   Most 
recently, MC3T3-E1 osteoblastic cell culture on smooth versus SLA surfaces was examined at the level of ERK 
signaling.  Greater Osterix (Sp7), osteopontin and osteocalcin expression were observed in cells cultured on 
SLA surfaces.  Associated with this enhanced Osteoinduction was reduced ERK1/2 phosphorylation, suggesting 
that topography-mediated signals involve the downregulation of the ERK pathway [34].  Continued mechanistic 
investigations are needed to define precisely how cells perceive, signal and integrate topographic cues from 
alloplastic materials to physiologic changes that result in tissue integration. 
      Osteoblastic differentiation - Runx2 is an essential transcription factor for osteogenesis; its removal results 
in no bone formation or osteoblastogenesis.  It binds to target gene promoters to affect their expression during 
osteoblastic differentiation and bone formation [35]. If surface topography alters adherent cellular 
differentiation, then one mechanism could involve topography-related changes in Runx2 expression.  Earliest 
reports of surface topography influences on RUNX-2 included studies of Masaki et al (2005) [36] and Guo et al 
(2007) [37] that evaluated the influence of HF treatment of Ti02 grit blasted implant surfaces on adherent MSC 
function.  Recently, elevated RUNX-2 expression was reported for human periodontal ligament cells cultured 
on the  SLactive surface [38]. 
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      Osterix (Sp7) represents the second key transcriptional regulator of Osteoinduction.   Sp7 is required 
downstream of Runx2.  Importantly, Sp7 is necessary for postnatal osteoblast and osteocyte function [39]. 
Masaki et al[36] first indicated that enhancing titanium substrate microtopography led to elevated Sp7 
expression in adherent osteoprogenitor cells.  Others including Perrotti et al (2012) [40] have demonstrated that 
compared to machined surfaces, adherent cell Sp7 expression on micron rough surfaces is elevated.  hMSC Sp7 
expression is positively influenced by culture on titanium substrated bearing nanoscale topographic 
enhancement [37,41-43] In confirmation of the significance of Osterix’s role in promotion of osseointegration, 
in vivo studies reveal that Osterix overexpression in labeled mouse bone marrow stem cells led to accelerated 
osseointegration[44].  Thus, in vitro studies of surface topography effects on Osteoinduction suggest that greater 
bone formation in vivo is due, in part, to surface dependent modulation of the osteoinductive transcription 
factors Runx2 and Osterix (Sp7). 
      More recently, investigations have pursued descriptive studies of cell – implant surface interactions in vitro 
using genome wide expression profiling techniques.  At least 13 publications report use of different arrayed 
gene assays for the purpose of characterizing the changes in gene expression that occur over time or as a 
function of surface modification.   For example, Vlacic-Zischke et al (2011) compared human mandible derived 
osteoblast gene expression following growth on SLA vs. SLactive surfaces [45].  When subjected to pathway 
analysis, gene expression data revealed the up-regulation of BMP pathway signaling as well as molecules 
involved in Wnt signaling.  Zhao et al (2010) examined rat osteoblastic cell culture on a unique porous Ti alloys 
surface [46].   When comparing data from studies using different cell models, markedly different results are 
observed (e.g. MG63 cells [47] vs. hMSC [48]).  Culture of hMSCs on topographically modified titanium 
substrates led to increased expression of both Runx2 and BSP where as MG63 cell culture at 24 hours did not 
reveal elevations in these key markers of Osteoinduction. 
      The aggregate data from focused evaluations of directed studies of one or another osteoinductive regulatory 
gene or from gene profiling studies regarding cells adherent to different implant surfaces indicates that surface 
topography can influence Osteoinduction.  With increasing surface roughness, elevated and / or earlier 
expression of Runx2, Osterix (Sp7), BMPs (notably BMP2 and BMP6), and Wnt pathway molecules including 
b catenin, has been reported.  In vitro, cells adherent to modeled dental implant surfaces demonstrate 
	   13	  
topography-dependent changes in the expression and function of several key regulators of Osteoinduction 
(Figure 1). 
      Extracellular matrix formation - Among the first observations of surface topography effects on adherent 
cell expression of ECM protein expression was the study of fibronectin mRNA levels that concluded that 
topography-induced changes of the cell led to increased fibronectin expression [49].   With specific emphasis on 
interfacial bone formation, attention has focused on bone matrix proteins known to be the product of 
osteoblastic cells [50].   
      Alkaline phosphatase is a commonly utilized marker of early osteoblastic differentiation that is repeatedly 
observed to be elevated in cells adherent to surfaces of increasing surface topography and Osteocalcin has been 
utilized as a marker of terminal osteoblastic differentiation [51,52].   Ogawa and colleagues have utilized both 
osteopontin and osteocalin expression levels to indicate the extent of osteoblastic differentiation [53,54]. These 
and many other investigations have revealed that culture-induced differentiation of osteoblast-like cell lines and 
mesenchymal stem cells is surface topography dependent.  This process is modeled by the sequential expression 
of alkaline phosphatase, osteonectin, osteopontin, and the penultimate emergence of bone sialoprotein and 
osteocalcin expression.  With increasing topographic complexity and / or increasing R(a) or S(a) values, 
cultured cells produce greater abundance of mRNAs encoding these matrix proteins at earlier time points.  
Suggested is earlier and greater bone formation in vivo at implants with enhanced surface topography.  
      Bone matrix is largely composed of type I collagen.  Cooper and co workers described the differential 
regulation of collagen biosynthesis in cells adherent to smooth and rough titanium surfaces [55].  This revealed 
greater collagen biosynthesis and higher levels of cross-linking gene expression within cells adherent to the 
topographically enhanced titanium substrates.  Similar investigations have revealed the positive influence of 
surface roughness on type I collagen mRNA expression, as well as other bone matrix components including 
osteopontin, osteocalcin and alkaline phosphatase [26].   
      These different molecules and the molecular knowledge of their regulation enables investigators to pursue 
studies that may indicate the mechanisms by which surface topographic cues enable cellular differentiation 
along the osteoblast lineage.   In vitro studies to date have a) confirmed that adherent cell expression of ECM 
protein and encoding mRNAs is affected by topography, b) demonstrated that changes in ECM expression in 
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turn affect adherent cell behavior, and c) shown how alterations in ECM protein biosynthesis of adherent cells is 
associated with changes in the physical properties of the protein / cell layer and its attachment to the modeled 
implant surface. 
      Osteoclastogenesis:  The accrual of bone mass at the implant surface requires the formation of new bone 
matrix and its mineralization.  The vast majority of cell culture studies addressing osseointegration have focused 
on osteoblastic production of bone matrix and mineralization.  However, bone accrual is balanced by 
osteoclastogenesis.   Few clinical, pre-clinical or in vitro studies of osseointegration have investigated 
osteoclastogenesis at the implant-bone interface or as a function of the implant surface per se.   
      Osteoclastogenesis is controlled by soluble inducing factors as well as insoluble membrane-bound ligands 
present on osteoprogenitor cells.  These factors and ligands represent both positive and negative mediators of 
osteoclast production.  The MSC expresses the central insoluble ligand that triggers monocyte differentiation to 
osteoclasts, namely RANKL.   The MCS and osteoblastic cells produce and secrete the key inhibitor of 
osteoclastogenesis, termed osteoprotegrin (OPG).   Additionally, osteoclastogensis is modulated by 
immunoregulatory cytokines including TGFb and IL6.  Other mediators include mechanostimulatory events and 
particulate debris that are beyond the scope of this review.   Three similar investigations using MG63 
osteosarcoma cells [56] , human periodontal ligament cells [38] ,and primary human osteoblasts cultured on 
smooth versus SLA and / or SLactive substrates [57,58].  RANLK expression was lower, while OPG expression 
was increased in cells adherent to the rougher surfaces.   Increased expression of OPG on a rough versus smooth 
surface was observed for both MG63 cells and alveolar primary osteoblasts [59]. In the MG63 model, integrin 
mediate signaling and protein kinase C activity were implicated in the increased expression of OPG [60], 
further demonstrating that surface cues directly impact adherent cell physiology.   
      Other cellular aspects of osseointegration modeled in vitro: While the majority of studies of 
osseointegration in cell culture have centered about the osteoblastic cell lineage, the process of osseointegration 
in vivo is not fully represented by surface – osteoblast interactions alone.   Other cell types are clearly observed 
to adhere before the attachment of osteoprogenitor cells or mesenchymal stem cells [61].  Primary among these 
other cells are the components of extravasated blood, notably the platelet.  Additionally, monocytes from the 
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circulation and cells of the innate immune system are eventually recruited to this site of surgical tissue damage.  
The direct interaction of these cells with the implant surface has received limited attention. 
      Davies and co-workers introduced the general concept that the topographic enhancement of blood platelet – 
implant surface interaction was central to the process of osteoconduction [62].  Subsequently, it was 
demonstrated that adhesion of platelets to microrough surfaces of increasing topographic complexity and 
dimension enhanced platelet activation [63,64].  More recently, assessment of the thrombogenic response with 
regard to surface topography was performed.  Thor et al (2007) demonstrated that 15 fold greater activation 
(transglutaminase release) for whole blood plated on grit blasted vs machined or HA surfaces [65].  Cell culture 
investigation of thrombogenesis was further able to distinguish greater transglutaminase release from blood 
platelets on SLactive vs. SLA surfaces [66].   In the context of this review, it is important to recognize the lack 
of transcription and mRNA expression occurring in platelets.  However, as remarkably rich sources of growth 
factors and cytokines, their regulated presence and activity may be important, indirect significance to the 
surface-mediated changes in osteoprogenitor cell phenotype that is of direct concern herein. 
      Monocytes or macrophages represent important cellular mediators of tissue responses to implanted 
biomaterials and have been known to be topography dependent in this function [67]. Monocytes display marked 
haplotaxis and monocyte adherence increases with surface topography [68].  Takebe et al (2003) [69] utilized 
anti beta3 integrin antibody treatment to demonstrate that J774A.1 cell adhesion and spreading as a function of 
surface topography was integrin- dependent and involved alterations in the cytoskeleton.  When murine 
macrophage like cells RAW 264.7 cells were cultured on surfaces of increasing roughness,  unstimulated 
macrophages increased TNF-α secretion .  Upon LPS stimulation, cells cultured on roughest surfaces produced 
the highest levels of IL-1b, IL-6 and TNF-α [70].   Using the J744A.1 cell line, in the absence of inflammatory 
LPS stimulation, only IL-1 levels were increased on the rougher surface [71] , once again indicating the 
important role cell models play in modeling biologic events surrounding the impact of surface topography on 
adherent cell phenotypes in vitro.  Further study of the role surface topography place in the initial interactions of 
an implant surface with blood and tissues is requires and can be facilitated using cell culture models and in vitro 
systems. 
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Conclusions:  
      The present literature concerning the molecular phenotype of cells adherent to and cultured on endosseous 
implant materials subjected to topographic and biological modification confirms in vivo and clinical data 
suggesting that topographic enhancement of the implant surface influences cell function directly.  Depending 
upon the adherent cell type, different biological processes may be modeled in cell culture.  With regard to 
osteoinduction and osteogenesis, cell culture studies clearly indicate that adhesion to surfaces of increasing 
topographic magnitude and complexity results in increased osteoinductive and bone matrix-specific gene 
expression.  These changes are associated with increases in BMP expression and Wnt pathway gene expression, 
suggesting that these pathways are influential in promoting osteogenesis of adherent osteoprogenitors.  The role 
of other adherent cell types, including platelets, monocytes, and lymphocytes has been recognized, but 
comprehensive evaluation of the impact of these cell types as well as the influence of surface topography upon 
their function adherent to the implant surface remains to be defined.   Studies of cell – substrate interactions 
involving molecular assessment have largely provided descriptions of adherent cell phenotypes.  Future studies 
can utilize the cell culture environment to investigate the mechanisms by which topographic cues influence 
adherent cell behavior related to the process of osseointegration. 
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Table 1: Surface modification and coatings examined in the in-vitro studies. 
Material 
(Bulk) 
Surface modification  
(With nanotopographic features*) 
Coatings after 
surface 
modification 
Coatings only  
(With nanotopographic 
features*) 
Titanium 
 Untreated/mirror 
polished/machined/electromachined 
[52,72-93]  
 Hydroxyapatite coating- 
Calcium phosphate [94-111, 
112*, 113-116, 117*, 118*, 
119,120*, 121]  
 Wet ground-grit [77,122-124]   Carbonated hydroxylapatite 
[125] 
 Grooved [126-128]  Hydroxyapatite outer layer 
and Fluorhydroxyapatite 
inner layer [97] 
 Drill channels [129]  Fluorhydroxyapatite [97] 
 Porous-powder metallurgy [130]  Calcium metaphosphate 
Anodized[108] 
 Acid etched 
[42,46,53,54,59,90,111,117,120,127,13
1-152]  
Sputter deposited 
TiO2 [149,151*, 
153*] 
Octacalcium phosphate 
(OCP) coated Ti [154] 
 Acid etching with chemical 
modification by exposing to NaOH 
(Alkali acid etched) [155] 
 Titania hydroxyapatite 
coatings (composite coating 
of  HA+TiO(2)) [116] 
[156,157] 
 Mod A [59,141-144]   Zinc Hydroxyapatite coating 
[115] 
 Acid etched with 
Photofunctionalization of titanium 
oxide: ultraviolet light mediated 
changes [158-160]  
 dicalcium pyrophosphate 
(Ca2P2O7, DCPP) [110] 
 Acid etched aged [160]  Mn(2+)-doped carbonate 
hydroxyapatite (Mn-CHA)  
[154] 
 Acid etching/Anodization [46]*  Porous surface-Laser 
Engineered Net Shaping 
(LENS) method- ti 
powder[161] 
 Blasted 
[43,69,118,120,134,135,137,145,162-
180]  
Hydoxyapatite[182] 
Calcium phosphate 
coating [172-174] 
Calcium phosphate 
coating with heat 
treatment [174] 
Ag particles electrodeposited 
onto the TiO2 nanotubular 
surface [182*] 
 Sandblasted with 
Photofunctionalization of titanium 
oxide: ultraviolet light mediated 
changes [160] 
 Hydroxyfluorine coating [95] 
 Sandblasted aged [160]  Titanium nitrate coating[95] 
 Blasted Acid etched [27,36*, 41,43*, 
48,51,52,55,57,58-
60,71,94,95,106,107,111,118,120,126,
134,139-145,164*, 166*, 167*, 168*, 
183,184,185*, 186-228,236*]  
Hydroxyapatite 
coating [210] 
Anatase coating 
[228] 
Calcium titanate-amorphous 
carbon (CaTiO(3)-aC) 
coating [105] 
 Blasted acid etched with heat treatment 
[226,227] 
 Ti-Plasma sprayed 
[51,57,60,94,107,114,134, 
135,140,162,163,190,191,193
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-199,201,207-209,229] 
ANODIZED [114,179,229-
231]  
 Mod SLA [27, 36,48,58,59,141-144, 
202,211-221] 
 Diamond-like carbon coating 
[95] 
 Blasted etched with modification using 
hydrogen peroxide [199] 
 Anatase titania coating 
[41*,47*,233*,234*]  
 Blasted Amino group ion implanted 
[179] 
 Rutile titania coating [41*] 
 Alkali heat treated [234-237]   Ti carbide coatings [238] 
 Anodized Alkali treatment [239]  Plasma sprayed and Amino 
group ion implanted [179] 
 Alkali heat treated with SBF 
[118,234,236] 
 Carbon-coated TiO(2) 
nanotubes [240*] 
 Oxidation: immersion in a solution of 
8.8 M H2O2/0.1 M HCl at 80°C for 
30 min [241] 
  
 Oxidation of either PT or SLA [242*]  Coating with titanium nitride 
oxide [243] 
 Anodization[22*,136,165,182*,240*, 
244*,245,246*,247,248,249*,250,251*
,252*,253*,254]  
Hydroxyapatite 
[99*,255] 
Titania coating non-specified 
[116,256,257]  
 Anodization Mg ion incorporated [165]  Phosphonic acid coated [258] 
 Anodization Mg ion incorporated with 
SBF [118] 
 Plasma-immersion 
implanting Si ion [259*] 
 Electrochemical treatment either with 
Ca or Ca and P [260] 
 Calcium ion implanted [261] 
 Heat treatment [73]  Hydrothermal treatment: 
Strontium ions and/or 
phoshate [262] phosphate 
[263] magnesium- [264*]; 
Calcium [265] 
 Glow discharge plasma (GDP) 
pretreatment[266] 
 A copolymeric hydrogel 
coating, poly-2-hydroxyethyl 
methacrylate-2-
methacryloyloxyethyl 
phosphate (P(HEMA-
MOEP)) [268] 
 Unspecified smooth/rough [268]  Zirconium coating  
[41*,99] 
   Alumina coating [41*,42*] 
   Anodized alumina coating 
[269*] 
Titanium alloys 
  
Ti6Al4V alloy 
 Grade polished/ grooved/ untreated 
[77,86,135,137,270-283]  
 Hydroxyapatite- calcium 
phospate [284-288] 
 Wet ground [77,289-291]  Coating with porous alumina 
ceramics [292,293] 
 Acid etched [137,294,295] Hydroxyapatite 
[295] 
Titanium plasma spraying 
[297]  
 Blasted[180,270-273,277,293,298-309] Hydroxyapatite 
[181] 
Titanium nitride 
coating [307] 
Titanium plasma spraying in 
addition to titanium nitride 
coating [297] 
	   19	  
 Blasted acid etched [311]  CaO-ZrO2-SiO2 (CZS) 
coating[311] 
 Shot peened [181] Hydroxyapatite 
[181] 
blends of hydroxyapatite and 
fluorapatite, with 
concentrations ranging from 
0 to 100% fluorapatite[286] 
 Selective Laser Sintering (SLS) [294]  Electrochemically deposited 
dicalcium phosphate 
dehydrate, so-called brushite 
[312] 
 MAO [306*]  Silicon-substituted 
hydroxyapatite (Si-HA) 
coatings [286] 
 Severe plastic deformation            
[313*, 314*] 
 Fluorohydroxyapatite [315] 
 Nanopore [308*,316*]  Titanium plasma spraying in 
addition to HA[231] 
 Electron beam melting process [317]  silicon (Si) nanofibers 
coating [318*] 
 Oxidation [93,319]  silicon oxide (SiO(2)) 
nanofibers coating  [318*] 
 Aged treatment (A:Passivated tt 
followed by aging in boiling deionized 
water for 10h)[320,321] 
 titanium oxide (TiO(2) 
nanofibers surface coating 
[318*] 
 Unspecified smooth/rough [268]  Bioactive glass coating [322] 
   Ion implantation with zinc 
(Zn–Ti–6Al–4V) [31] 
   Ion implantation magnesium 
(Mg–Ti–6Al–4V) [31] 
   Coating  alkoxide-derived 
hydroxy carbonate apatite 
(CHAP–Ti–6Al–4V) [31] 
TiMo12Zr6Fe2 (TMZF) discs  [323] 
NiTi 
 Mirror polished [75,93]  Hydroxyapatite[181] 
 Oxidized [93]   
Ti-6Al-7Nb  
 Untreated [80]   
TiZr (Ti-50 wt %Zr)  
 Grit ground [124]   
TiNb (Ti-50 wt %Nb) alloy discs 
 Grit ground [124]   
 fine-ground[135]   
Ti-5Zr-3Sn-5Mo-15Nb alloy 
 MAO[324]   
Ti13Nb13Zr alloy 
   Hydroxyapatite coating 
[288*] 
CrCoMo alloy Zimaloy 
 Untreated/polished  
[73,85,135,273,274,277] 
 Porocoated [277] 
 Etched [147]   
 Heat treatment [73]   
 Blasted [273,305]   
Stainless steel 
 [75,76,80,135,277,325,326]an   
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austenitic Ni-reduced SSt [276,281] 
 Etched [147]   
Tantalum  Untreated [73,85]  chemical vapour deposition 
(CVD) process [73] 
Nickel  [75]   
ZrO [326]   
ZrO2 ceramics 
 Untreated [327]   
Zirconia (yttria-stabilized tetragonal zirconia: ZrO2 93.5%, Y2O3 5.1%) 
 Untreated [78,328,329]  Zi-Unite [250] 
 Grooved  [328]   
 UV light [330]   
Yttrium-stabilized tetragonal zirconia polycrystals zirconia discs reinforced with 25% alumina 
 Machined [225,250]  ATZ discs with a modified 
surface (ATZ-mod)[250] 
 Abraded[225]   
 Abraded acid etched [225]   
Novel zirconia alloy ((Y,Nb)-TZP/alumina- zirconia/alumina composite 
 Smooth [331]   
Alumina (polycrystalline alumina ceramic Al2O3 99.5% purity) ceramics 
 Untreated [78,332]  Magnesium ion implanted 
[332] 
   Polymeric powder coating 
with TiO2 or silica 
nanoparticles [333*] 
Glass ceramics[84] 
CaSiO(3) ceramic disks [334,335] 
calcium silicate ceramics, sphene (CaTiSiO5) coating [335] 
Hardystonite (Ca(2)ZnSi(2)O(7)) ceramics  [334] 
Hydroxyapatite 
 As received [112,229,291,325,336-
339] 
 Plasma sprayed with 
HA[229] 
 Calcined [338]   
 Sintered [84,113,282,338,340]   
 Sintered with microchannels[342]   
calcium titanium phosphates CaTi(4)(PO(4))(6) [106] 
calcium titanium zirconium phosphates CaZr(4)(PO(4))(6) 
[106] 
Silicon wafers 
 Etched [49,342]  Coated with 
cpTi[49,342,343] 
 Untreated smooth [49,342]  Coated with cpTi[49,342] 
Polysterene culture plates 
   Sputter coated with titanium, 
titanium oxide, Alumina 
oxide,zirconia oxide and 
calcium phosphate [344] 
; Titanium [30,72] 
Polycarbonate membranes 
   Titanium [345*] 
Fiber reinforced composites 
 Blasted [346]  Bioactive Glass [346] 
Bioactive glass 45S5, S53P4 [256,325] 
Glass slides 
   Titanium- Tobacco Mosaic 
Virus and TMV 
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-Phos [345,347*] 
   Polyelectrolyte multilayer 
film self assembly[348] 
   Nanocrystalline deposition of 
Cp Ti, Ti6Al4V, TiNb30 and 
TiNb13Zr13) [349] 
PMMA [325] 
Ultra-high-molecular-weight polyethylene (UHMWPE) [339] 
Polyethylene [134] 
Carbon/carbon composite [134] 
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Table2: Cell culture models used at different implant surfaces. 
Cell models References 
SaOS-2  [106,107,120,124,162,163,186,187,189,190,260,274,275,279,281,305
,321,340,350,351]  
MC3T3-E1   [37,72,74,81,82,87,92,98,105,114,115,152,177-180,185,186,226-228, 
262-265,318,322,348,352-356]  
MG-63  [27,47,51,52,58-60,79,93,95,99,102,108,134,136,137,140,143-145, 
157,169,170, 188,189,192,195-197,201-203,206-209, 215, 216, 218, 
221-224,231-233, 235, 242, 247, 255, 261, 267, 281, 285, 292, 293, 
298,300,304,308,316,326,327,329,357-359]  
C3H10T1/2  
 
[74] 
C2C12 [354] 
Osteosarcoma cell line U2OS  [113] 
ROS-17/2.8 osteosarcoma cell line [75] 
Human osteosarcoma HOS TE85 
cells 
[96,97,331] 
 
HEPM (Human Embryonic Palatal 
Mesenchymal Cells 
[36,121,155,168,171,272,338] 
 
Primary human osteoblast cells  
 
[31, 57-59, 73, 76, 80, 83, 86, 106, 107, 116, 118, 125, 129, 130, 135, 
176,181,184,198,199,211,212,214,215,218,220,225,229,238, 239, 
244,273,279,283,294,301,302,309,319,320,323,332,334,335,341,360,
361] 
Human bone marrow derived 
osteoblast cells 
[89,154,282,287,289,290,325] 
Human mesenchymal stem 
cells(hMSCs) and human bone 
marrow cells 
[22,41,43,48,58,85,111,125,146,150,158,160,164,166,167,183,216, 
217,240,241,252,254,269,277,280,284,288,295,297,307,311,315, 
339,345,362] 
hFOB 1.19 [147,238,250,312,317,362] 
Human fetal osteoblast cells 
(hFOB)  
[119] 
 
osteoblastic precursor cell line 
(OPC1) established from fetal bone 
tissue  
[161,244,245] 
 
Rat bone marrow (RBM) cells  [42,84,101,103,104,110,172-174, 236, 237, 251, 256, 259, 330, 347, 
363] 
Primary rat osteoblasts [46,90,91,100,156,200,205,219,248,249,253,276,291,299,313,314, 
324,349,364] 
Rat bone marrow derived 
osteoblasts 
[30,53,54,132,137,151,153,159,257,346,365] 
 
Rat periosteum derived cells  
 
[131,149] 
Rat osteoblastic cells-CRP10/30 
cells 
[258] 
UMR-106-01-BSP /non-
mineralizing subclone of UMR-
BSP; UMR-U1 cells (negative 
mineralization control) 
 [271] 
 
Rat osteoblastic cells 
(ROS.MER#14), an osteosarcoma 
line of immortalized cells 
[238] 
Calvarial chick osteoblasts [336] 
 
 
Bone formative group cells [138] 
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(BFGCs) derived from bone 
marrow of beagle's femur : 
consisted of hematopoietic stem 
cells (HSC) and osteogenetic stem 
cells (OSC)  
 
2T9 mouse osteoblast progenitor 
cell line 
[122] 
Primary mouse osteoblasts [74,112,234]  
Mouse bone marrow derived 
mesenchymal stem cells 
[296] 
 
Rabbit bone marrow derived 
mesenchymal stem cells 
[210] 
 
Primary chondrocytes from Rats-
resting zone and growth plate zone  
[268,344] 
J774A.1 [69,71,109,278] 
RAW264.7  [117,122]  
 
Mouse bone marrow cell culture 
along with osteoclast 
differentiation  media M-CSF and 
RANKL  
[266] 
 
Human monocytes 
 
[166,246,254,335] 
Dendritic cells differentiated from 
human mononuclear cells  
[213] 
 
Human aortic endothelial cells 
(HAEC)  
 
[218] 
HUVECs 
 
[88,141,144] 
Purified and immortalized human 
dermal microvascular endothelial 
cells (HMEC-1)  
[335] 
 
Human gingival fibroblasts (HGF)  
 
[49,127,128,182,204,328,342,343] 
Rat oral fibroblasts  [133] 
 
NIH3T3 fibroblasts [152,366] 
 
Adipose derived MSCs [280] 
 
Platelet concentrate- human [142] 
 
Schwann cells derived from 
neonatal rats 
[94] 
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Table 3: Genes examined in in-vitro culture models with different implant surfaces along with their 
functional gene ontology annotation. 
Genes examined Biological process GO annotation References 
miRNA  [79,232,233,326,327] 
Hsp47 (heat shock protein 
47) 
response to unfolded protein; negative 
regulation of endopeptidase activity; 
regulation of proteolysis 
[55] 
HSP70 (heat shock 70kDa 
protein) 
protein folding; post-Golgi vesicle-mediated 
transport; cellular membrane organization  
[275] 
 
cyclin-dependent kinase 2; 
cyclin-dependent kinase 4: 
cyclin-dependent kinase 6 
cell division [127,128] 
 
cyclin A1 Cell division [250] 
cyclin A2 Cell division [128] 
 
cyclin D1  Cell division [112,127,128,331] 
 
cyclin E Cell division [127,128] 
 
cyclin-dependent kinase 
inhibitor 1A (p21, Cip1); 
cyclin-dependent kinase 
inhibitor 1B (p27, Kip1) 
Cell cycle checkpoint [127,128] 
 
cyclin-dependent kinase 
inhibitor 2A 
Cell cycle checkpoint [250] 
PCNA (proliferating cell 
nuclear antigen) 
cell proliferation [250] 
 
antigen identified by 
monoclonal antibody Ki-67 
cell cycle; meiosis; cell proliferation [239] 
 
c-myc  cell proliferation [127] 
 
Ubiquitin C 
 
cell cycle checkpoint;DNA damage 
response 
[85] 
RP59 multicellular organismal development; cell 
differentiation; regulation of osteoblast 
differentiation 
[234] 
RUNX3 (runt-related 
transcription factor 3) 
regulation of transcription, DNA-
dependent; transcription from RNA 
polymerase II promoter; protein 
phosphorylation; induction of apoptosis; 
cell proliferation; negative regulation of cell 
cycle; negative regulation of epithelial cell 
proliferation 
[250] 
SOX9  cartilage condensation; regulation of [149,296] 
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(SRY (sex determining 
region Y)-box 9) 
 
transcription from RNA polymerase II 
promoter; transcription from RNA 
polymerase II promoter 
MSX-2  
(msh homeobox 2) 
 
Sequence-specific DNA binding 
transcription factor activity;osteoblast 
differentiation; multicellular organismal 
development; negative regulation of cell 
proliferation;  
[234] 
DLX5  
(distal-less homeobox 5) 
Skeletal system development; osteoblast 
differentiation; endochondral ossification; 
multicellular organismal development 
[234,264] 
 
RUNX2  
(Runt-related transcription 
factor 2) 
Ossification; osteoblast differentiation; 
transcription 
[36,37,41-43, 46, 48, 55, 
73,85, 90, 112, 114, 
130,146,166,168,170,171
,200,212,228,234,238, 
243,248,249,260-262, 
269-271,280, 283, 286, 
289,290,294-296, 322, 
324,333,345,347,362] 
Sp7 transcription factor Regulation of transcription; osteoblast 
differentiation 
[36,37,41,43,55,90,112,166, 
168,228,295] 
ALP  
(alkaline phosphatase) 
Skeletal system development; biomineral 
tissue development 
[36,41,43,46,53,55,84-86, 90, 
92,100,101,104-107, 112, 
114,119,121,130,135,143, 
144,146,152,161,168,180, 
185,211,212,226,227,238, 
239,241,243-245, 248-250, 
260,262-265, 274, 279, 280, 
284, 285, 287, 295, 301, 302, 
311,312,317,333-335, 340, 
345,354, 355,360,362] 
 
BSP (integrin-binding 
sialoprotein) 
Ossification; cell adhesion; extracellular 
matrix organization; biomineral tissue 
development 
[36,37,41,43,48,73,84,86,106
,107,112,116,125,162,164, 
168,178,183,201,220,228, 
234, 250, 253, 260, 262, 264, 
271,274,277,286,294,295, 
301,302,311,317,333,335, 
345,346,348,362] 
OC (Osteocalcin) Skeletal system development; osteoblast 
differentiation; osteoblast development; 
bone mineralization; regulation of 
osteoclast differentiation 
[22,30,36,41-43,46,52-55,57, 
59, 73, 76, 80, 82, 83, 85, 86, 
90-93,96-98, 100, 101, 103, 
106, 107, 110, 112, 114, 115, 
118,120,124,129,130,131, 
134,136,139,143-147,150-
153, 155-160, 164, 167, 168, 
170, 171, 174, 176, 180, 
185,188-190,195,196,199-
202, 206, 207,209-212, 218, 
220-229, 
234,237,238,240,242,243, 
246,248-253, 256, 257, 262-
265,267,269,272,274,276, 
277,280-282, 285, 286, 289, 
290,292,295,297,300-302, 
307,309, 311, 314,317-319, 
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321,324,330,334,335,345-
348, 351, 352,355,357,359-
361,364,365] 
OPN (Osteopontin) Ossification; cell adhesion; positive 
regulation of cell-substrate adhesion; 
biomineral tissue development 
[22,30,42,43,46,48,53-55, 72, 
84-86,91,98,105-107, 112, 
114,116,131,132,146,149-
151,153,155,158-160, 162, 
164,177,180,210,211,234, 
239-241,248-251, 257, 260, 
267,262,263,265,277,286, 
288,289,291,294,295, 297, 
309,311,314, 321, 324, 330, 
334,347-349,353,355] 
ON (secreted protein, 
acidic, cysteine-rich) 
(osteonectin) 
Ossification; regulation of cell proliferation; 
cellular response to growth factor stimulus 
[81,86,106,107,116,125,126,
250,288,291,294,296, 309, 
321,331] 
DMP1 (dentin matrix acidic 
phosphoprotein 1) 
ossification; positive regulation of cell-
substrate adhesion; extracellular matrix 
organization; biomineral tissue development 
[234] 
OMD (osteomodulin) cell adhesion [178] 
Wnt 5a multicellular organismal development; 
positive regulation of gene expression;  
[48] 
 
CTNNB (catenin (cadherin-
associated protein), beta 1) 
canonical Wnt receptor signaling pathway;  [283,354] 
 
Axin2 
 
intramembranous ossification; chondrocyte 
differentiation involved in endochondral 
bone morphogenesis; dorsal/ventral axis 
specification; regulation of Wnt receptor 
signaling pathway; bone mineralization;  
[354] 
Snail 
 
osteoblast differentiation; mesoderm 
formation; multicellular organismal 
development; positive regulation of 
transcription, DNA-dependent; regulated by 
Wnt signaling pathway 
[354] 
Wisp2 (WNT1 inducible 
signaling pathway protein 2) 
 
regulation of cell growth; cell adhesion; 
signal transduction; cell-cell signaling; 
negative regulation of cell proliferation 
[354] 
Connexin43 transport; apoptosis; muscle contraction; 
signal transduction; cell-cell signaling; gap 
junction assembly 
[354] 
 
BMP1 
(bone morphogenetic 
protein 1) 
skeletal system development; cartilage 
condensation; ossification; multicellular 
organismal development; cell differentiation 
[55] 
 
BMP2  
(bone morphogenetic 
protein 2) 
skeletal system development; osteoblast 
differentiation;positive regulation of bone 
mineralization 
[46,69,71,109,114,164,171, 
220,243,248,249,287,295, 
324,362] 
BMP4  
(bone morphogenetic 
protein 4) 
osteoblast differentiation; positive 
regulation of pathway-restricted SMAD 
protein phosphorylation; positive regulation 
of bone mineralization; 
[324] 
 
BMP6  
(bone morphogenetic  
protein 6) 
skeletal system development;positive 
regulation of pathway-restricted SMAD 
protein phosphorylation; positive regulation 
of bone mineralization 
[220] 
 
BMP7 skeletal system development; ossification; [130,250] 
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(bone morphogenetic  
protein 7) 
positive regulation of bone mineralization; 
SMAD protein signal transduction 
 
 
SMAD1 
(SMAD family member 1) 
osteoblast fate commitment; regulation of 
transcription, DNA-dependent; 
transforming growth factor beta receptor 
signaling pathway 
[280] 
 
TGFB1 (transforming 
growth factor, beta 1) 
chondrocyte differentiation; SMAD protein 
complex assembly; regulation of cell 
proliferation; response to wounding; 
regulation of collagen biosynthetic process 
[52,55,59,60,69,71,75,83,118
,134-136, 140, 145, 154, 175, 
195,196,201,207-209,221-
224, 238, 243, 250, 268, 276, 
278,281,300,314,356,357, 
359] 
TGFBR1(transforming 
growth factor, beta receptor 
1); TGFBR2(transforming 
growth factor, beta receptor 
2) 
positive regulation of mesenchymal cell 
proliferation; positive regulation of SMAD 
protein import into nucleus 
[127,128] 
 
EGFR (Epidermal growth 
factor receptor) 
cell morphogenesis; ossification; cell 
proliferation; positive regulation of cell 
proliferation; cell-cell adhesion 
[127] 
FGFR1 (fibroblast growth 
factor receptor 1) 
skeletal system development; positive 
regulation of cell proliferation 
[127] 
 
FGF-2 (fibroblast growth 
factor 2 (basic)) 
 
regulation of cell proliferation; wound 
healing; positive regulation of blood 
vessel;regulation of cell cycle 
[218] 
EGF (epidermal growth 
factor) 
 
angiogenesis; platelet degranulation; DNA 
replication; positive regulation of cell 
proliferation 
[218] 
IGF1 (insulin-like growth 
factor 1) 
 
skeletal system development; blood 
coagulation; positive regulation of cell 
proliferation; bone mineralization involved 
in bone maturation; positive regulation of 
osteoblast differentiation 
[314] 
Collagen production Skeletal system development; blood vessel 
development; osteoblast differentiation; 
intramembranous ossification; 
endochondral ossification 
[30,46,51,55,76,82,89,98,102
,129,133,147,151,154,157, 
170,181,186,197,219,231, 
248,258,268,276,292,295, 
305,315,323,336,341,344, 
350,357] 
COL1  
(collagen, type I,  
alpha 1) 
Skeletal system development; blood vessel 
development; osteoblast differentiation; 
intramembranous ossification; 
endochondral ossification 
[30,36,53,55,72,73,84-87, 90, 
91,103,105-107, 112, 114, 
116,121,125,130-133, 143, 
146,149,152,153,158-160, 
162-164, 167, 168, 177, 179, 
182,185,187,211,212,226, 
228,234,238,250,257,260, 
265,274,277,279,280,285-
288,296,298,302,309,311, 
312,314,317,319,322,324, 
328,333-335, 345, 347, 348, 
353,355,360,361,365] 
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COL II  Skeletal system development [133,149,250,277,296,339] 
COL III (collagen, type III, 
alpha 1) 
skeletal system development; blood vessel 
development; cell-matrix adhesion 
[30,53,182,250,328,339] 
 
COLIX (collagen, type IX, 
alpha 1) 
chondrocyte differentiation; cell adhesion; 
organ morphogenesis 
[149] 
COL10a1 (collagen, type X, 
alpha 1) 
skeletal system development [296] 
lysyl hydroxylases 
(LHs);LH1,LH2,LH3 
protein modification process; hydroxylysine 
biosynthetic process; collagen fibril 
organization 
[55,87] 
 
 
Lysyl oxidases 
(LOX, LOXL1–4]  
protein modification process; collagen fibril 
organization 
[55] 
 
Prolyl hydroxylases 
(LEPRE1, P4HA1) 
collagen fibril organization [53,55,133] 
 
Sulfatase 1 Heparan sulfate proteoglycan metabolic 
process; negative regulation of fibroblast 
growth factor receptor signaling pathway; 
bone development 
[178] 
Decorin organ morphogenesis; wound healing; 
extracellular matrix binding ;peptide cross-
linking via chondroitin 4-sulfate 
glycosaminoglycan; 
[55,87,250]  
 
Biglycan Blood vessel remodeling; peptide cross-
linking via chondroitin 4-sulfate 
glycosaminoglycan; extracellular matrix 
binding 
[55,87]  
Fibromodulin Transforming growth factor beta receptor 
complex assembly; wound healing 
[87]  
Lumican collagen fibril organization; cartilage 
development; collagen binding 
[87]  
Laminin 
 
regulation of cell adhesion; regulation of 
cell migration; extracellular matrix 
structural constituent; 
[309,328,339,345] 
Vitronectin cell adhesion; cell-matrix adhesion; 
extracellular matrix organization 
[88,119,161-163,280,309] 
Vitronectin receptor ---- [88] 
TN (tenascin) cell adhesion; signal transduction; response 
to wounding 
[162,163,187,188] 
fibronectin extracellular matrix structural constituent; 
angiogenesis; cell adhesion; response to 
wounding; cell migration; peptide cross-
linking; platelet activation; substrate 
adhesion-dependent cell spreading; 
leukocyte migration; regulation of cell 
shape 
[46,49,88,126-128, 133, 162, 
163, 182, 186, 187, 248, 280, 
292,293,309,321,324,328, 
339,343,347] 
 
CD44 molecule cell-matrix adhesion; cell-cell adhesion; 
cytokine-mediated signaling pathway 
[259,349] 
 
ICAM-1 (intercellular 
adhesion molecule 1); 
selectin E 
Leukocyte migration; cell-cell adhesion; 
leukocyte cell-cell adhesion 
[141,182] 
 
VCAM-1(vascular cell 
adhesion molecule 1) 
Inflammatory response; cell adhesion; 
leukocyte cell-cell adhesion regulation of 
immune response; leukocyte tethering or 
[135] 
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rolling 
EPCR (Endothelial cell 
protein C-receptor)  
Immune response; blood coagulation; 
antigen processing and presentation 
[141] 
 
CADHERIN E Cell-cell adhesion [162,292]  
VE-cadherin  Cell-cell adhesion [88,335] 
N-cadherin  Cell-cell adhesion [292,293] 
MOUSE Emr(F4/80) cell adhesion; G-protein coupled receptor 
protein signaling pathway; neuropeptide 
signaling pathway 
 [266] 
 
Vinculin  
 
blood vessel development; regulation of 
Wnt receptor signaling pathway; canonical 
Wnt receptor signaling pathway involved in 
positive regulation of wound healing 
[244,245,251,283,293] 
vWF  (von Willebrand 
factor) 
Cell adhesion; blood coagulation; response 
to wounding; cell-substrate adhesion 
[88,141] 
 
PECAM-1 
(platelet/endothelial cell 
adhesion molecule) 
platelet degranulation; cell adhesion; signal 
transduction; blood coagulation; cell 
recognition; platelet activation; leukocyte 
migration 
[88] 
vascular endothelial growth 
factor A 
angiogenesis; patterning of blood vessels; 
vasculogenesis; response to hypoxia 
[59,142,182,218,242] 
 
iNOS response to hypoxia;nitric oxide 
biosynthetic process;blood coagulation; 
positive regulation of vasodilation 
[81]  
 
PDGF (platelet-derived 
growth factor alpha 
polypeptide) 
 
Angiogenesis; response to hypoxia; positive 
regulation of mesenchymal cell 
proliferation; platelet degranulation; cell-
cell signaling 
[142] 
Ang-1 (angiopoietin 1) 
 
regulation of endothelial cell proliferation; 
sprouting angiogenesis; leukocyte 
migration; positive chemotaxis 
[218] 
TM (Thromobomodulin)  Negative regulation of blood coagulation; 
leukocyte migration 
[141] 
 
integrin, alpha 1 cell adhesion; cell-matrix adhesion; 
integrin-mediated signaling pathway; cell 
chemotaxis 
[128,172,173,187,264,273, 
305] 
integrin, alpha 2 cell adhesion; cell-matrix adhesion; 
integrin-mediated signaling pathway; organ 
morphogenesis 
[163,172,173,187,264,273, 
305] 
 
integrin, alpha 3 cell adhesion; cell-matrix adhesion; 
integrin-mediated signaling pathway 
[113,172,173,273,345]  
 
integrin, alpha 4 cell adhesion; heterophilic cell-cell 
adhesion; leukocyte cell-cell adhesion; 
[113,172,173,273,345]  
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integrin-mediated signaling pathway; 
regulation of immune response; leukocyte 
migration 
 
integrin, alpha 5 angiogenesis; cell-substrate junction 
assembly; cell adhesion; heterophilic cell-
cell adhesion; leukocyte cell-cell adhesion; 
integrin-mediated signaling pathway; 
leukocyte migration 
[113,127,128,163,172,173, 
188,264,273,305,309] 
integrin, alpha 6 cell-substrate junction assembly; cell 
adhesion; integrin-mediated signaling 
pathway; regulation of apoptosis;leukocyte 
migration 
[113,172,173,187,273] 
 
integrin, alpha V cell adhesion; cell-matrix adhesion; 
integrin-mediated signaling pathway 
[113,188,212,273,305,340, 
344]  
integrin, beta 1 cell migration involved in sprouting 
angiogenesis; cellular defense response; cell 
adhesion; cell-matrix adhesion; integrin-
mediated signaling pathway; multicellular 
organismal development; cellular response 
to mechanical stimulus 
[31,46,104,113,163,172,173,
182,187,188,203,212, 248-
250, 259, 264, 273, 305, 309, 
313, 324, 328, 331, 332,340] 
 
integrin, beta 3 cell adhesion; cell-matrix adhesion; 
integrin-mediated signaling pathway; 
regulation of bone resorption; leukocyte 
migration; angiogenesis involved in wound 
healing 
[104,172,173,188,250,305] 
 
integrin, beta 5 cell adhesion; cell-matrix adhesion; 
integrin-mediated signaling pathway; 
multicellular organismal development 
[305,345,250] 
 
integrin alpha2 beta1 
 
platelet degranulation; cell adhesion; cell-
matrix adhesion; integrin-mediated 
signaling pathway; blood coagulation; 
platelet activation 
[292,332] 
integrin alpha3 beta1 
 
cell-matrix adhesion; integrin-mediated 
signaling pathway 
[332] 
 
Integrin alpha 5 beta 1 cell-matrix adhesion; integrin-mediated 
signaling pathway 
[88,292,332] 
 
Integrin, alpha V beta3 ---- [88,163,246,332] 
 
CSF (colony stimulating 
factor 1 (macrophage)) 
macrophage differentiation; regulation of 
ossification; osteoclast differentiation; 
positive regulation of cell migration; 
positive regulation of mononuclear cell 
proliferation; monocyte activation 
[100,238,278] 
OPG (tumor necrosis factor 
receptor superfamily, 
member 11b) 
Skeletal system development; apoptosis; 
extracellular matrix organization; negative 
regulation of bone resorption 
[41,57,59,60,73,100,143,144,
166,167,190,196,199, 202, 
206,242,243,278,286,300, 
319,334,335,354,358, 361]  
RANK (tumor necrosis 
factor receptor superfamily, 
member 11a, NFKB 
activator) 
cell-cell signaling; positive regulation of 
cell proliferation; osteoclast differentiation 
[122] 
 
RANKL (tumor necrosis 
factor (ligand) superfamily, 
Positive regulation of osteoclast 
differentiation; positive regulation of bone 
[73,81,100,167,196,206,242,
243,286,319,334,335, 358, 
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member 11) resorption; cytokine-mediated signaling 
pathway 
361]  
 
TRAF6 (TNF receptor-
associated factor 6) 
signal transduction; regulation of apoptosis; 
positive regulation of osteoclast 
differentiation; negative regulation of 
transcription, DNA-dependent; positive 
regulation of NF-kappaB transcription 
factor activity 
[122] 
 
catK (Cathepsin K) Proteolysis; bone resorption [122,336]  
 
calcitonin receptor Activation of adenylate cyclase activity by 
G-protein signaling pathway 
[267,336] 
 
carbonic anhydrase II Positive regulation of osteoclast 
differentiation; positive regulation of bone 
resorption; secretion 
[335] 
 
TRAP (acid phosphatase 5, 
tartrate resistant) 
response to cytokine stimulus; bone 
resorption; bone morphogenesis 
[122,246,266,277] 
 
MMP1  
(matrix metallopeptidase 1) 
Proteolysis; blood coagulation; metabolic 
process; collagen catabolic process; 
leukocyte migration 
[135] 
 
MMP2 (matrix 
metallopeptidase 2) 
Angiogenesis; proteolysis; metabolic 
process; collagen catabolic process 
[55,342]  
 
MMP9 (matrix 
metallopeptidase 9) 
Skeletal system development; proteolysis; 
extracellular matrix organization; collagen 
catabolic process 
[55, 335]  
TIMP2  
(TIMP metallopeptidase 
inhibitor 2) 
Negative regulation of cell proliferation; 
regulation of cAMP metabolic process; 
regulation of MAPKKK cascade 
[335] 
 
TIMP1–4                    
(TIMP metallopeptidase 
inhibitor1-4) 
---- [55] 
TNF-α                         
(tumor necrosis factor) 
Inflammatory response; immune response [73,116,134,165,213,276, 
278] 
 
Interleukin 1, alpha- pro-
inflammatory cytokine 
Inflammatory response; immune response; 
cell proliferation; wound healing 
[278] 
 
Interleukin 1, beta Inflammatory response; immune response; 
signal transduction; cell-cell signaling;  
[71,117,213,278] 
Interleukin 6 Inflammatory response; immune response [71,75,117,187,238,276,281,
357]  
Interleukin 8 Inflammatory response; immune response [135,213] 
Interleukin 10 Inflammatory response; cell-cell signaling; 
regulation of gene expression; leukocyte 
chemotaxis 
[71,165,213,278] 
 
Interleukin 11 Inflammatory response; immune response [73] 
interleukin 12, interleukin 
17A 
immune response [117] 
 
IL-1 R alpha , IL-12p70, IL-
15, IL-18 ,IL-16 
immune response [213] 
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MCP-1 (CCL2)  angiogenesis; response to hypoxia; 
chemotaxis; inflammatory response; 
cytokine-mediated - signaling pathway 
[117,213,278] 
 
 
MIP-1α (CCL3) ; MIP-1 β 
(CCL4) ; RANTES (CCL5); 
Eotaxin (CCL11);MDC 
(CCL22) 
chemotaxis; inflammatory response; 
immune response 
[117]; MIP-1 [213] 
 
SDF-1 (CxCL12) 
(chemokine (C-X-C motif) 
ligand 12) 
chemotaxis; immune response; cell 
adhesion; signal transduction 
[117] 
 
Cox-2 (prostaglandin-
endoperoxide synthase 2 
(prostaglandin G/H synthase 
and cyclooxygenase) 
regulation of inflammatory response; 
response to glucocorticoid stimulus 
[354] 
 
PGE2 (prostaglandin E 
synthase 2) 
prostaglandin biosynthetic process; fatty 
acid biosynthetic process; cell redox 
homeostasis; secretion 
[52,134,136,140,145,174,175
,195,196,201,207,208, 221-
224,268,300,352,359] 
 
NPAS2(neuronal PAS 
domain protein 2) 
Transcription, DNA-dependent; central 
nervous system development 
[296] 
BDNF (brain-derived 
neurotrophic factor) 
Nervous system development; axon 
guidance 
[94] 
NGF (Nerve growth factor) Peripheral nervous system development; 
regulation of neuron differentiation; 
regulation of axonogenesis 
[94] 
FAK  [171,214,299,332,340] 
p-ERK; p-JNK ;p-FAK  ----- [81,192,309,340] 
Erk; p-eErk1 
 
------ [31,74] 
Akt-1; MEK1 ;ERK2  ------ [127] 
 
c-fos transcription, DNA-dependent [31,299,340] 
c-jun transcription, DNA-dependent [29,340] 
RhoA; Rac1 ;cdc42 ;Rho 
Kinase  
 [127] 
Shc (SHC (Src homology 2 
domain containing) 
transforming protein 1) 
angiogenesis; response to hypoxia; 
epidermal growth factor receptor signaling 
pathway; Ras protein signal transduction; 
positive regulation of cell proliferation; cell-
cell adhesion; neuron differentiation; organ 
regeneration; actin cytoskeleton 
reorganization; intracellular signal 
transduction 
[31,332] 
 
PLD1a,1b,2a&2b 
(phospholipase D1, 
phosphatidylcholine-
specific) 
phosphatidic acid biosynthetic process; 
chemotaxis; cell communication; small 
GTPase mediated signal transduction; Ras 
protein signal transduction 
[202] 
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phospholipase C-gamma2 
(Plc-gamma2)  
 
intracellular signal transduction [298] 
protein kinase C, alpha intracellular signal transduction [127,202] 
 
	   34	  
Table 4: Technique used in in-vitro culture models for molecular assessment of osseointegration with 
different implant surfaces 
Method of testing References 
Northern blotting [84,236,274,279,291,301,302,309,342] 
 
RT-PCR [30,53,54,69,71,73,98,100,103,109,116,122
,127-129,131-133, 137, 138, 143, 147, 149, 
150, 151, 153,158-160, 164, 170, 171, 178, 
198,202-204, 214, 234, 238, 253, 257, 260, 
261,266,277-279,285-290, 294-296, 298, 
301,302,312-314, 324, 328, 330, 331, 333, 
364-366] 
Quantitative real time RT-PCR [27,36,37,41-43, 46, 48, 71, 72, 85, 87, 90, 
91, 94, 101, 104, 105, 112, 114, 121, 122, 
130,141,144,146,152,168,177,180,182,183,
185,187,188,200, 206,210,212,215-217, 
220,226-228, 235, 238, 240, 241,243,248-
250,254,259,262-265, 267, 271, 272, 280, 
284,293,311,317,321,322,333-335, 340, 
345-348,353-355,358,360,362] 
In situ hybridization [86,106,107] 
Immunoassay-ELISA 
(OC, PGE2, TGF-B1, IL-1 alpha, IL-1B, MCP-1, IL-10, 
IL-12, IL-17A, SDF-1 (CxCL12), RANTES (CCL5), 
MCP-1 (CCL2), MIP-1α (CCL3), MIP-1 β (CCL4), 
MDC (CCL22) and Eotaxin (CCL11), FGF2, EGF, M-
CSF, BDNF, NGF, IL-6, OPG, VEGFA, DKK1, DKK2, 
BMP2-BMP4, BMP6, OPN, RANKL, COLI, IGF-1, 
PDGF, TNF-alpha, MMP1, VCAM1) 
[27,52,57-60, 73, 75, 76, 80, 82, 83, 93, 94, 
96, 101,103,109,110,115,117,118,129,134-
137, 139, 140,142,144,145,147,154-157, 
165, 167, 175, 176, 179, 181, 187, 189, 190, 
195,196,199,202, 205-209,216-218,220-
227, 231, 234, 237, 242, 243, 252, 254, 256, 
268, 276, 278, 281, 292, 297,300,307, 314, 
315, 318, 319, 321, 348, 351, 
352,254,357,359, 361] 
Immunochemistry 
(Vinculin, ALP, PECAM-1, Vitronectin, Fibronectin 
receptor, VN receptor, VE-cadherin, von Willebrand 
factor, Fibronectin, α5β1 and α (v) β3), OC, BSP, OPN, 
TN, Runx2, collagen) 
[86,88,92,106,107,119,124,161,162,163, 
181, 200,211,244-246,273,283,309] 
 
Radioimmunoassay [27,52,97,123,134,136,140,145,147,169, 
175, 195,196,201,202,205,207,208-
210,215-218,221-224, 229-242, 268, 282, 
300, 338, 359] 
Gelatin Zymography and reverse zymography/ 
MMP-TIMP2 
MMP2 [342] 
Immunoblotting [31,74,81,98,127,192,235,275,292,293,305,
309, 332,340,356] 
Immunofluorescence [22,125,203,239,251,269,277,293,332,341] 
Collagen synthesis:  
3H-proline incorporation into collagen fibers; 
Sirius red based stain assay 
[30,51,53,102,133,151,170,197,219,295, 
305, 336,365] 
Immunogold labeling & SEM [126] 
Cytochemical stain TRAP [246,266] 
Flow cytometry [113,163,172-174, 187, 204, 261, 292, 332, 
339, 349] 
[35S] Methionine-labeled fibronectin  [49,343] 
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[35S] Sulfate incorporation [51,197,268] 
miRNA microarrays 
miRNA microarrays containing 329 probes designed 
from the human miRNA sequence 
[79,232,233,326,327] 
 
Wider genome profiling 
Human 19.2 K DNA microarray [304,308,316,329] 
 
Human 20K DNA microarray (MWG Biotech AG, 
Ebersberg, Germany) 
[47] 
 
cDNA microarray-18,401 genes   [120] 
 
     GeneChip Mouse Genome 430 2.0 Array (34,000 genes)-
affymetrix 
[178] 
Whole genome-Illumina Sentrix® Human-6 v2 
expression BeadChips-47,000 probe sets  
[48,220] 
 
Genefilters GF211: 12,626 genes 
 
[320] 
cDNA microarray GCK 5.0 K human chip (Genocheck, 
Korea) - 5049 genes 
[247] 
Rat gene microarray: Research Genetics GF300 nylon 
microarray (Invitrogen Corporation, Carlsbad, CA). 
These arrays have 1633 named rat gene 
sequences.relative level of specific groups of genes 
related to bone and cartilage development, cell adhesion 
and extracellular matrix proteins, transcription factors, 
bone morphogenetic proteins, phospholipases, and 
protein kinases  
[363] 
Atlas™ Human Cancer 1.2 gene array containing 1176 
genes  
[184,198] 
Human cDNA microarray (1152 elements)  [95,99,108,255] 
A microarray containing a total of 687 cDNA sequences [325] 
cDNA GEArrayTM kit for Human Osteogenesis, HS-
026-4 www.superarray.com)  
[110] 
An array of osteogenesis-related genes (human 
osteogenesis RT2 Profiler PCR array, PAHS-0026A – 
SuperArray Bioscience, Frederick, MD)) 76 related genes 
[41,55] 
 
RT profiler PCR array for ECM and adhesion molecules [345] 
Murine PCR Array (PAMM-011, SABiosciences, 
Frederick, MD, USA). This array profiles 84 key genes 
involved in mediating immune cascade reactions during 
inflammation and includes chemokines, cytokines, 
interleukins and their receptors..  
[116] 
GE-Superarray system,>80 genes [166] 
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Table 5: Genome wide expression profiling in in-vitro culture models for molecular assessment of 
osseointegration. 
Model Surface examined Technique used Days of 
analysis 
Reference 
Primary 
human 
osteoblasts -
3rd molar 
extraction 
sites 
SLA, mod SLA vs. Glass cover 
slips 
Whole genome-Illumina 
Sentrix® Human-6 v2 
expression BeadChips-
47,000 probe sets 
72 hrs [220] 
hMSCs SLA, SLActive, SMO (polished) Whole genome-Illumina 
Sentrix® Human-6 v2 
expression BeadChips-
47,000 probe sets 
3, 24, 72 
or 120 h 
[48] 
MC3T3-E1 
pre-
osteoblastic 
cells 
FN-immobilized titanium 
(Fibronectin coating using the 
tresyl chloride activation 
technique) vs untreated titanium 
GeneChip Mouse 
Genome 430 2.0 Array 
(34,000 genes)-
affymetrix 
14 days 
 
 
[178] 
 
MG-63 Anatase coating of titanium Human 20K DNA 
microarray (MWG 
Biotech AG, Ebersberg, 
Germany) 
24 hrs [47] 
 
MG-63 Ti6Al4V disks machined 
(SR=0.77+_0.28) vs. Biolok, 
Blasted with tricalcium phosphate 
and light nitric acid tt 
(SR=1.93+_0.37) 
Biolok, Nanopore SR=1.05+_0.34 
vs. TPSS surface 2.74, or only 
medium and cells 
Human 19.2 K DNA 
microarray 
24 hrs [308] 
MG-63 zirconium oxide discs (Cercon, 
Degussa Dental, Hanau, Germany) 
Human 19.2 K DNA 
microarray 
24,48 hrs [329] 
MG-63 Disks of machined titanium , vs. 
nanoPORE (Out-Link, Sweden and 
Martina, Due Carrare, Padova, 
Italy).The surface roughness (Sa) 
was 0.77±0.28 for the machined 
disks and 1.05±0.34 for the 
nanoPORE disks 
Human 19.2 K DNA 
microarray 
24,48 hrs [316] 
MG-63 Machined grade 3 titanium vs. 
titanium pull spray superficial 
[TPSS]:produced through 
micromechanical removal of parts 
of the superficial oxide layer with 
the use of aluminum oxide 0.5 
mm/micropoints.The Ra value was 
0.30 for the machined surface and 
2.74 for the TPSS surface. 
Human 19.2 K DNA 
microarray 
24,48 hrs [304] 
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MG-63 Machined vs anodized Ti 
surface:The roughness of 
machined Ti surface was 0.54 °+_ 
0.16 µm and the roughness of 
anodized one was 0.88 °+_ 0.13 
µm 
cDNA microarray GCK 
5.0 K human chip 
(Genocheck, Korea) - 
5049 genes 
24 hrs [247] 
Saos-2 1)Tapered Internal (BioHorizons 
Implant Systems, Inc., 
Birmingham, AL) and Resorbable 
Blast Texturing with Laser-Lok 
collar; (Ra, not 
available).2)Nanotite (3i Implant 
Innovations, Inc., Palm Beach 
Gardens, FL), osseotite surface 
combined with a discrete 
crystalline deposition of nanometer 
scale calcium phosphate; (Ra, 0.28 
± 0.06 µm). 
3) Full Osseotite (FOSS; 3i 
Implant Innovations, Inc.), 
osseotite surface: dual acid-etched 
with HF and then HCl/H2SO4; (Ra, 
0.86 ± 0.14 µm).4)Straumann 
SLActive Standard Implant 
(Institut Straumann AG, Basel, 
Switzerland), sandblasted with 
large grits (0.25–0.50 mm), acid-
etched with HCl/H2SO4, rinsed 
under N2 protection, and preserved 
in isotonic NaCl solution; (Ra, 
2.93 ± 0.46 µm).5)SwissPlus 
(Zimmer Dental, Inc., Carlsbad, 
CA), grit-blasted with 
hydroxylapatite (Microtextured 
Titanium, MTX). As referring 
control, cells grown in absence of 
dental implant were used (1–2 µm, 
as provided by the manufacturer). 
TCP was used as control 
C  DNA microarray-18,401 
genes 
72 hrs [120] 
 
primary 
human 
osteoblasts 
(hOB) 
Ti6Al4V polished (control) vs. 
passivated samples (P: nitric acid 
treatment-30%-1 hr)  vs. Aged 
treatment (A:Passivated treatment 
followed by aging in boiling 
deionized water for 10h) 
Genefilters GF211: 
12,626 genes 
 
4,24,48 
and 120 
hrs 
[320] 
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Figure 1:  
 
Figure 1: Topography-dependent signaling and phenotype. Alloplastic substrates vary widely in bulk 
composition and topography (Table 1). Multiple signaling pathways directly or indirectly mediate topography 
dependent changes in the adherent cell phenotype. Numerous primary, immortalized, and tumor-derived cell 
models have been involved (Table 2). These pathways represent those involved in cell-adhesion and bone 
development and repair. Included are (a) integrins [46,248,324] that interact directly with the surface, (b) 
serine/threonine kinase receptors (eg, TGFβ and BMP signaling [69,196,224], (c) G-protein coupled receptors 
(eg, PTH, Wnt), (d)tyrosine kinase receptors (eg, PDGF, IFG-1 [142,314]) (e) GTPases (eg, Rho1, RAS), (f) b-
cadherin, (g) RANKL [100], (OPG) [243], (i) osteoblast differentiation transcription factors (Runx2, Osx). 
Cellular responses examined focus on osteoblast-specific phenotype but include a wider range of physiologic 
responses (Table 3) 
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Chapter 2 
Molecular Assessment of Osseointegration In Vivo; A review of current literature 
 
Abstract: 
This paper reports on the results of a structured review of the literature concerning in vivo molecular assessment 
of osseointegrated endosseous dental implants. A search of electronic databases was performed up to and 
including August 2011. Thirty articles met the inclusion criteria. A descriptive evaluation and analysis of the 
gene expression date concerning the process of osseointegration were performed. Broad consensus was 
observed among the study results, perhaps as a result of the similar targeted gene expression events. More 
recent investigations using gene arrays or gene profiling techniques offer new insights into the fundamental 
molecular events that support the osseointegration process. Evidence for the influence of surface topography on 
osteogenesis and osteoinduction has been reported. Additional investigations are required to further solidify the 
functional associations between individual or orchestrated gene expression events and the clinical result of 
osseointegration.  
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Introduction: 
      Current tooth replacement strategies typically consider the alloplastic-integrated replacement of missing 
teeth using endosseous dental implants as a primary choice among available modes of therapy.  Among the 
many reasons for selection of this mode of therapy include the often-cited reproducibility of the biologic 
integration of the endosseous implant.  Such reproducibility in the clinical management of a biological response 
is accepted without question. Yet, important questions remain.  Do current implant technologies address all 
current needs?  Can clinicians explain experienced failures?  Answers to such questions require careful 
understanding of the biologic process of osseointegration. 
      Osseointegration is defined as a direct structural and functional connection between ordered living bone and 
the surface of a load-carrying implant [1].   Essential elements of this definition include the implicit 
understanding that vital bone remains in apposition to the endosseous implant surface throughout its functional 
(loaded) lifetime.   Implant success is often discussed in qualitative and quantitative terms of the amount of 
bone formed at the endosseous implant interface.  The earliest identifiable influences on this feature of 
osseointegration were the qualitative and quantitative clinical perceptions of local bone prior to implant 
placement. [2] Early failures were attributed to clinical error leading to lack of primary stability or infection.  
Delayed failures were attributed to reduced bone volume (low bone to implant contact) attributable to 
diminished bone volume and quality.   The role of systemic diseases or conditions on osseointegration further 
suggested that the healing potential of the local bone tissues affected bone formation at the endosseous implant. 
      The past decade has revealed an increasing interest in the improvement of osseointegration through 
modification of the endosseous dental implant surface.  Implant surface topography, as recently reviewed by 
Wennerberg and Albrektsson [3] can be modified to alter the interfacial bone response.  With the caveat that our 
definition of a ‘rough surface’ is limited, moderately rough (S(a)> 1 -2 micron) surfaces show stronger bone 
responses (increased BIC, increased torque removal) than other surfaces.   Another recent review of 
experimental surface alterations ranging from the application of structural peptides and proteins (e.g., collagen) 
to diverse growth factors and morphogens (e.g., BMPs) revealed more diverse positive and negative outcomes 
for these different approaches.  New techniques to apply ultra thin CaP coatings (vapor deposition, sputter 
coating, ESD, biomimetic deposition) were observed to improve bone integration as compared to non-coated 
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titanium implants [4].  These recent reviews display a wide range of current activities that seek to improve the 
osseointegration result in attempts to address the increasing challenges clinicians address by placing implants in 
individuals with reduced bone volume, reduced bone density, and impaired wound healing (e.g., diabetes, 
osteoporosis, radiation therapy, chemotherapy). 
      Evaluation of the result of osseointegration is possible by simple clinical methods.  Tactile approaches that 
include tapping and reverse torque estimations serve the majority of clinicians well in discerning successful 
versus failed osseointegration.  While more controversial in its physical interpretation, quantifying stability 
using resonance frequency (ISQ) can reveal changes in implant integration over time that reflect the gain or loss 
of interfacial bone supporting the osseointegration result [5].   When the body of literature concerning bone-to-
implant contact was reviewed at the histological level, a clear advantage for increased surface topography was 
revealed [6].   Human clinical investigations comparing different implant surfaces also suggest that 
modification of surface topography leads to alteration in the local bone responses leading to increased bone-to-
implant contact [7-10].    There is sufficient data at multiple levels ranging from animal studies to direct human 
histology indicating that the process of osseointegration can be modulated to increase bone to implant contact.  
Precisely how this is achieved has not been clearly delineated.  Without a complete understanding of the 
molecular and cellular process of osseointegration, therapeutically relevant targets for improving the result may 
be poorly defined. 
      The molecular basis of biology and of disease has been established as a principle determinant in managing 
human health.  Only recently has the molecular basis of osseointegration been considered (Figure 1).  The 
nature of tissue biology at, on or adjacent to the implant surface has not been carefully elucidated.  However, 
recent activities have begun to highlight both the fundamental processes that contribute to interfacial bone 
formation and how different implant-surface parameters may influence these processes that eventually lead to 
bone formation at the alloplastic / tissue interface.  Several laboratories demonstrated that it is possible to 
interrogate these molecular processes by retrieval of tissues and implanted endosseous devices from animal 
models (Figure 2).  Early reports focused on demonstrating that gene expression events known to be evident in 
the process of bone formation were recapitulated at the forming bone to implant interface [11]  and others 
demonstrated that the osteoinductive genes that promote stem cell differentiation to osteoprogenitor cells 
(namely RUNX-2 and Osterix) were expressed by implant-adherent cells in vivo and were elevated on surfaces 
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with topographies that enhanced bone to implant contact  [12].   Most recently, wider evaluations of gene 
expression in tissues surrounding dental implants have indicated that other significant biologic processes may 
be involved in healing of the endosseous implant [13,14]. The aim of this review is to identify the model 
systems, molecular platforms and targeted gene expression events involved in existing phenotype at the level of 
protein-encoding mRNA expression.  Anticipated (and repeatedly demonstrated in the literature) is the surface-
dependent modulation of mRNA expression within the implant-surface adherent cells. 
Materials and methods:  
      For the literature to be included in this review, the following eligibility criteria were used: in vivo reports 
assessing the molecular process of osseointegration, and articles published only in English. Studies related to 
wear particles , letters to the editor and reviews were excluded. 
     Search Strategy: A thorough search was performed up to and including August, 2011 through the following 
databases: PubMed (1948 to August, 2011), using the following terms: (titanium[tw] OR zirconium[tw] OR 
dental implant*[tw]) AND (gene expression[MeSH Terms] OR gene expression[tw] OR differentiation[tw] OR 
rna[MeSH Terms] OR rna[tw] OR messenger rna[tw] OR mrna[tw]),  EMBASE via OVID (1947 to 
August,2011) using: (Titanium.mp. or zirconium.mp. or tooth implantation/ or dental implant*.mp. and gene 
expression.mp. or exp gene expression/ or exp DIFFERENTIATION/ or differentiation.mp. or ena.mp. or exp 
RNA/ or messenger rna.mp.[mp=title,abstract,subject headings,heading words, drug trade name, original 
title,device manufacturer, drug manufacturer] or mrna.mp.[mp=title,abstract,subject headings,heading words, 
drug trade name, original title,device manufacturer, drug manufacturer], and BIOSIS Previews via ISI Web of 
Science (1969 to August,2011), ISI Citation via ISI Web of Science (1955 to date) using the following words: 
Topic=((titanium OR zirconium OR "dental implant*") AND ("gene expression" OR differentiation OR rna OR 
rna OR "messenger rna" OR mrna)). Titles and abstracts were screened for possible inclusion in the review. The 
full text of the articles judged to be relevant by the title and abstract was read and independently evaluated 
against the eligibility criteria. In addition, a hand search of the reference lists of original studies that were found 
to be relevant was conducted. 
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Results: 
      Thirty articles met the inclusion criteria. Characteristics of the included in-vivo reports including model 
systems used, techniques used for molecular assessment of the osseointegration process, genes examined and 
wide gene expression profiling studies are presented in Table 1,2,3 and 4 respectively.  
Different in vivo models are represented and include mouse, rat, mini-pig and rabbit animal models.  Human 
studies have recently provided additional molecular data concerning the molecular processes surrounding 
osseointegration.   These various studies all share similar major observations. The molecular processes of bone 
formation suggested by previous histological assessments and in vitro examinations of implant surface effects 
on osteoblast function are supported by these targeted assessments of osseointegration.  Broad consensus is 
observed among these study results.  One possible explanation for this consensus is that the early questions 
asked regarding the molecular process underscoring osseointegration have been directed about known aspects 
of bone formation and repair in general.   
      The spectrum of molecular events targeted in these studies in narrow.  Osteoinduction represented by the 
expression or abundance of Runx-2 and Osterix, key transcriptional regulators of stem cell commitment to 
osteoblastogenesis, has been explored in many of these investigations.  Osteogenesis reflected by the expression 
of collagen type I and bone-specific or enriched protein encoding mRNAs has also been observed.  The 
increased expression of mRNAs including Collagen type I, osteopontin, osteonectin, bone sialoprotein, and 
decorin has been observed as a function of time as well as ‘enhanced’ surface topography in all of the reported 
studies.  One general conclusion is that, irrespective of possible modulation of mRNA abundance temporally or 
quantitatively, osseointegration involves osteoinduction from progenitor cells and the subsequent elaboration of 
a bone matrix comprised of the basic components involved in bone repair. 
      Genome wide assessment of bone formation and repair conducted in vivo reveal a standard progression of 
cellular events indicated by gene expression [15].  Most investigations have focused on the impact of implant 
surface on the molecular process of osseointegration. Seventeen studies have specifically explored bone-
specific gene expression as a function of implant surface and time. The general observation is that surface 
topography influences the pattern of gene expression for bone-related proteins (OPN, ON, BSP, COLI, ALP). 
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Perhaps more significantly, the impact of surface topography (and related chemistry) on osteoinduction has also 
been specifically addressed by measuring expression of Osx and Runx2. 
      Gene profiling studies ask a much broader question and can explore a wide range of possible biological 
processes including osteoinduction and osteogenesis. Only several gene profiling studies involving 
osseointegration have yet to be reported.  For example, results from a human model reported on biological 
events surrounding osteogenesis, related angiogenesis and some interest on osteoclast recruitment and activity 
[13].  In a most recent report using targeted gene arrays, Bryington et al [14]  explored gene expression events 
surrounding inflammation as related to early wound healing.  Most interestingly, these reporting of these studies 
have focused on osteogenesis and related angiogenesis. The full value of >20,000 genes representing multiple 
processes remain underexplored. 
Discussion: 
      Model systems:  The selection of models for in vivo investigations involves understanding the value of 
desired endpoints and the applicability and translation to the human clinical situation.  Much of the early 
research involving osseointegration was performed in extraoral sites that proved valuable in assessment of the 
extent of bone formation along the implant surface [16].   Mechanical testing of the implant / bone interface 
required the use of surrogate tests of function that include push out or reverse torque testing that do not fully 
replicate the biomechanics of dental implant function [17].  Typically, these models involved implants that 
approximated the dimension and form of clinical implants, but often were designed to best meet the demands of 
the animal model.  (e.g., [18]).   Despite these limitations, use of in vivo models to study osseointegration in 
extraoral sites has contributed to our knowledge of surface topography and mechanical loading on the 
histological result of osseointegration [3,6].  
      Studies on dental implant osseointegration have focused broadly on the effects of implant design, local bone 
physiology effects, masticatory (dys)function effects, or oral environmental effects (biofilm-mediated processes 
of peri-mucositis and peri-implantitis) largely through the histological evaluations of osseointegration.  The 
majority of studies published represent single time-point studies that infer one or several biological processes 
were responsible for the results observed through histology (and radiography).   A molecular and cellular 
interrogation of the biologic processes that contribute to osseointegration of endosseous implants requires 
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careful model selection.  In addition to anatomic, dimensional and biomechanical concerns, an in vivo 
examination of the molecular and / or cellular processes contributing to osseointegration requires selection of 
model systems for which sufficient molecular and cellular tools of assessment are readily available.  
Unfortunately, the commonly utilized models for histology (rabbits, dogs, and to a lesser extent mini-pigs and 
sheep) provide fewer advantages for molecular assessment than do small animal models including rats and 
mice.  The main advantages of using rats and mice for studies of biologic processes of physiology and 
pathology include 1) known genomes [19,20], 2) ready access to tools for molecular assessment, 3) relative low 
cost, 4) a wealth of knowledge regarding the molecular basis of biologic processes (including osteoinduction, 
osteogenesis, and osteoclastogenesis) in these specific models, and 5) the ability to specifically alter the 
genomes of mice and rats to create models that test individual genes encoding proteins that may directly affect 
osseointegration.  Recent review of this field suggests that mice have become a preferred model system for bone 
research because of their genetic and pathophysiological similarities to humans, relatively low costs and the 
availability of the genome sequence information [21]. The value of genetic mouse models of bone physiology 
was recently underscored in a review of osteoclastogenesis where the authors stated that this approach has 
identified novel molecules and highlighted their involvement in vivo, confirmed human mutations and 
expanded the knowledge of mechanisms [22]. 
      The rat model for study of bone physiology and repair is advantageous because of its relatively large size 
that facilitates surgical intervention.  Several mutations or conditions of the rat have permitted forward genetic 
studies.  For example, diabetic or osteopetroic conditions have been evaluated in terms of osseointegration 
using mutant rat strains [22,23].  Further advances are now promised with using reverse genetic approaches that 
can systematically and controllably alter the genome to affect phenotypic changes.  Only recent technical 
advances in manipulating the rat genome have made this a realistic possibility [24]. Anticipated is the use of 
this technology to demonstrate the role of specific genes in the process of osseointegration. 
      Methods to assess gene expression: A major advantage of studying the process of osseointegration at the 
molecular level is the potential to identify key steps in the process that may be clinically influenced.  These 
‘targets’ are identifiable, but are dependent on the methods used to assess gene expression.  Gene expression 
data is readily available at the level of mRNA that encodes proteins, which define the phenotype of interest 
(here interfacial bone formation).  At the level of mRNA, assessments can be made using exploratory methods 
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(identification of novel or relatively high or low expressed molecules), qualitative methods (present or not), 
semi-quantitative methods, and quantitative methods.   Most techniques all depend upon nucleotide 
complimentarily and RNA hybridization methods that require knowledge of all mRNA sequences now available 
through the sequencing of the rat genome[25].   
      Building on histological methods, sections of tissues representing the implant/bone interface can be treated 
with antibodies for specific proteins and these proteins can be identified using immunohistochemistry.  This 
technique, widely used in pathology, is not readily applied to ground sections embedded in acrylic resins that 
are frequently used for endosseous implants.  When applied to fractured sections with the implant removed, the 
risk of interface damage exists.  If successful, the result remains semi-quantitative.  Another means of 
phenotypic characterization involves identification of specific mRNAs within tissues on histologic sections.  In 
situ hybridization is the process of RNA hybridization of known RNA sequences within tissues (i.e. express by 
a particular cell).  The methodology is robust, yet technically challenging.  When accomplished it too offers a 
semi-quantitative assessment of the expression of an individual RNA encoding a protein within cells and tissue. 
      Ogawa and colleagues [26] used a exploratory method termed Differential display to identify differences 
among mRNAs expressed on two different implant surfaces in vivo.  This approach identified at least three 
mRNAs (TO1, TO2, TO3) with elevated expression in tissues adjacent to implant surfaces following placement 
in the rat tibia.  This and other subtractive gene cloning methods reveal differences by dismissing what appear 
to be the more common and similar mRNAs and is a powerful exploratory tool in biology.   The ultimate role or 
impact of these identified genes on the process of osseointegration remains to be fully elucidated. 
      mRNA quantification has been enabled by a process termed quantitative-Reverse Transcription Polymerase 
chain reaction (qRT-PCR).  This method has been largely automated and today it is possible to perform this 
process on sets of targeted mRNAs or on all mRNAs represented in a tissue (gene profiling) simultaneously.   
These approaches offer opportunities to explore many aspects of physiology through interpretation of large 
datasets using complex computer based algorithms.   One such data base is ‘the Gene Ontology”, a project that 
collaboratively  assists in structuring vocabularies that describe gene products in terms of a) biologic processes, 
c) cellular components and c) molecular functions.  Genes observed by a process of gene profiling (looking a 
the relative abundance of all genes expressed) can be organized according to specific functions or 
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processes[27].  With respect to osseointegration, some of these processes might include ”differentiation” or 
“ossification” or “skeletal development” and they are identified by the GO program based upon the expression 
of mRNA molecules.   Where one or another single mRNA expression event might not provide insight to an 
important process, the organized expression of multiple mRNAs can often point toward a specific cellular 
components, molecular function or biologic process.  These powerful tools can be applied to defining in more 
complete terms the process of osseointegration.  This elucidation can provide new clues to the questions all 
clinicians have regarding the underlying causes of implant failure. 
      Genes examined: Distinct yet overlapping phases of healing are associated with osseointegration including 
clot formation, inflammation, bone repair and remodeling. The sequential changes in cell populations are 
orchestrated in a manner to weigh the balance toward bone formation. This involves the migration of 
mesenchymal stem cells, proliferation and promotion of osteoblastic differentiation. 
      Cell proliferation around implants in-vivo was modestly investigated (3,11). Proliferating cell nuclear 
antigen (PCNA) ; a protein that acts as a processivity factor for DNA polymerase delta in eukaryotic cells 
[28]was used to indicate cell proliferation(3). This protein is also involved during DNA repair (Bravo R, Celis 
JE, 1980).  Period Homolog 2 (Per2); involved in the circadian rhythm also plays a role in the regulation of the 
cell proliferation [29]Expression of Per genes in osteoblasts negatively regulates osteoblast proliferation. In the 
context of osseointegration, per2 expression period homolog 2 (Per2), were upregulated around implants vs. 
osteotomy sites at 2 weeks and diminished by vitamin D deficiency [30]. This may be expected as proliferation 
and differentiation of osteoblastic cells are inversely related. 
      Osseointegration at endosseous implants requires activation of processes relevant to osteoinduction, 
osteoconduction and osteogenesis [31]. Osteoinduction is the process by which primitive, undifferentiated cells 
are stimulated to develop into osteoprogonitor cells [32].  Key effectors of osteoinduction include Runx2 and 
Osx. Both are transcription factors necessary for osteoblast differentiation by controlling osteoblast-specific 
gene expression at target genes such as ALP, COLI, OPN and OC [33-38]. Runx2 or Osx gene ablation in mice 
results in complete absence of bone development [39,40]. Modulation of Runx2 and Osx expression by the 
implant surface topography has been observed by several investigations. In-vivo reports modestly investigated 
the role of Osx (1 study). Runx2 and Osx expression are positively influenced by increased surface roughness 
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[12,41-43]. The elevated expression of Runx2 or Osx are paralleled by upregulation of bone-specific proteins 
(ALP, OC ,BSP expression [12,42,43] .  PPAR-y ; a key transcription factor for adipocyte differentiation, is 
also implicated in the proliferation and differentiation of several cell types including osteogenic cells [44] and 
macrophages [45]. The PPAR-y directs MSC differentiation toward the adipocyte lineage with a negative 
dominant regulatory effect on osteoblast differentiation  [46]. Omar et al [43], investigated the expression of 
PPAR-γ as a function of time and surface treatment. PPAR y was significantly higher at the machined surface 
(0.3um) compared to oxidized (Ra=1.2um) surface 1 day after implantation. Nevertheless, at day 3, the 
expression of PPAR-γ was higher at the oxidized surface. The authors proposed further studies are needed to 
establish the role of this transcription factor in implant adherent cells. 
      Osteogenesis was monitored by measurement of bone-specific proteins (ALP, BSP, OPN, ON, OC and 
COL1). Greater expression of bone-specific proteins is suggestive of greater osteogenesis and more bone 
formation. Elevations in expression of specific-bone proteins were reflected by higher torque removal values 
[41,47] at rougher implant surfaces at the micron and nanoscale levels. Collagen type I is the most abundant 
protein in bone [48] and is secreted at the early stages of osteoblast differentiation. The mechanical strength of 
bone reflects the inherent properties of its constituents. Collagen biosynthesis at the implant surfaces has been 
investigated in-vivo widely by means of type I COL expression. On the other hand, stability of collagen is 
largely dependent on several posttranslational modifications catalyzed by prolyl 4-hydroxylase, prolyl 3-
hydroxylase and the family of Lysyl hydroxylases. Additional modifications by Lysyl oxidase (LOX) allow 
intermolecular and interfibrillar crosslinks between collagen fibrils [49,50]. An in-vitro investigation [51] 
demonstrated a positive influence of surface roughness on expression of the aforementioned collagen modifying 
genes. Current in-vivo reports have not examined the potential role of collagen modifying genes in the process 
of osseointegration. Other ECM components investigated in the context of osseointegration include vinculin 
[52], fibronectin [53] and various proteoglycans [54]; decorin and biglycan. Proteoglycans role in establishing 
bone-titanium interfacial adhesion has been established in-vitro by demonstrating that administration of GAG 
degradation enzyme reduced the bond strength of titanium and cultured rat bone marrow-derived osteoblastic 
cells [55]. 
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      The process of osteogenesis is affected by several growth and differentiation factors. BMPs (Bone 
morphogenic proteins), members of transforming growth factor family, are one group of stimuli known to 
induce MSCs or osteoblast progenitors to undergo osteogenic differentiation. The role of BMP signaling 
pathway in in-vivo osseointegration was mostly investigated through monitoring expression levels of BMP2 (7 
studies).   However, BMP signal transduction is regulated at different levels in the cell. It can be influenced by 
extracellular antagonists such as noggin, chordin, follistatin, etc which bind to BMPs and prevent their 
interaction with receptors [56].  The only extracellular BMP antagonist that was examined in vivo was Noggin. 
The reported study was examining the effects of local application rh-TGF-b2 in an implant model on 
modulating gene expression [57] . Elucidation of the role of the various regulatory mechanisms in BMP 
signaling in osseointegration requires further elucidation.  Reports on factors that may play a role in 
osseointegration also included studies examining TGF-beta and its receptors [43,54,57] . TGFB acts as an 
important autocrine and paracrine factor in the regulation of bone formation and resorption. It has been 
implicated to stimulate the replication of precursor cells of the osteoblastic lineage, in addition to its stimulatory 
effect on bone collagen synthesis [58]. Yet, it also plays a role in stimulating bone resorption by differentiated 
osteoclasts [59]. TGF-b exerts its function by interacting with a heterotetrameric complex of type I and type II 
TGF-b receptors. The expression of dominant-negative TGFb receptors in osteoblast cells in vivo causes an 
age-dependent increase in trabecular bone mass, due to decreased bone resorption by osteoclasts [60]. 
      Angiogenesis is of pivotal importance during the initial healing process of osseointegration. Factors that 
play a role in angiogenesis include but not limited to VEGF, bFGF, Ang-1 [61], PDGF-B, Insulin-like growth 
factor and HIF (Hypoxia-inducible transcription factor). VEGF, a molecule known to induce 
neovascularization, has also been shown to stimulate bone healing and skeletal growth [62,63]. VEGFA acts 
through its receptor Flk-1/KDR.  VEGF leads to an upregulation of BMP2 in endothelial cells that can act 
reciprocally on the osteoblast lineage inducing osteogenesis [64]. Few studies investigated angiogenesis in the 
context of osseointegration. 
      Modulation of the inflammatory process in the early phases of healing following implant placement 
provides a key element in implant fixation. Inflammatory related processes in implant adherent cells may 
pioneer biological mechanisms for driving differentiation of cells, including osteoprogenitors, osteoclast 
precursors, etc that affect osseointegration. Furthermore, differential expression of chemokines and their 
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receptors affects recruitment of several cells including inflammatory cells, osteogenic cells and their progenitors 
[65,66]. Inflammatory response to different implant surfaces was investigated by the quantification of the 
relevant gene expression of TNF-alpa (7 studies), IL-1 beta (3 studies), IL-6 (2 studies), IL-8R (1 study), IL-10 
(1 study), IL-11 (1 study), CCL2 (2studies) and CXCR4 (1 study).  
      Bone accrual at the implant surface also involves resorption and remodeling. Osteoclast differentiation is a 
tightly regulated process dependent on an osteoblast-derived member of the tumor necrosis factor (TNF) 
superfamily; RANKL (receptor activator of the NFkB ligand), which binds to its receptor RANK on monocytes 
[67].  Osteoprotegrin (OPG) plays an essential role in the control of bone resorption by acting as soluble decoy 
receptor for RANKL. Thus, OPG functions to decrease osteoclast formation and activity [68,69] .Efficient 
degradation of bone is dependent on the production and activation of various matrix-degrading enzymes; 
cathepsin K [70,71] , several MMPs [72,73] and TRAP [74]. Activation of the matrix-degrading enzymes is 
dependent on the acidification of the lacunar space [75] achieved by the action of an essential enzyme carbonic 
anhydraseII, in addition to a vacuolar ATPase electrogenic proton pump [76,77]. Another phenotypic marker 
for osteoclast is Calcitonin receptor, which expression correlates well with bone resorption [78,79] . 
Quantification of osteoclast-related genes was investigated briefly in vivo. Implant surface features modulated 
expression of bone resorption transcripts [47,80,81]. 
      In an extraoral model of bone healing against endosseous implant surfaces; Donos et al (2011) [82] 
extended previous investigations of guided bone regeneration that indicated more broad gene regulation 
involving increased skeletogenesis and resuced inflammatory gene regulation over a 7 – 14 day period.   In this 
study, they found that SLA surfaces displayed relevant gen ontology changes for many cellular processes, 
particularly at 14 days.  Included were skeletal system development and signaling changes associated with the 
Wnt pathway, and Ras and Rho pathways.  The authors highlighted 41 genes upregulated in the mesenchymal 
stem cell differentiation, angiogenesis ontologies as well.  They concluded that regeneration associated ith 
microrough and polished implant surfaces is associated with unique gene expression profiles.    Another gene 
profiling study focused on early healing (days 4, 7 and 14) of SLActive implants inserted in the retromolar pad 
area of human volunteers [83].  Large numbers of differentially regulated genes (increasing and decreasing) 
were observed at each time point.    At 4 days, several central inflammation-related biological processes were 
represented (NFkB cascade, lymphocyte proliferation, macrophage activation).  Several osteoinductive genes 
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including SATB2 and Sp7 (Osterix) were elevated between 4 and 14 days.  This investigations highlights 
important molecular differences between early healing events that include inflammation and Wnt signaling and 
late healing events that included VEGF signaling, skeletal system development, and continued Wnt signaling.    
Further investigations have included use of gene profiling to compare the molecular events that occur at SLA 
vs. SLActive implant surfaces.  Clear differences were observed in gene ontologies. For example, at day 7, the 
MAPK singling pathway was significantly elevated (P< 0.0004) in tissues associated with the SLActive 
implant.  At day 14, for example, BMP signaling pathway was also increased (P< 0.03).  In general, these early 
gene profiling studies of the osseointegration process have confirmed that surface topography or hydrophobicity 
influences the behavior of tissues in ways that include fundamental processes of inflammation and wound 
healing, as well as many aspects of osteogenesis and biomineralization.   
Conclusions:  
      In vivo molecular assessment of osseointegration can be achieved at multiple levels involving protein and 
mRNA.  The quantitative assessment of bone-related mRNA expression is commonly reported with data 
supporting the concept that implant surface features that are associated with increased bone to implant contact 
are able to positively influence the process of bone formation.  Several reports demonstrate that surface features 
also promote osteoinduction by the elevated expression of key transcriptional regulators of this process.  Recent 
studies using gene profiling successfully characterized gene expression events in the tissues surrounding 
implants and within implant adherent cells. Processes preceding osteoinduction and events that follow the 
elaboration of a mineralized matrix have been highlighted by gene profiling studies.  These molecular details 
may represent additional targets for therapeutic improvement.  Further investigations using in vivo molecular 
assessment, combined with reverse genetic approaches will enable identification of biological factors that both 
promote osseointegration and underscore its failure. 
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Figure1: 
 
Figure 1.  The result of osseointegration can be appreciated histologically (left).  Note the presence of cells 
within the bone and adjacent to the implant surface as bone has formed over a four week period in a canine 
model.   The process(es) that lead to this result are dependent on the differentiation of mesenchymal stem cells 
to osteoblasts by the process of osteoinduction(right).  The key transcriptional regulators that control 
osteoblastogenesis are Runx2 and Osterix.  One important question regarding implant surface influence on 
osseointegration is “what is the effect of surface on the expression of these transcriptional regulators in implant 
adherent or adjacent cells?”  Committed osteoblasts elaborate a collagen-rich matrix that is embellished with 
bone-specific extracellular matrix proteins that control tissue formation and mineralization.  Many studies have 
revealed that the nature of the implant surface alters the expression of bone-specific extracellular matrix 
proteins.  These fundamental relationships between the implant and cells that produce bone matrix are 
accompanied by many other cell type-implant relationships that have not yet been elucidated. 
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Figure2: 
 
 
Figure 2: Obtaining molecular information from endosseous implants begins by placement of an implant with 
defined surface character into the bone marrow (left).  Intentional explantation of the implant at early time 
points relative to mineralization leads to implant retrieval with adherent cells (center).  When different implant 
surfaces are implanted, retrieval of implants with adherent cells permits the evaluation of adherent cell 
phenotype at the level of protein-encoding mRNA expression.  Anticipated (and repeatedly demonstrated in the 
literature) is the surface-dependent modulation of mRNA expression within the implant-surface adherent cells. 
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Table1: In vivo models used for molecular assessment of osseointegration 
Model Site –intervention if present References 
Rats – Sprague Dawley;Wistar   
 Tibiae [84] [85] [12] [86] [41] [52] [43] 
[47] 
 Femurs [87] [30] [26] [11] [54][53] 
 Femurs- Intramedullary implants [57] [88] 
 Femurs - nicotine exposure [89] 
 Ovariectomzed female rats [11] [90] 
 Tibiae-unloaded by tail 
suspension-osteopenic model 
[91] 
 
 Maxilla [92] 
 Calvarial defects covered by 
teflon membrane and Ti disks 
[82] 
 
New Zealand white rabbits   [81] [93] [94] [95] 
Minipigs Frontal skull [42] 
Mice   
 Mouse Tibiae [96] 
 Femurs ; COX-2−/− and COX-
2+/+ mice  
[97] 
 
Human volunteers  The retromolar area-trephine [13] [83] 
 
Table2: Methods used to assess gene expression adjacent to different implant surfaces in in-vivo models. 
Method used References Role 
Differential display-polymerase chain-
reaction  
[11] Exploratory 
Immunohistology [95] [88] [30] [84] [86] [52][43] Qualitative 
Immunofluorescence [85] Qualitative 
In situ hybridization  [87] [96] [92] Qualitative and semi-
quantitative 
Histochemistry; TRAP and ALP  [96] [84] 
 
Qualitative and semi-
quantitative 
RT-PCR  [57] [30] [26] [54] [90] Semi-quantitative 
qReal-Time-PCR [97] [12] [53] [41] [81] [52] [43] 
[47] [93] [94] [91] [42] [89] 
Quantitative  
Wide genome expression profiling  [13] [83] [82] [30] Quantitative 
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Table 3: Molecular assessment of osseointegration in in-vivo models along with Gene Ontology 
classification 
Genes examined Gene Ontology Classification References 
PCNA (proliferating cell 
nuclear antigen) 
Cell proliferation [85] 
Per2  (period homolog 2) regulation of transcription, DNA-
dependent; circadian rhythm 
[30] 
 
PPARy (peroxisome 
proliferator-activated receptor 
gamma) 
Transcription, DNA-dependent; 
positive regulation of fat cell 
differentiation 
[43] 
 
RUNX2 (runt-related 
transcription factor 2) 
Ossification; osteoblast 
differentiation; transcription 
[96] [57] [12] [41] [81] [43] [47] 
[93] [94] [89] 
Sp7 transcription factor Regulation of transcription; 
osteoblast differentiation 
[42] 
 
ALP (alkaline phosphatase) Skeletal system development; 
biomineral tissue development 
[96] [57] [84] [12] [41] [43] [47] 
[42] 
BSP  
(integrin-binding sialoprotein) 
Ossification; cell adhesion; 
extracellular matrix organization; 
biomineral tissue development 
[12] [41] [26] [90] [95] [89] 
 
OC (Osteocalcin) Skeletal system development; 
osteoblast differentiation; 
osteoblast development; bone 
mineralization; regulation of 
osteoclast differentiation 
[97] [96] [57] [84] [85] [87] [41] 
[81] [26] [54] [43] [47] [90] [93] 
[94] 
OPN (Osteopontin) Ossification; cell adhesion; 
positive regulation of cell-
substrate adhesion; biomineral 
tissue development 
[96] [57] [53] [41] [30] [26] [54] 
[90] [95] [89] [57] 
 
ON (secreted protein, acidic, 
cysteine-rich) (osteonectin) 
Ossification; regulation of cell 
proliferation; cellular response to 
growth factor stimulus 
[53] [87] [30] [26] [90] [95] 
COL1A  
(collagen, type I, alpha 1) 
Skeletal system development; 
blood vessel development; 
osteoblast differentiation; 
intramembranous ossification; 
endochondral ossification 
[96] [57] [87] [30] [81] [26] [54] 
[90] [93] [95] [94] [42] 
 
COL IIA (collagen, type II, 
alpha 1) 
Skeletal system development [96] [30] [26] [54] [95] [89] 
 
COL IIIA (collagen, type III, 
alpha 1) 
skeletal system development; 
blood vessel development; cell-
matrix adhesion 
[90] 
COLIXA (collagen, type IX, 
alpha 1) 
chondrocyte differentiation; cell 
adhesion; organ morphogenesis 
[54] 
COLXA1 (collagen, type X, 
alpha 1) 
 
skeletal system development [30] 
collagen XIIA1 (collagen, type 
XII, alpha 1) 
 
skeletal system development; cell 
adhesion; collagen fibril 
organization 
[92] 
Vinculin  
 
Blood vessel development; 
regulation of Wnt receptor 
signaling pathway; canonical Wnt 
receptor signaling pathway 
involved in positive regulation of 
[52] 
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wound healing 
Fibronectin Extracellular matrix structural 
constituent; angiogenesis; cell 
adhesion; response to wounding; 
cell migration; peptide cross-
linking; platelet activation; 
substrate adhesion-dependent cell 
spreading; leukocyte migration; 
regulation of cell shape 
[53] 
integrin, beta 1 cell migration involved in 
sprouting angiogenesis; cellular 
defense response; cell adhesion; 
cell-matrix adhesion; integrin-
mediated signaling pathway; 
multicellular organismal 
development; cellular response to 
mechanical stimulus 
[26] [52] [90] 
integrin, beta 2 cell-matrix adhesion; integrin-
mediated signaling pathway; cell-
cell signaling; multicellular 
organismal development 
[52] 
integrin, beta 3 cell adhesion; cell-matrix 
adhesion; integrin-mediated 
signaling pathway; regulation of 
bone resorption; leukocyte 
migration; angiogenesis involved 
in wound healing 
[26] [52] [90] 
Decorin & Biglycan organ morphogenesis; wound 
healing; extracellular matrix 
binding ;peptide cross-linking via 
chondroitin 4-sulfate 
glycosaminoglycan; 
[54] 
BMP2 (bone morphogenetic 
protein 2) 
skeletal system development; 
osteoblast differentiation;positive 
regulation of bone mineralization 
[57] [84] [85] [54] [43] [89] 
 
BMP4 (bone morphogenetic 
protein 4); BMP7 (bone 
morphogenetic protein 7); 
osteoblast differentiation; positive 
regulation of pathway-restricted 
SMAD protein phosphorylation; 
positive regulation of bone 
mineralization; 
[57] 
The BMP antagonist Noggin skeletal system development; 
osteoblast differentiation; 
negative regulation of BMP 
signaling pathway 
[57] 
TGF-β 1 (transforming growth 
factor, beta 1) 
chondrocyte differentiation; 
SMAD protein complex 
assembly; regulation of cell 
proliferation; response to 
wounding; regulation of collagen 
biosynthetic process 
[57] [54] [43] 
 
TGF-β2 (transforming growth 
factor, beta 2); TGF-β3 
(transforming growth factor, 
beta 3) 
SMAD protein import into 
nucleus;  cell proliferation 
[57] 
 
TGF-BR1(transforming growth 
factor, beta receptor 1); TGF-
positive regulation of 
mesenchymal cell proliferation; 
[57]  
 
	   79	  
BR2(transforming growth 
factor, beta receptor 2) 
positive regulation of SMAD 
protein import into nucleus 
IGF1  
(insulin-like growth factor 1) 
 
skeletal system development; 
blood coagulation; positive 
regulation of cell proliferation; 
bone mineralization involved in 
bone maturation; positive 
regulation of osteoblast 
differentiation 
[57] [81] 
IGF-1 Receptor 
[IGF-1R]  
 
signal transduction; positive 
regulation of cell proliferation; 
positive regulation of cell 
migration 
[57] 
FGF-2  
(fibroblast growth factor 2 
(basic)) 
 
regulation of cell proliferation; 
wound healing; positive 
regulation of blood 
vessel;regulation of cell cycle 
[91] 
PDGF-B  
(platelet-derived growth factor 
beta polypeptide) 
positive regulation of endothelial 
cell proliferation; monocyte 
chemotaxis; platelet 
degranulation; response to 
wounding 
[43] 
Hif-1 α 
(hypoxia inducible factor 1, 
alpha subunit) 
 
response to hypoxia; positive 
regulation of endothelial cell 
proliferation;transcription, DNA-
dependent; positive regulation 
vascular endothelial growth factor 
production; positive regulation of 
chemokine production; regulation 
of transforming growth factor-
beta2 production  
[91] 
vascular endothelial growth 
factor A 
 
 
Angiogenesis; patterning of blood 
vessels; vasculogenesis; response 
to hypoxia 
[57] [84] [91] 
Fms-like tyrosine kinase 1 [Flt-
1]) 
patterning of blood vessels; 
response to hypoxia; sprouting 
angiogenesis; vascular endothelial 
growth factor receptor signaling 
pathway 
[57]  
 
Epas1 (endothelial PAS domain 
protein 1) 
angiogenesis; response to 
hypoxia; multicellular organismal 
development; cell differentiation 
[91] 
Ang-1 (angiopoietin 1) 
 
regulation of endothelial cell 
proliferation; sprouting 
angiogenesis; leukocyte 
migration; positive chemotaxis 
[91] 
OPG (tumor necrosis factor 
receptor superfamily, member 
11b) 
Skeletal system development; 
apoptosis; extracellular matrix 
organization; negative regulation 
of bone resorption 
[86] 
RANK (tumor necrosis factor 
receptor superfamily, member 
11a, NFKB activator) 
Cell-cell signaling; positive 
regulation of cell proliferation; 
osteoclast differentiation 
[86] 
RANKL (tumor necrosis factor 
(ligand) superfamily, member 
Positive regulation of osteoclast 
differentiation; positive regulation 
[86] [91] 
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11) of bone resorption; cytokine-
mediated signaling pathway 
TRAP (acid phosphatase 5, 
tartrate resistant) 
response to cytokine stimulus; 
bone resorption; bone 
morphogenesis 
[96] [81] [47] [93] [94] [42] [43] 
[91] 
 
catK (Cathepsin K) Proteolysis; bone resorption [53] [43] [47] 
calcitonin receptor Activation of adenylate cyclase 
activity by G-protein signaling 
pathway 
[81] 
H+-ATPase  
 
ATP hydrolysis coupled proton 
transport; proton transport 
[81] 
TNF-α (tumor necrosis factor) Inflammatory response; immune 
response 
[81] [52] [43] [47] [91] [57] [94] 
 
Interleukin 1, beta Inflammatory response; immune 
response; signal transduction; 
cell-cell signaling;  
[52] [43] [47] 
 
Interleukin 6 Inflammatory response; immune 
response 
[81] [94] 
Interleukin 8 receptor Inflammatory response; immune 
response 
[52] 
 
Interleukin 10 Inflammatory response; cell-cell 
signaling; regulation of gene 
expression; leukocyte chemotaxis 
[81] [94] 
Interleukin 11 Inflammatory response; immune 
response 
[91] 
MCP-1 (CCL2)  Angiogenesis; response to 
hypoxia; chemotaxis; 
inflammatory response; cytokine-
mediated - signaling pathway 
[52] [53] 
CXCR4 (chemokine (C-X-C 
motif) receptor 4) 
Response to hypoxia; 
inflammatory response; regulation 
of chemotaxis 
[52] 
 
Cox-1 (prostaglandin-
endoperoxide synthase 1 
(prostaglandin G/H synthase 
and cyclooxygenase) 
Prostaglandin biosynthetic 
process; regulation of cell 
proliferation 
[97] 
Cox-2 (prostaglandin-
endoperoxide synthase 2 
(prostaglandin G/H synthase 
and cyclooxygenase) 
Regulation of inflammatory 
response; response to 
glucocorticoid stimulus 
[97] [57] 
ED1 (CD68 molecule) Marker of macrophages [88] 
CD 163 A marker for tissue macrophage [43] 
Periostin A marker for osteogenic cells [43] 
PGP 9.5 (marker of axons), 
Calcitonin Gene-Related 
peptide (constituent of sensory 
axons and neuropeptide 
involved in bone remodeling), 
GAP-43 (marker of sprouting 
axons) 
 [88] 
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Table 4: Wide genome expression profiling studies in vivo. 
Model Surface examined Technique used Day of analysis Reference 
Retromolar area - 
human 
volunteers-
trephine 
SLA surface vs. 
SLActive 
Human WG-6 V3 
array (Illumina)  
4,7 and 14 days Donos et al, 
2011[13]  
Retromolar area - 
human 
volunteers-
trephine 
SLActive Human WG-6 V3 
array (Illumina) 
4,7 and 14 days Ivanovski,S. et 
al,2011[83] 
 
Calvarial defects 
- Wistar rats total 
covered by teflon 
membrane and Ti 
disks 
Polished Ti- SMO 
vs. microrough 
surface SLA 
Affymetrix Gene 
Chip Rat 
Expression Set 230 
v 2.0 
7 and 14 days Donos et al, 
2011[82] 
 
Rat femur T-shaped Ti4Al6V 
implant-surface 
treated by dual 
acid-etching 
followed by 
cystalline 
deposition of HA 
particles –(tissue 
collected in the 
hollow chamber 
vs. osteotomy sites 
without implants 
were analyzed) – 
control vs. vitamin 
D deficient diet 
Agilent Rat Whole 
Genome- two 
color channel 
microarray-41,000 
genes 
2 weeks Mengatto,C.M et 
al,2011[30] 
 
Rat femur cp Titanium 
implants vs 
osteotomy healing 
sites  
DNA microarray 
where 20,000 rat 
genes (Agilent Rat 
Oligo array, 
Agilent 
Technologies)  
1 wk,2 wks and 4 
wks 
Kojima et al, 2008 
[53] 
Rat femur Experimental cp Ti 
T-shaped implants 
.The implant 
surface was either 
machined (turned 
by a lathe) or 
treated by acid-
etching 
(Osseotite)-(1) the 
osteotomy control 
group, (2) the 
machined titanium 
implant group, and 
(3) the acid-etched 
titanium implant 
group (4) untreated 
control group 
Differential 
display-
polymerase chain-
reaction 
3 days, 1,2 and 4 
weeks post-surgery 
Ogawa,T.et al, 
2006[11] 
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Chapter 3 
Comparative Molecular Assessment of Early Osseointegration in Implant-Adherent Cells: Rat model 
 
Abstract: 
Objective: to identify the early molecular processes involved in osseointegration associated with a micro 
roughened and nanosurface superimposed featured implants.  
Materials and methods: Thirty-two titanium implants with surface topographies exhibiting a micro roughened 
(AT-II) and nanosurface superimposed featured implants (AT-I) were placed in the tibiae of 8 rats and 
subsequently harvested at 2 and 4 days after placement. Total RNA was isolated from cells adherent to retrieved 
implants. A whole genome microarray using the Affymetrix Rat gene 1.1 ST Array followed by validation of 
select genes through qRT-PCR was used to describe the gene expression profiles that were differentially 
regulated by the implant surfaces. 
 Results: Whilst significant differences at the gene level were not noted when comparing the two-implant 
surfaces at each time point, the microarray identified several genes that were differentially regulated at day 4 vs. 
day 2 for both implant surfaces. A total of 649 genes were differentially regulated at day4 vs. day2 in AT-I and 
392 genes in AT-II implants. Functionally relevant categories related to ossification, skeletal system 
development, osteoblast differentiation, bone development, bone mineralization and biomineral tissue 
development were upregulated and more prominent at AT-I (day 4 vs. day2) compared to AT-II. Analysis of the 
downregulated gene lists (day 4 vs. day 2) with average fold change >2 (were not stastically significant) 
revealed the biological processes involved with the inflammatory/immune response gene expression. The 
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number of genes that were associated with the inflammatory/immune response category was greater for AT-I 
than AT-II. 
Conclusions: The presence of nanosurface features modulated in vivo bone response. This work confirms 
previous evaluations and further implicates modulation of the inflammatory/immune responses as a factor 
affecting the accrual of bone mass shortly after implant placement. 
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Introduction: 
      The placement of endosseous implants is a common treatment option to treat edentulism. The success of 
dental implants is based on the concept of osseointegration introduced by Branemark[1]. Despite the high 
success rates achieved, implant failures that mandate implant removal do occur. Factors attributing to implant 
failures include local and systemic conditions such as reduced bone volume, reduced bone density, 
periodontitis, and impaired wound healing (e.g., diabetes, smoking, osteoporosis, radiation therapy, 
chemotherapy) [2-6]. Efforts to enhance osseointegration of dental implants allowing for faster prosthetic 
rehabilitation and improved success rates in clinically challenging situations, included modifications to the 
physical and chemical properties of the implants surfaces. It is well demonstrated that implants with moderately 
rough surfaces (average height deviation of 1-2µm) [7] enhance the rate and quality of osseointegration with 
greater bone-to-implant contact and higher resistance to torque removal[8-12]. 
      In contrast to micron-features of alloplastic materials, bone is composed of constituent nanofeatures[13]. 
Nanostructured materials are those with features less than 100nm in at least one dimension[14]. Simulation of 
nanofeatures at implant surfaces has shown favorable bioactivities with titanium surfaces[15]. Enhanced in vivo 
bone responses to implants with nanofeatures compared to machined or micro roughened surfaces measured by 
histological and biomechanical means have been shown in several animal models (eg, rabbits, dogs, rats) [16-
23]. The topography of titanium surface at the nanolevel has been reported to modulate differentiation, 
proliferation, and increase expression of osteogenic markers[17,24,25]. Yet, the exact role of nanosurface 
topography on the molecular events occurring early in the process of osseointegration remains poorly 
understood. Prior studies mainly focused on select target genes; typically markers for osteoblasts including 
Cbfa1/Runx2 [26,27] , Osterix (Osx) [26-29] , Osteocalcin (Ocn) [30-34] , Osteopontin (Opn) [35-38] , 
Collagen I [39-42]  and Alkaline phosphatase (Alp) [27,29,43,44] .  
      It is of interest to further investigate the overall gene expression profiles by implant adherent cells during 
the early phase of osseointegration. The advent of gene expression microarrays allows the rapid and high-
throughput quantification of thousands of genes simultaneously [45]. Microarray analysis may unveil the 
regulation of individual genes that might not be identified otherwise. These molecular details may represent 
targets for future therapeutic improvement. Most recently, this approach has been applied in vitro in the analysis 
of MG63 osteoblastic- cell response to a nanoporous Ti6AL4V surface (produced by blasting with tricalcium 
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phosphate and light nitric acid treatment; nanoPORE, Out-Link, Sweden and Martina, Due Carrare, Padova, 
Italy) [46]. However, we recognize that the biological environment in vivo is very different from the in vitro 
conditions and contains a variety of cells that each can respond to the implant surface and produce several 
cytokines and growth factors influencing each other’s behavior. Few whole genome-wide profiling studies have 
been reported using in-vivo models [47-49] . Profiles of gene expression of in vivo bone healing with or without 
titanium implants (osteotomy sites) were described in a rat model [48,50] at different time points with 1 week 
time point representing the earliest analysis[50].  Moreover, Donos et al [47]  reported on the gene expression 
profiles associated with a moderately rough surface (SLA) compared to a chemically modified moderately 
rough surface (SLActive) in a human model. The microarray analysis was carried out at 4, 7 and 14 days post 
surgery.  
      Various methods have been developed in order to create a nanosurface. Typically applied techniques 
include lithography, ionic implantation, anodization, acid etching, alkali treatment, peroxidation and sol-gel 
deposition[15,51]. Recently, Johansson et al. [52], reported on a newly developed nanosurface (AT-I) produced 
by sequential chemical treatment with oxalic acid and hydrofluoric acid preceded by blasting with titanium 
oxide particles. These implants were tested in a rabbit model and compared with implants with micro-
roughened surface (AT-II). The results demonstrated greater 2D bone-to-implant contact and 3D removal torque 
values for the nanosurface implants. The objective of the present study was to further investigate the effect of 
this newly developed nanosurface (AT-I) topography imposition on the whole genome expression profiles at 
early time points in the process of osseointegration using an in-vivo rat model and compare it to those of the 
micro-roughened surface (AT-II).  
Materials and methods: 
Implants: 
      Newly developed implant surfaces of commercially pure titanium grade IV screws (2.0mmx3.0mm) were 
used in this study.  The test samples were manufactured per protocol described previously by Johansson et al, 
2011[52]. Briefly, the samples were degreased, blasted with titanium oxide particles and rinsed in sterile water. 
These samples were then treated in a different sequential process resulting in two different surface structures. 
One sample group was treated in oxalic acid, named AT-II, while the other group was treated in oxalic acid and 
hydrofluoric acid sequentially (AT-I). All implants are washed by sterile water and beta-sterilized. 
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Surface characterization: 
      The implant surfaces were examined by a high-resolution scanning electron microscope [ESEM XL30, FEI 
Company,5651 GG Eindhoven, the Netherlands] . The three-dimensional surface parameters were determined 
using optic interferometry (MicroXam, Phase-Shift, Tucson,AZ). Three specimens of each surface type was 
analyzed , and each specimens was analyzed in three areas. Errors of form were removed using a Gausian filter 
size of 50x50mm.  Surface roughness values were reported by the Sa  and Sdr% values per the suggested 
guidelines by Wennerberg A & Albrektsson T for the topographic evaluation of implant surfaces. [53] 
The Sa represents the average height of the analyzed area  
The Sdr represents the developed interfacial area ratio %  
      The chemical nature of the surfaces was examined using X-ray photoelectron spectroscopy (XPS). A 
Quantum 2000 ESCA Scanning Microscope A Quantum 2000ESCA Scanning Microscope (Physical 
Electronics, Chanhassen,MN, USA) with an X-ray source of monochromatic A1Ka was used to obtain a 
spectrum for each surface. The mean numbers and standard deviation (SD) were deduced from measurements of 
three implants per group with two regions per implants resulting in n=6 per implant type. The wettability was 
measured by using the sessile drop technique on titanium coins with the AT-I and AT-II surfaces.  
Model: 
      A rat tibia model of osseointegration was used [18,54]. All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina, Chapel Hill (IACUC ID: 10-127.0). Eight 
male Sprague Dawley rats (326-350 g) were purchased from Harlan laboratories and acclimated for 7 days prior 
to initiation of studies. Anesthesia was achieved using Ketamine/Xylazine (80-100mg/kg and 10 mg/kg 
respectively) along with supplemental local anesthesia (Lidocaine 2% with epinephrine (1:100,000) .The 
dorsal/medial aspect of the tibiae was identified, shaved, and disinfected using betadine and 70% ethanol scrub. 
Using aseptic technique, a full thickness myocutaneous flap was made and carefully retracted to reveal the 
medial aspect of the tibia bone. With sterilized stainless steel burs, two drill holes were created with copious 
irrigation. The drill holes were made approximately 5 mm apart .Two implants (cp titanium) were placed in 
each tibia to provide sufficient RNA for each experimental sample. For every time point (day2 and 4), 4 rats 
were used. Each animal received two AT-I implants in one tibia and two AT-II implants in the contralateral 
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tibia (randomly distributed). The periosteum was adapted over the site using interrupted 4-0 chromic gut sutures 
for subcuticular closure. The skin was then closed using vicryl sutures. Animals were monitored continuously 
following surgery. Ambulation was the defined criteria for immediate recovery. A postoperative analgesic was 
provided for 48 hours after surgery, by means of subcutaneous ketoprofen injections (5mg/kg) once daily. At 
the time of sacrifice, each animal was placed in a CO2—saturated chamber.  Death was assured by thoracotomy 
and severance of the inferior vena cava for exsanguination.  
RNA isolation: 
      At 2 and 4 days following surgery, animals were euthanized. Immediately thereafter, the tibia sites were 
isolated and the implant site was exposed using sterile technique and the entire tibias were harvested and the 
implants were explanted by fracture of the tibia. For evaluation of mRNA expression in cells adherent to 
explanted endosseous implant surfaces, the implants were rinsed in cold PBS immediately following retrieval 
and then placed into 1000 µl of Tri-reagent. Total RNA was isolated from the lysates using the standard Tri-
reagent protocol and collected by ethanol precipitation. This was followed by purification using RNeasy 
MinElute Clean up kit (Qiagen, Valencia, CA, USA).  RNA was assessed for quality and quantity using a 
bioanalyzer (Agilent, Santa Clara, CA, USA) and nanodrop ND-1000 spectrophotometer (Nanodrop, 
Wilmington, DE) respectively. Samples were processed and hybridized to the Affymetrix Rat gene 1.1 ST 
Array at the UNC core facility following the manufacturer’s recommended protocols and reagents (Affymetrix, 
San Clara,CA). The Rat Gene 1.1 ST Array Plate interrogates more than 27,000 well-annotated genes with more 
than 720,000 distinct probes. The raw microarray data is available online at the NCBI-GEO 
(http://www.ncbi.nlm.nih.gov/geo/) database, accession number GSE35976. 
Microarray data analysis:  
      Data analysis was completed using GeneSpring software v.11.5.1 (Agilent Technologies, Santa Clara, CA). 
2-Way ANOVAs statistical analysis was applied to determine differentially expressed genes among the various 
parameters (implant surface type and time points). Further analysis included pairwise comparisons of each 
implant surface independently at the different time points (day4 vs. day 2). A p-value of 0.05 was used as the 
threshold for statistical significance. Exported lists included significant genes, fold changes and p-values for 
comparisons. These lists of genes were then condensed into organized classes of related biology using The GO 
Ontology Browser function in the GeneSpring. Significant GO P<0.05 was corrected for multiple sampling 
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using the method of Benjamini and the Hochberg false discovery rate method[55]. In addition, to focus on the 
major gene expression changes, we analyzed genes with over twofold-changed expression compared to control.  
Real-time quantitative PCR: 
      Following microarray analysis, quantitative real-time PCR (qRT-PCR) was performed using the same RNA 
samples in order to validate expression patterns for select genes. We have selected the following genes for this 
RT-qPCR validation: highly upregulated genes (Phex, Aspn, Satb2), known osteoblast marker (Bsp), highly 
downregulated genes with greater than 2 fold change (Il-1ß, Cxcl2, Ccl3 (all belonged to the inflammatory 
response). First strand cDNA was synthesized (Superscript III, Invitrogen) from total RNA (500 ng) in a 
standard 20-µl reaction. Subsequently, equal volumes of cDNA were used to run real-time PCR reactions 
specific for mRNAs encoding the following markers: phosphate regulating endopeptidase homolog, X-linked 
(Assay ID: Rn00448130_m1), pannexin 3 (Assay ID: Rn01640170_m1), SATB homeobox 2 (Assay ID: 
Rn01438160_m1), Ibsp (Assay ID: Rn00561414_m1), interleukin 1 beta (Assay ID: Rn00580432_m1), 
chemokine (C-C motif) ligand 3 (Assay ID: Rn01464736_g1), chemokine (C-X-C motif) ligand 2(Assay ID: 
Rn00586403_m1). Reactions were performed using TaqMan Universal PCR Master Mix and thermocycling in 
an ABI 7200 real-time thermocyler (Applied Biosystems, Foster City, CA). Relative mRNA abundance was 
determined by the 2− ΔΔCt method and reported as -fold induction. GAPDH mRNA abundance was used for 
normalization[56]. Samples were run in triplicate and the average was used for further analysis. The data points 
analyzed were 2 and 4 days. The surface-matched Day2 was used as a calibrator. 
Results: 
Surface analysis: 
      SEM images (Figure1) revealed a micro-roughened surface for AT-II, whereas AT-I produced by the 
additional treatment of hydrofluoric acid is comprised of nanostructures superimposed on a moderately 
roughened surface. Measurements of surface parameters (Table 1) showed that the two surfaces examined have 
similar Sa values. XPS analysis (Table 2) showed a significantly higher carbon signal for the AT-II sample and 
presence of oxalate in the surface oxide for this sample. Both surfaces were hydrophobic (AT; a contact angle 
of 90-110°, AT-II; a contact angle of ~ 90°). 
Microarray data: 
      To gain insight into the mechanisms by which surface topography influences the process of 
	   96	  
osseointegration, quadriplicate genome wide expression studies of implant adherent cells were performed as a 
function of time (t=2,4 days) with either micro (AT-II) or nanosurface topology implants (AT-I). 
2-Way ANOVA was applied to determine differentially expressed genes among the various parameters (implant 
surface type and time points). No genes were identified (p-value<0.05) to be different when comparing the 2 
implants surfaces at each time point. Further analysis included pairwise comparisons of each implant surface 
independently at the different time points (day 4 vs. day2) to allow understanding of the early molecular events 
occurring at either surface (AT-I, AT-II). 649 genes were found to be differentially expressed (p-value ≤0.05) at 
AT-I; of these, 601 were upregulated, and 48 were downregulated. On the other hand, 392 genes were found to 
be differentially expressed (p≤0.05) at AT-II; of these, 294 were upregulated and 98 were downregulated (Table 
3). The identity of the top 35 genes differentially expressed at the two implants surfaces (day 4 vs. day 2; p-
value<0.05) is shown in tables 4 and 5. Another table (table 6) was created to include list of top 25 differentially 
expressed genes (p-value≤0.05) at AT-I (Day 4 vs. day2) with their fold regulation in AT-I, AT-II. 
Nevertheless, the downregulated subset of genes that reached statistical significance (p-value <0.05) did not 
include any with fold regulation more than 2. The top 25-downregulated genes at AT-I and AT-II are listed in 
tables 7 and 8. 
Validation of Affymetrix microarray data by qRT-PCR 
      The abundance of selected gene transcripts was analyzed on each implant surface at the different time points 
using RT-qPCR. Table 9 summarizes results obtained with the two techniques for the selected genes (Aspn, 
Phex, Satb2, Bsp, Cxcl2, Ccl3, Il-1ß). The results were expressed as mean fold change. Results obtained from 
RT-qPCR were in full concordance with those from microarray, validating our microarray results. 
Identification of significant gene ontologies associated with the different implant surfaces  
      GO analysis was carried out on the differentially regulated genes between day 4 and day 2 (fold change ≥2; 
p ≤0.05) at both implants surfaces. These sets of genes comprised only upregulated genes and did not include 
downregulated genes. As mentioned earlier, the downregulated subset of genes that reached statistical 
significance included only genes with less than 2 fold downregulation. To focus on the major changes that 
might have been caused by reduced expression, another analysis was carried out on the downregulated genes 
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with more than 2 fold  (p-value>0.05).  
GO terms upregulated at AT-I, AT-II (day 4 compared with day 2) 
      The gene functional annotation identified at AT-I consisted of a large variety of processes. 80 terms 
satisfied p≤0.05. Functionally relevant categories relevant to ossification, skeletal system development, skeletal 
system morphogenesis, osteoblast differentiation, bone development, bone mineralization and biomineral tissue 
development were clearly demonstrated at AT-I.  Fourteen genes associated with ossification were differentially 
upregulated (P≤0.05) at AT-I. The increased expression of ossification genes at the AT-I surface is consistent 
with the notion that there is an active and accelerated bone formation at this time point (Day4). These genes 
included Fgfr2 (4.55 fold), Ostn (2.23 fold), Dmp1 (9.67 fold), Bmp3 (8.25 fold), Aspn (14.61 fold), Col11a1 
(5.91 fold), Mef2c (2.03 fold), Col11a2 (2.3 fold), Dlx5 (3.86 fold), Ptn (2.63 fold), Sp7 (3.55 fold), Pth1r (5.88 
fold), Runx2 (2.33 fold) and Satb2 (9.15 fold). This list also demonstrates the representation associated to 
extracellular matrix, developmental processes, cell adhesion, collagen fibril organization and regulation of cell 
proliferation. Interestingly, there was a representation of neurogenesis and axonogenesis.  
      Nevertheless, 70 GO terms satisfied the p-value cut off 0.05 in AT-II. Several functionally GO categories 
were over-represented in the list of genes that were up regulated at AT-II, including the category of extracellular 
matrix, cell adhesion and collagen fibril organization. Likewise to AT-I, neurogenesis was also prominent at 
AT-II. Significantly, the category related to bone was limited to ossification and skeletal system development. 
Bone biomineralization and biomineral tissue development were not identified by this GO analysis at AT-II 
surface. The counts of genes involved in both categories in AT-II were less than those in AT-I; with skeletal 
development count limited to 7 genes in AT-II opposed to 15 genes in AT-II and ossification count limited to 3 
in AT-II opposed to 14 in AT-I.  Furthermore, our results identify higher p-values for both ossification 
(p=0.0025) and skeletal system development (p=0.00122) in AT-II in comparison with the p-values for these 
categories in AT-I (ossification; p-value=8.66E-09, skeletal system development; p-value=1.01E-07). The p-
value for each GO term reflects the enrichment in frequency of that GO term in the entity list, which further 
emphasizes the presence of enhanced bone response in AT-I at this early stage of osseointegration (Day4). 
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GO terms downregulated at AT-I, AT-II (day 4 compared with day 2) 
      Further functional annotation analysis of the downregulated lists of AT-I and AT-II highlighted several 
categories in this domain. 205 terms satisfied p≤0.05 in AT-I, with only 21 terms in AT-II. Table 12 outlines the 
top 25 GO terms in AT-I and table 13 outlines the 21 terms that met the eligibility criteria in AT-II.  
      An overrepresentation of functional annotations associated with inflammatory response, immune response 
and chemotaxis were essentially demonstrated by both surfaces. However, examination of the number of genes 
associated with each GO term in both lists show that AT-I is by far associated with a higher number of genes in 
each functional GO term. This implies that AT-I surface might have a role in rapidly downregulating a wide 
range of genes associated with the inflammatory and immune response processes in the early days following 
implant placement. This is also highlighted when we examine the list of genes downregulated at both surfaces 
(Tables 7 and 8) with further more downregulation of several inflammatory genes at AT-I. We recognize that 
these lists of genes did not reach statistical significance. However, this could be due to the proximity of the two 
data points analyzed.  
Discussion: 
      This study describes the detailed genetic responses to a micro-roughened (AT-II) and nanostructured (AT-I) 
implant surfaces in a rat tibia model. With the advent of o molecular biology techniques, comparative analysis 
of gene expression of a large number of genes spanning a significant fraction of the genome using microarrays 
and not only a few selected activities is possible. This also allows interrogation of broad biological processes as 
well as individual genes. This analysis effectively reveals the early cellular and molecular mechanisms that 
drive the process of osseointegration at both surfaces using the Affymetrix Rat gene 1.1 ST Array. The 
transcriptional analysis described in this study reports the gene expression profiles associated with 
osseointegration at days 2 and 4 following implant placement. The choice of time points was taken to detect 
very early molecular events. 
      Whilst significant differences at the gene level were not noted when comparing the two-implant surfaces at 
each time point, the general trend was striking. Pairwise comparisons of each implant surface at the two time 
points (day 4 vs. day 2) allowed us to further comprehend the initial wound healing process associated with 
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each implant surface. 649 genes were found to be differentially expressed at AT-I and 392 genes were found to 
be differentially expressed at AT-II. The gene expression profile in AT-I at day 4 is characteristic of induced 
bone formation with the over-representation of the functional biological processes related to ossification, 
skeletal system development, osteoblast differentiation and biomineral formation with greater number of genes 
that were up-regulated in each category in response to the AT-I surface compared with the AT-II surface. 
Hence, more rapid bone formation is expected with AT-I surface. This is in agreement with published 
histological and biomechanical data comparing these two implant surfaces at 6 weeks in a rabbit model showing 
greater implant-bone contact and higher torque removal values for AT-I surface compared with AT-II surface 
[52]. The genes associated with skeletogenesis at AT-I included Fgfr2, Ostn, Dmp1, Bmp3, Aspn, Col11a1, 
Mef2c, Col11a2, Dlx5, Ptn, Sp7, Pth1r, Runx2, Satb2, Shox2, Papss2, Pdgfra, Gli3, Mmp2, Tbx15, Ryk, Vdr 
and Phex. Implants placed in the jaws often penetrate the bone marrow cavity coming in direct contact with 
several different cell types including hematopoietic cells, fibroblasts, vascular pericytes and those with an 
osteogenic capacity (including osteoblasts and MSCs), which was definitely the case in our rat tibia model. The 
potential of a surface to elicit osseointegration is dependent on its ability to induce the differentiation of 
pluripotent mesenchymal stem cells along the osteoblast cell lineage and stimulate the secretion of a calcified 
matrix by these osteoblasts [57]. This is orchestrated by several transcriptional factors, among which is 
RUNX2, OSX and SATB2 which regulate the expression of several bone matrix extracellular protein genes that 
encode for bone sialoprotein, osteocalcin and collagen type I [58-61]. Modulation of Runx2 and Osx expression 
by the presence of nanosurface features on implant surfaces topography has been observed by several 
investigations [18,24,26]. Recent evidence showed that SATB2 is a downstream of OSX. Satb2 knock out mice 
exhibit multiple craniofacial defects including a significant truncation of the mandible, a shortening of the oral 
maxillofacial bones, and defects in osteoblast differentiation [61] . The potential role of SATB2 in 
osseointegration has been observed in a recent microarray data demonstrating its differential upregulation (2.5 
fold) on a chemically modified surface (SLActive) between day 4 and day 14 [49] in a human model. Other 
genes in our data lists associated with skeletogenesis that were also upregulated in the aforementioned 
microarray data included COL11A1, COL11A2, PHEX, DLX5, SP7, PTHR1, PTN and PDGFRA. The precise 
role of each of these genes in the modulation of osseointegration requires further investigation.  
      Furthermore, day 4 demonstrated the representation associated to extracellular matrix, cell adhesion, 
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collagen fibril organization and regulation of cell proliferation in both surfaces.  
      We realize that the process of osseointegration maybe affected by regulation of other cells resident  in the 
blood clot and bone marrow. Analysis of implants adherent gene expression profiles that were downregulated at 
day 4 suggested a decline in the inflammatory/immune responses. Even though this subset of genes did not 
reach statistical significance; which could be due to the proximity of the two data points analyzed, its relevance 
is very critical. Indeed, AT-I was by far associated with greater number of genes associated with 
inflammatory/immune responses that were downregulated. Furthermore, this is highlighted with further more 
downregulation of several inflammatory associated genes at AT-I (Tables 7 and 8). The role of implant surface 
topography and/or chemistry on modulating the inflammatory/immune response has been suggested by several 
studies. An in vivo study using the rat tibia model demonstrated a higher expression of Tnf-α (after 6 and 28 
days) and Il-1β (6, 14 and 28 days) on machined surfaces compared to the oxidized implants[62]. Furthermore, 
an in vitro investigation using RAW264.7 cells grown on a nanoscale calcium phosphate coated titanium 
implants elicited a gene expression profile with marked downregulation of several pro-inflammatory cytokines 
(Tnf-α, Il-1β, Il-1f8), chemokines (Ccl2, Ccl3, Ccl5, Ccl8, Ccl11, Ccl12) and the chemokine receptors Ccr1 and 
Xcr1[63]. On the other hand, the effect of chemical modification of titanium implants on macrophage cytokine 
gene expression has been reported; hydrophilic implant surfaces (SLActive) resulted in a significant 
downregulation of key pro-inflammatory cytokines Tnf-α, Il-1α, Il-1β and the chemokine Ccl-2 in RAW 264.7 
cells 24 hours post seeding compared with either smooth polished or sandblasted acid-etched (SLA) surfaces 
[64].  
      These surface specific responses suggest that the presence of nanotopographic cues on the titanium surface 
topography may modulate the various implant adherent cells resulting in unique differential phenotypes 
affecting inflammatory, mesenchymal stem cells, and osteoblastic cells. These biological advantages acquired 
by the imposition of nano-features through triggering of gene expression crucial for osteoblast differentiation, 
skeletal development and the rapid decline in inflammatory related processes in nanosurface adherent cells may 
provide a cardinal role into how we can make more bone faster. However, the present study did not segregate 
potential effects of surface chemistry.  
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Conclusion: 
      The present study investigated experimental surfaces with either nanosurface vs. a moderately rough surface 
in a rat tibia model at early implantation times. Here, initial efforts were deployed to unravel the molecular 
mechanism early in the process of osseointegration associated with micro-roughened and nanosurface dental 
implants. The nanosurface modulates earlier and higher bone repair response as revealed by the recruited 
expression of gene involvements in the processes related to skeletal development, ossification and osteoblast 
differentiation. A potential role of the nanosurface in downregulating the inflammatory/immune responses at a 
faster rate than a micro-roughened surface is implicated. Comprehensive understanding of the complex 
biological events occurring the bone implant interface will ultimately lead to improve biologically driven 
strategies for improved osseointegration.  In this study distinct biochemical responses that underlie the process 
of osseointegration to the nanosurface were revealed, which could not have been observed through the use of 
selected gene studies or through in vitro exams. Further detailed studies using additional points may verify the 
significance of the results obtained. In addition, complementary in vitro and in vivo studies (using genetically 
modified animals) are required to identify the biological roles of the isolated gene transcripts. 
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Figure 1.  Scanning electron microscopic  (SEM) evaluation of tested implant surfaces (a) AT-I surface blasted 
with TiO2 particles and sequentially treated in oxalic and hydrofluoric acid (b) AT-II surface blasted with TiO2 
particles and treated in oxalic acid at 5000X magnification (c) AT-I and (d) AT-II at 50000X.Note that AT-I 
surface is randomly covered with topography features of approximately 100nm. 
 
a                                                                                 b 
 
c                                                                                  d 
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Table 1: 
Surface roughness values as determined by optical interferometry ((MicroXam, PhaseShift). 
Sample Sa (µm) Sdr (%) 
AT-I 1.50 (0.15) 45.52 (8.98) 
AT-II 1.58 (0.16) 66.01 (10.43) 
The mean numbers and standard deviation (SD) are deduced from measurements of three implants per group 
with three regions per implant type (n=27). 
 
 
Table 2:Quantitative chemical surface composition (atomic percentage) as determined by X-ray 
photoelectron spectroscopy (Quantum 2000ESCA Scanning Microscope, Physical Electronics) 
Surface 
type 
C1s N1s O1s Ti2p Si2p F1s 
AT-I 24.48 (5.36) 1.06 (0.59) 52.31 (3.72) 20.88 (3.47) 0.50 (1.11) 0.31(0.79) 
AT-II 30.41 (7.66) 1.40 (0.62) 48.62 (5.02) 19.36 (3.56) 0.13   (0.2)     -----               
The mean numbers and standard deviation (SD) are deduced from measurements of three implants per group 
with two regions per implants resulting in n=6 per implant type. 
 
Table 3. Number of genes differentially expressed (Day 4 vs. Day 2) 
Comparison Differentially 
expressed genes 
* 
Downregulated 
genes* 
Upregulated 
genes* 
Upregulated 
genes with FC 
>2 
Downregulated 
genes with FC 
>2  
AT-I 649 48 601 419 93 
AT-II 392 98 294 314 19 
* Upregulated (>1.1) and downregulated (<1.1) genes with p-value <0.05. FC; fold change 
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Table 4.: List of the top 35 differentially regulated genes at AT-I (Day4 vs. Day2). P-value <0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
Transcripts 
Cluster Id 
Gene 
symbol 
Gene description Fold 
change 
P-
value 
10916247 Panx3 pannexin 3 14.85 0.016 
10797660 Aspn asporin 14.61 0.018 
10933664 Phex phosphate regulating endopeptidase homolog, X-linked 13.14 0.015 
10797657 Omd osteomodulin 10.70 0.020 
10744687 Slc13a5 solute carrier family 13 (sodium-dependent citrate 
transporter), member 5 
10.15 0.018 
10810817 Smpd3 sphingomyelin phosphodiesterase 3, neutral 9.89 0.022 
10775375 Dmp1 dentin matrix acidic phosphoprotein 1 9.67 0.016 
10928191 Satb2 SATB homeobox 2 9.15 0.023 
10775573 Bmp3 bone morphogenetic protein 3 8.25 0.043 
10867761 Mmp16 matrix metallopeptidase 16 7.00 0.022 
10726676 Ifitm5 interferon induced transmembrane protein 5 6.65 0.016 
10853963 Ptprz1 protein tyrosine phosphatase, receptor-type, Z 
polypeptide 1 
6.60 0.020 
10729377 Mamdc2 MAM domain containing 2 6.36 0.015 
10895075 Dcn decorin 6.26 0.044 
10809540 Mmp2 matrix metallopeptidase 2 6.18 0.036 
10869616 Ptprd protein tyrosine phosphatase, receptor type, D 6.14 0.015 
10818502 Col11a1 collagen, type XI, alpha 1 5.91 0.018 
10883212 Cgref1 cell growth regulator with EF hand domain 1 5.90 0.034 
10920524 Pth1r parathyroid hormone 1 receptor 5.88 0.039 
10811248 Adamts18 ADAM metallopeptidase with thrombospondin type 1 
motif, 18 
5.52 0.029 
10896263 Cthrc1 collagen triple helix repeat containing 1 5.43 0.048 
10834982 Cercam cerebral endothelial cell adhesion molecule 5.23 0.015 
10738177 Fkbp10 FK506 binding protein 10 5.22 0.023 
10803323 Cdh2 cadherin 2 5.22 0.016 
10890951 Slc8a3 solute carrier family 8 (sodium/calcium exchanger), 
member 3 
5.02 0.015 
10744939 Serpinf1 serine (or cysteine) peptidase inhibitor, clade F, member 
1 
5.00 0.038 
10759177 Tmem119 transmembrane protein 119 4.96 0.023 
10815679 Mme membrane metallo endopeptidase 4.85 0.023 
10733258 Adamts2 ADAM metallopeptidase with thrombospondin type 1 
motif, 2 
4.80 0.022 
10847474 Creb3l1 cAMP responsive element binding protein 3-like 1 4.76 0.023 
10764050 Fmod fibromodulin 4.76 0.022 
10846340 Fkbp7 FK506 binding protein 7 4.70 0.034 
10729667 Dkk1 dickkopf homolog 1 (Xenopus laevis) 4.69 0.039 
10842500 RGD15628
46 
similar to Docking protein 5 (Downstream of tyrosine 
kinase 5) (Protein dok-5) 
4.63 0.050 
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Table 5. List of the top 35 differentially regulated genes at AT-II (day4 vs. day2). P-value ≤0.05. 
 
 
 
Transcripts 
Cluster Id 
Gene 
symbol 
Gene description Fold 
change 
P-
value 
10933664 Phex phosphate regulating endopeptidase homolog, 
X-linked 
10.90 0.037 
10775375 Dmp1 dentin matrix acidic phosphoprotein 1 9.74 0.036 
10744687 Slc13a5 solute carrier family 13 (sodium-dependent 
citrate transporter), member 5 
7.87 0.046 
10928191 Satb2 SATB homeobox 2 7.22 0.045 
10761446 LOC687426 similar to G protein-coupled receptor 133 6.65 0.031 
10853963 Ptprz1 protein tyrosine phosphatase, receptor-type, Z 
polypeptide 1 
6.02 0.037 
10726676 Ifitm5 interferon induced transmembrane protein 5 5.84 0.032 
10818502 Col11a1 collagen, type XI, alpha 1 5.64 0.047 
10817583 Itga10 integrin, alpha 10 5.60 0.031 
10764050 Fmod fibromodulin 5.38 0.032 
10871775 Rhbdl2 rhomboid, veinlet-like 2 (Drosophila) 5.30 0.031 
10809540 Mmp2 matrix metallopeptidase 2 5.24 0.049 
10729667 Dkk1 dickkopf homolog 1 (Xenopus laevis) 5.23 0.031 
10883212 Cgref1 cell growth regulator with EF hand domain 1 4.98 0.049 
10739455 Gprc5c G protein-coupled receptor, family C, group 5, 
member C 
4.76 0.031 
10890951 Slc8a3 solute carrier family 8 (sodium/calcium 
exchanger), member 3 
4.71 0.031 
10869616 Ptprd protein tyrosine phosphatase, receptor type, D 4.67 0.037 
10715416 Loxl4 lysyl oxidase-like 4 4.50 0.032 
10915131 Fat3 FAT tumor suppressor homolog 3 (Drosophila) 4.39 0.041 
10847474 Creb3l1 cAMP responsive element binding protein 3-like 
1 
4.38 0.032 
10759177 Tmem119 transmembrane protein 119 4.37 0.039 
10733258 Adamts2 ADAM metallopeptidase with thrombospondin 
type 1 motif, 2 
4.33 0.034 
10773435 Cpz carboxypeptidase Z 4.30 0.034 
10744939 Serpinf1 serine (or cysteine) peptidase inhibitor, clade F, 
member 1 
4.23 0.046 
10742766 Slc36a2 solute carrier family 36 (proton/amino acid 
symporter), member 2 
4.20 0.032 
10726620 Sprn shadow of prion protein homolog (zebrafish) 4.16 0.041 
10895075 Dcn decorin 4.06 0.044 
10855348 Zfp862 zinc finger protein 862 3.91 0.034 
10752695 Robo2 roundabout, axon guidance receptor, homolog 2 
(Drosophila) 
3.89 0.037 
10846340 Fkbp7 FK506 binding protein 7 3.88 0.046 
10739449 Gprc5c G protein-coupled receptor, family C, group 5, 
member C 
3.85 0.039 
10860499 Sema3d sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3D 
3.70 0.031 
10715667 Kazald1 Kazal-type serine peptidase inhibitor domain 1 3.67 0.034 
10866535 Rerg RAS-like, estrogen-regulated, growth-inhibitor 3.65 0.031 
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Table 6. List of top 25 differentially expressed genes at AT-I (Day 4 vs. day2) with their fold regulation in 
AT-I, AT-II. 
Gene 
symbol 
Gene description Fold change 
([ATI-Day4] vs 
[ATI-Day2]) 
Fold change 
([ATII-Day4] 
vs [ATII-
Day2]) 
Panx3 pannexin 3 14.85* 10.79 
Aspn asporin 14.61* 6.66 
Phex phosphate regulating endopeptidase homolog, X-linked 13.14* 10.90* 
Bglap bone gamma-carboxyglutamate (gla) protein 12.66 10.05 
Omd osteomodulin 10.70* 7.11 
Slc13a5 solute carrier family 13 (sodium-dependent citrate 
transporter), member 5 
10.15* 7.87* 
Smpd3 sphingomyelin phosphodiesterase 3, neutral 9.89* 6.85 
Dmp1 dentin matrix acidic phosphoprotein 1 9.67* 9.74* 
Satb2 SATB homeobox 2 9.15* 7.22* 
Bmp3 bone morphogenetic protein 3 8.25* 5.93 
Mmp16 matrix metallopeptidase 16 7.00* 5.42 
Ibsp integrin-binding sialoprotein 6.94 4.91 
Ifitm5 interferon induced transmembrane protein 5 6.65* 5.84* 
Ptprz1 protein tyrosine phosphatase, receptor-type, Z 
polypeptide 1 
6.60* 6.02* 
Mamdc2 MAM domain containing 2 6.36* 5.36 
Dcn decorin 6.26* 4.06* 
Mmp2 matrix metallopeptidase 2 6.18* 5.24* 
Ptprd protein tyrosine phosphatase, receptor type, D 6.14* 4.67* 
Col11a1 collagen, type XI, alpha 1 5.91* 5.64* 
Cgref1 cell growth regulator with EF hand domain 1 5.90* 4.98* 
Pth1r parathyroid hormone 1 receptor 5.88* 4.46 
Adamts18 ADAM metallopeptidase with thrombospondin type 1 
motif, 18 
5.52* 5.03 
Cthrc1 collagen triple helix repeat containing 1 5.43* 4.09 
Cercam cerebral endothelial cell adhesion molecule 5.23* 4.49 
 
*P-value <0.05. 
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Table 7. Top 25 downregulated genes at AT-I.  
 
Gene 
symbol 
Gene description Fold change  
([AT-I-Day4] vs. 
[AT-I-Day2]) 
Cxcl2 chemokine (C-X-C motif) ligand 2 -9.74 
Niacr1 niacin receptor 1 -5.88 
Irg1 immunoresponsive 1 homolog (mouse) -5.33 
Car4 carbonic anhydrase 4 -5.06 
Nos2 nitric oxide synthase 2, inducible -4.90 
Ccl3 chemokine (C-C motif) ligand 3 -4.72 
Il1b interleukin 1 beta -4.56 
Cxcl1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha) 
-4.29 
Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 -4.29 
Il1a interleukin 1 alpha -3.73 
G0s2 G0/G1switch 2 -3.72 
Isg15 ISG15 ubiquitin-like modifier -3.64 
Ptgs2 prostaglandin-endoperoxide synthase 2 -3.46 
Il6 interleukin 6 -3.21 
Il23a Interleukin 23, alpha subunit p19 -3.17 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 -3.14 
Upp1 uridine phosphorylase 1 -3.13 
Cxcl3 chemokine (C-X-C motif) ligand 3 -3.10 
Clec4e C-type lectin domain family 4, member e -3.09 
Rab20 RAB20, member RAS oncogene family -3.07 
Ier3 immediate early response 3 -2.96 
Cd274 CD274 molecule -2.81 
Osm oncostatin M -2.74 
Slpi secretory leukocyte peptidase inhibitor -2.73 
Il1rn interleukin 1 receptor antagonist -2.64 
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Table 8. Top 25 downregulated genes at AT-II. 
 
 
Gene symbol Gene description Fold change 
 ([ATII-Day4] vs. [ATII-
Day2]) 
Cxcl2 chemokine (C-X-C motif) ligand 2 -3.22 
Niacr1 niacin receptor 1 -3.08 
Il6 interleukin 6 -2.87 
Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 -2.47 
Upp1 uridine phosphorylase 1 -2.24 
Ass1 argininosuccinate synthetase 1 -2.20 
Rab20 RAB20, member RAS oncogene family -2.20 
Irg1 immunoresponsive 1 homolog (mouse) -2.15 
Il1b interleukin 1 beta -2.13 
Fam111a family with sequence similarity 111, member A -2.12 
G0s2 G0/G1switch 2 -2.10 
Far2 fatty acyl CoA reductase 2 -2.09 
Clec4e C-type lectin domain family 4, member e -2.07 
Prtn3 proteinase 3 -2.06 
Plekhb1 pleckstrin homology domain containing, family B 
(evectins) member 1 
-2.05 
Ms4a3 membrane-spanning 4-domains, subfamily A, member 3 -2.03 
Fetub fetuin B -1.97 
RGD1565374 similar to hypothetical protein LOC199675 -1.96 
Slpi secretory leukocyte peptidase inhibitor -1.94 
Car4 carbonic anhydrase 4 -1.93 
Cxcl3 chemokine (C-X-C motif) ligand 3 -1.87 
Mx2 myxovirus (influenza virus) resistance 2 -1.86 
Tspo translocator protein -1.82 
Nos2 nitric oxide synthase 2, inducible -1.82 
Il1r2 interleukin 1 receptor, type II -1.81 
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Table 9. The validation of the array data was carried out by qRT-PCR of select number of transcripts for 
equal number of AT-I and AT-II samples (n=3). 
 
Gene 
symbol 
Gene 
description 
Affymetrix 
fold change 
AT-I (day 4 
vs. day 2) 
qRT-
PCR fold 
change 
AT-I (day 
4 vs. day 
2) 
Affymetrix 
fold change 
AT-II (day 4 
vs. day 2) 
qRT-PCR fold 
change AT-II(day 4 
vs. day 2) 
Panx3 pannexin 3 14.85* 16.95 10.79 10.18 
Phex phosphate 
regulating 
endopeptidase 
homolog, X-
linked 
13.14* 14.31 10.90* 10.74 
Satb2 SATB 
homeobox 2 
9.15* 10.05 
 
7.22* 7.25 
Ibsp integrin-binding 
sialoprotein 
6.94 7.99 4.91 5.73 
 
Cxcl2 chemokine (C-
X-C motif) 
ligand 2 
-9.74 -10.4 -3.22 - 3.7 
Ccl3 chemokine (C-
C motif) ligand 
3 
-4.72 -4.93 -1.71 - 2.02 
Il1b interleukin 1 
beta 
-4.56 -4.17 -2.13 -2.17 
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Table 10. Top 60 GO terms for differentially regulated genes at AT-I (Day 4 vs Day2). 80 terms satisfied  
p < 0.05  
 
GO 
ACCESSION 
GO Term Corrected p-
value 
Count in Selection 
GO:0031012 extracellular matrix 5.39E-12 24 
GO:0007275 multicellular organismal development 4.90E-10 46 
GO:0032502 developmental process 1.35E-09 50 
GO:0044421 extracellular region part 8.66E-09 24 
GO:0001503 ossification 8.66E-09 14 
GO:0048856 anatomical structure development 1.73E-08 41 
GO:0007155 cell adhesion 1.73E-08 25 
GO:0022610 biological adhesion 1.73E-08 25 
GO:0048731 system development 2.15E-08 38 
GO:0005576 extracellular region 9.42E-08 42 
GO:0001501 skeletal system development 1.01E-07 15 
GO:0005578 proteinaceous extracellular matrix 1.18E-07 14 
GO:0048513 organ development 5.24E-07 28 
GO:0009653 anatomical structure morphogenesis 1.50E-06 23 
GO:0048705 skeletal system morphogenesis 8.29E-06 6 
GO:0002062 chondrocyte differentiation 2.37E-05 7 
GO:0009887 organ morphogenesis 3.24E-05 10 
GO:0031175 neuron projection development 7.56E-05 14 
GO:0048812 neuron projection morphogenesis 7.56E-05 12 
GO:0007409|
GO:0007410 
axonogenesis 8.38E-05 11 
GO:0000904 cell morphogenesis involved in differentiation 8.56E-05 12 
GO:0048666 neuron development 9.23E-05 14 
GO:0048468 cell development 1.02E-04 19 
GO:0030030 cell projection organization 1.53E-04 14 
GO:0048667 cell morphogenesis involved in neuron 
differentiation 
2.46E-04 11 
GO:0048858 cell projection morphogenesis 2.54E-04 12 
GO:0007399 nervous system development 2.71E-04 19 
GO:0048699 generation of neurons 2.71E-04 14 
GO:0032990 cell part morphogenesis 2.71E-04 12 
GO:0007156 homophilic cell adhesion 2.71E-04 10 
GO:0009888 tissue development 2.88E-04 13 
GO:0022008 neurogenesis 3.56E-04 14 
GO:0004222 metalloendopeptidase activity 4.03E-04 10 
GO:0030154 cell differentiation 4.43E-04 27 
GO:0051216 cartilage development 5.73E-04 9 
GO:0005886|
GO:0005904 
plasma membrane 6.57E-04 50 
GO:0000902|
GO:0007148|
GO:0045790|
GO:0045791 
cell morphogenesis 6.57E-04 13 
GO:0048869 cellular developmental process 8.35E-04 27 
GO:0030182 neuron differentiation 8.75E-04 14 
GO:0001649 osteoblast differentiation 9.74E-04 5 
GO:0071944 cell periphery 0.001 50 
GO:0032989 cellular component morphogenesis 0.002 13 
GO:0016337 cell-cell adhesion 0.002 11 
GO:0005509 calcium ion binding 0.003 20 
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GO:0035107 appendage morphogenesis 0.003 7 
GO:0035108 limb morphogenesis 0.003 7 
GO:0030199 collagen fibril organization 0.003 5 
GO:0048736 appendage development 0.004 7 
GO:0060173 limb development 0.004 7 
GO:0008237 metallopeptidase activity 0.004 11 
GO:0043062 extracellular structure organization 0.005 8 
GO:0005913 cell-cell adherens junction 0.005 6 
GO:0060348 bone development 0.006 2 
GO:0030198 extracellular matrix organization 0.007 8 
GO:0030326 embryonic limb morphogenesis 0.007 7 
GO:0035113 embryonic appendage morphogenesis 0.007 7 
GO:0030282 bone mineralization 0.009 4 
GO:0031214 biomineral tissue development 0.009 5 
GO:0042127 regulation of cell proliferation 0.011 13 
GO:0004714 transmembrane receptor protein tyrosine 
kinase activity 
0.014 2 
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Table 11. Top 60 GO terms for the differentially regulated genes at AT-II satisfying the criteria of fold 
upregulation >2 and p-value <0.05. 70 terms satisfying the p-value cut off of 0.05 
GO 
ACCESSION 
GO Term Corrected p-
value 
Count in 
Selection 
GO:0031012 extracellular matrix 3.92E-10 18 
GO:0005576 extracellular region 3.78E-07 32 
GO:0005578 proteinaceous extracellular matrix 3.78E-07 11 
GO:0044421 extracellular region part 6.84E-07 18 
GO:0007155 cell adhesion 7.27E-07 19 
GO:0022610 biological adhesion 7.27E-07 19 
GO:0032502 developmental process 2.98E-05 25 
GO:0048856 anatomical structure development 5.09E-05 21 
GO:0007275 multicellular organismal development 6.86E-05 25 
GO:0030030 cell projection organization 6.86E-05 11 
GO:0048731 system development 1.69E-04 21 
GO:0048699 generation of neurons 2.17E-04 12 
GO:0031175 neuron projection development 4.09E-04 11 
GO:0048468 cell development 5.76E-04 12 
GO:0022008 neurogenesis 6.87E-04 12 
GO:0000904 cell morphogenesis involved in differentiation 7.09E-04 9 
GO:0030198 extracellular matrix organization 7.14E-04 8 
GO:0022603 regulation of anatomical structure 
morphogenesis 
7.75E-04 2 
GO:0048666 neuron development 7.82E-04 11 
GO:0007156 homophilic cell adhesion 8.56E-04 8 
GO:0048812 neuron projection morphogenesis 8.56E-04 9 
GO:0008237 metallopeptidase activity 8.84E-04 10 
GO:0004222 metalloendopeptidase activity 0.001 8 
GO:0001501 skeletal system development 0.001 7 
GO:0043062 extracellular structure organization 0.001 8 
GO:0007409|
GO:0007410 
axonogenesis 0.001 8 
GO:0009653 anatomical structure morphogenesis 0.001 11 
GO:0000902|
GO:0007148|
GO:0045790|
GO:0045791 
cell morphogenesis 0.002 10 
GO:0048858 cell projection morphogenesis 0.002 9 
GO:0032990 cell part morphogenesis 0.002 9 
GO:0001503 ossification 0.003 3 
GO:0030182 neuron differentiation 0.003 11 
GO:0005886|
GO:0005904 
plasma membrane 0.003 35 
GO:0048667 cell morphogenesis involved in neuron 
differentiation 
0.003 8 
GO:0032989 cellular component morphogenesis 0.004 10 
GO:0007399 nervous system development 0.005 15 
GO:0071944 cell periphery 0.005 35 
GO:0045595 regulation of cell differentiation 0.005 3 
GO:0016043 cellular component organization 0.006 20 
GO:0008046 axon guidance receptor activity 0.006 3 
GO:0060284 regulation of cell development 0.009 2 
GO:0021891 olfactory bulb interneuron development 0.009 2 
GO:0030154 cell differentiation 0.009 15 
GO:0030199 collagen fibril organization 0.010 4 
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GO:0021889 olfactory bulb interneuron differentiation 0.013 2 
GO:0048513 organ development 0.013 14 
GO:0048869 cellular developmental process 0.013 15 
GO:0071840 cellular component organization or biogenesis 0.013 20 
GO:0002062 chondrocyte differentiation 0.014 3 
GO:2000026 regulation of multicellular organismal 
development 
0.015 2 
GO:0005592 collagen type XI 0.017 2 
GO:0050925 negative regulation of negative chemotaxis 0.017 2 
GO:0009887 organ morphogenesis 0.018 4 
GO:0016337 cell-cell adhesion 0.021 8 
GO:0051128 regulation of cellular component organization 0.023 2 
GO:0019838 growth factor binding 0.030 1 
GO:0050793 regulation of developmental process 0.030 3 
GO:0009888 tissue development 0.032 5 
GO:0009880 embryonic pattern specification 0.038 2 
GO:0010453 regulation of cell fate commitment 0.038 1 
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Table 12. Top 25 GO terms for downregulated genes at AT-I (Day 4 vs Day 2). 205 terms satisfied p <0.05 
and fold dowregulation >2. 
 
GO 
ACCESSION 
GO Term Corrected p-
value 
Count in 
Selection 
GO:0006954 inflammatory response 1.79E-14 17 
GO:0005126 cytokine receptor binding 1.81E-12 10 
GO:0006952|
GO:0002217|
GO:0042829 
defense response 1.81E-12 19 
GO:0005125 cytokine activity 3.36E-12 13 
GO:0009611|
GO:0002245 
response to wounding 4.65E-12 18 
GO:0009607 response to biotic stimulus 8.17E-12 15 
GO:0006955 immune response 8.61E-11 16 
GO:0006950 response to stress 9.78E-11 23 
GO:0002376 immune system process 2.06E-10 18 
GO:0051707|
GO:0009613|
GO:0042828 
response to other organism 1.56E-09 14 
GO:0051704|
GO:0051706 
multi-organism process 3.37E-09 14 
GO:0009617|
GO:0009618|
GO:0009680 
response to bacterium 1.50E-08 12 
GO:0032496 response to lipopolysaccharide 2.85E-08 10 
GO:0002237 response to molecule of bacterial origin 4.57E-08 10 
GO:0008009 chemokine activity 4.57E-08 7 
GO:0042379 chemokine receptor binding 5.14E-08 7 
GO:0042493|
GO:0017035 
response to drug 8.89E-08 14 
GO:0009605 response to external stimulus 1.26E-07 13 
GO:0030593 neutrophil chemotaxis 1.33E-07 6 
GO:0050896|
GO:0051869 
response to stimulus 1.58E-07 35 
GO:0051384 response to glucocorticoid stimulus 2.02E-07 9 
GO:0031960 response to corticosteroid stimulus 3.71E-07 9 
GO:0050900 leukocyte migration 8.66E-07 7 
GO:0030595 leukocyte chemotaxis 2.32E-06 6 
GO:0060326 cell chemotaxis 4.96E-06 6 
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Table 13. GO terms related to downregulated genes at AT-II. 21 terms satisfied p <0.05 and fold 
dowregulation >2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GO 
ACCESSION 
GO Term corrected p-
value 
Count in 
Selection 
GO:0001780 neutrophil homeostasis 0.008 2 
GO:0001781 neutrophil apoptosis 0.004 2 
GO:0002237 response to molecule of bacterial origin 0.013 4 
GO:0002262 myeloid cell homeostasis 0.016 2 
GO:0002376 immune system process 0.016 6 
GO:0002526 acute inflammatory response 0.016 2 
GO:0005125 cytokine activity 0.047 2 
GO:0006952| 
GO:0002217| 
GO:0042829 
defense response 0.014 5 
GO:0006953 acute-phase response 0.004 2 
GO:0006954 inflammatory response 0.003 5 
GO:0006955 immune response 0.013 5 
GO:0009611| 
GO:0002245 
response to wounding 0.016 5 
GO:0009617| 
GO:0009618| 
GO:0009680 
response to bacterium 0.024 4 
GO:0010574 regulation of vascular endothelial growth factor 
production 
0.016 1 
GO:0030593 neutrophil chemotaxis 0.047 2 
GO:0032496 response to lipopolysaccharide 0.012 4 
GO:0032755 positive regulation of interleukin-6 production 0.047 2 
GO:0033028 myeloid cell apoptosis 0.005 2 
GO:0045429 positive regulation of nitric oxide biosynthetic 
process 
0.047 2 
GO:0050995 negative regulation of lipid catabolic process 0.016 2 
GO:0051707| 
GO:0009613| 
GO:0042828 
response to other organism 0.047 4 
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Chapter 4 
Early molecular assessment of osseointegration in humans 
 
Abstract: 
Objective: To determine the early temporal wide genome transcription regulation by the surface topography at 
the bone-implant interface of implants bearing micro-roughened or superimposed nanosurface topology. 
Materials and methods: Four commercially pure titanium implants (2.2 x5.0mm) with either a moderately 
roughened surface (TiOblast) or super-imposed nanoscale topography (Osseospeed) were placed (n=2/surface) 
in edentulous sites of eleven systemically healthy subjects and subsequently removed after 3 and 7 days. Total 
RNA was isolated from cells adherent to retrieved implants. A whole genome microarray using the Affymetrix 
Human gene 1.1 ST Array was used to describe the gene expression profiles that were differentially regulated 
by the implant surfaces. 
 Results: There were no significant differences when comparing the two-implant surfaces at each time point. 
However, the microarray identified several genes that were differentially regulated at day 7 vs. day 3 for both 
implant surfaces. Functionally relevant categories related to the extracellular matrix, collagen fibril organization 
and angiogenesis were upregulated at both surfaces (day7 vs. day3). Abundant upregulation of several 
differential markers of alternative activated macrophages was observed (eg. MRC1, MSR1, MS4A4A, SLC38A6 
and CCL18). The biological processes involved with the inflammatory/immune response gene expression were 
concomitantly downregulated.  
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Conclusions: Gene regulation implicating collagen fibrillogenesis and extracellular matrix organization as well 
as the inflammatory/immune responses involving the alternative activated pathway are observed in implant 
adherent cells at early (3-7 days) after implantation. These gene expression events may indicate an important 
role for surface in modulating collagen fibrillogenesis as well as immunomodulation that play pivotal roles in 
altering bone accrual and biomechanical physical properties of the implant-bone interface. 
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Introduction: 
      Dental implants are of therapeutic benefit in the pursuit of alloplastic tooth replacement. The success of 
contemporary dental implants is largely attributed to the process of osseointegration. Osseointegration is a term 
defined as the direct structural and functional combination between the bone and the implant at the level of light 
microscopy [1]. The formed bone tissue microstructure is predominantly affected by the remodeling processes 
occurring in the early phase of peri-implant healing at the level of the bone-implant interface [2-4].  The implant 
surface serves as an intricate signaling cue for the attached cells playing an important role in altering the rate 
and quality of osseointegration [5-8]. The different physico/chemical features of the implant surface influence 
the biomolecular and cellular interactions with the implant [9-15]. Roughened surfaces enhance focal adhesion 
formation [16], promote cell commitment to the osteoblastic lineage and support greater expression of 
phenotype specific markers [17-19]. These changes result in greater bone formation evidenced by in-vivo 
histomorphometric and removal torque studies with improved bone anchorage of the roughened titanium 
implants than smoother surfaces [7,20]. In the dynamic research field of implants, a multitude of biomaterial 
modification approaches with nanoscale features have been pursued [21]. Various reports support that 
embellishment of the micron-rough surface with nanoscale features further enhances osteoblast differentiation 
[9,22-24], which could also promote stability and increase interfacial biomechanical locking with bone [25-28].  
      In contrast to the direct bone to implant contact representing osseointegration, fibrous encapsulation of 
implants leading to their failures remains a clinical challenge in situations where there is lack of primary 
implant stability, poor bone quality, or patients with compromised healing capacity such as those with a history 
of head and neck irradiation, uncontrolled diabetes, chronic periodontitis, smoking, etc.[29-31]. Fibrous 
encapsulation represents a repair mechanism of tissue directed by the cellular responses to the implanted device 
environment. 
      A comprehensive understanding of the molecular and cellular processes relevant to peri-implant healing is 
critical for achieving therapeutically relevant targets to positively influence implant osseointegration. Research 
devoted to deciphering the molecular mechanisms controlling implant-bone interface development is mostly 
interrogated through in vitro investigation in cell culture. A systematic review revealed approximately 90% of 
these studies focused on osteoblastic cell model able to differentiate under culture stimulation [32]. Key 
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observations indicated that adhesion to surfaces of increased topographic magnitude results in increased 
osteoinductive and bone matrix specific gene expression. Achieving optimum peri-implant healing requires an 
orchestration of the complex biological and molecular events of cell migration, proliferation, extracellular 
matrix (ECM) deposition, angiogenesis and remodeling. Apposition of a mature mineralized bone matrix is 
dependent on pivotal events of the early healing cascade.  For example, the quality of the bone-implant interface 
may be determined by the hierarchical micro-architecture of its ECM constituents in which collagen plays a 
central role [33]. A recent in vitro investigation described the differential regulation of collagen biosynthesis in 
cells adherent to smooth and rough titanium surfaces [34].  This revealed greater collagen biosynthesis and 
enhanced expression of several collagen-modifying genes including prolyl hydroxylases, lysyl oxidases and 
lysyl hydroxylases within cells adherent to the roughened titanium substrates. Information about the role of the 
aforementioned genes and other potential collagen modifying genes in modulating implant integration in in-
vivo models is still missing.  
      Additionally, among the many factors contributing to non-healing is impairment in the production of 
cytokines by local inflammatory cells and fibroblasts and reduced angiogenesis. Implant adherent macrophages 
and multinuclear cells are detected prior to bone formation at the surfaces of different materials inserted in bone 
[35]. However, their role in osseointegration remains poorly defined. Recent evidence suggests a positive 
influence of macrophages during bone healing in fracture models. Alexander et al [36] demonstrated that 
depletion of macrophages in Mafia transgenic mice is associated with significantly suppressed collagen type I 
bone matrix deposition and mineralization during bone healing in vivo in a tibia fracture model.  
      While in vitro studies can be a valuable tool and provide important insights into the biological mechanisms 
underlying osseointegration, they do not fully recapitulate the complex in-vivo microenvironment [37,38]. 
Various animal models have been used previously to evaluate the early molecular events at the implant surface 
interface. Most studies employed either qRT-PCR or immunohistochemistry [39]. However, these studies are 
limited in the number of genes that could be identified due to the non-global nature of these approaches. A 
recent investigation evaluated early molecular events (day4 vs day2) occurring at either a moderately roughened 
surface (AT-II) or a moderately roughened surface with super-imposed nanofeatures (AT-I) in a rat model using 
Affymetrix array [40]. Functionally relevant categories related to ossification, skeletal system development, 
osteoblast differentiation, bone development, bone mineralization and biomineral tissue development were 
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upregulated and more prominent with at AT-I (day 4 vs. day2) compared to AT-II. However, the bone turnover 
and resorption in a rat is several times faster than in a human [41]. In contrast to the rat model where early signs 
of new bone formation appear within 7 days after implantation and complete bone formation around a 
moderately roughened implant is achieved in 28 days [42- 44], osseointegration in human bone occurs at a 
slower pace and is achieved later [45]. Still, these timelines are significantly affected by the implant surface 
topography [46]. Understanding the kinetics of early phases of healing in human in vivo models of 
osseointegration should be more fully investigated. The aim of this study is to determine the early temporal 
molecular events associated with osseointegration in a human model in the implant adherent cells by assessing 
the whole genome expression profile at days 3 and 7 following the insertion of either a micro-roughened 
implant (TiOblast) or a moderately roughened with superimposed nanofeatures (Osseospeed). 
Materials and methods: 
Preparation of the model implants: 
      Forty-four screw-shaped mini-implants (2.2 x5.0 mm) were manufactured by AstraTech Dental (AstraTech, 
Molndal, Sweden) from grade IV commercially pure titanium. One sample group (n=22) was grit blasted with 
75µm particles TiO2 (AstraTech AB TiOBlastTM), while the other group (n=22) was blasted with TiO2 particles 
in a similar manner and further subjected to HF immersion treatment according to Osseospeed manufacturing 
procedure (AstraTech AB OsseospeedTM). All samples were washed by sterile water and beta-sterilized 
according to standard protocols for manufacture of dental implants. 
     Previous studies on surface roughness, expressed in Sa-values according to the methods described by 
Wennerberg et al. [47] reported Sa-values ~ 1-1.2 µm for TiOBlast implants (TiO-moderately roughened) and 
1.4-1.5 µm for the Osseospeed implants (OS). HF immersion produces discrete 50-200 nm nanofeatures on the 
OS surface (moderately roughened with superimposed nanofeatures). In addition, XPS analysis studies 
identified the presence of fluoride at approximately 1.0 % on the OS surface but not on the TiO surface [22,48]. 
Subjects’ inclusion  
      The study protocol was approved by the Institutional Review Board (IRB) at University of North Carolina at 
Chapel Hill (IRB protocol #10-1963).  
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      Eleven systemically healthy individuals who were either partially or completely edentulous were included in 
this study. The absence of at least 2 teeth, with adequate bone volume to allow placement of four mini-implants 
without impingement on vital anatomical structures (sinuses, nerves and adjacent teeth) and an edentulous 
period of at least 6 months were defined criteria for enrollment. Patients who were smokers, or with any 
systemic condition that could affect bone healing such as uncontrolled diabetes, history of radiotherapy in the 
head and neck region, taking corticosteroids or bisphosphonates, etc, were excluded. Included were 9 females 
and 2 males between the ages 47-69 with a mean age of 60.2. 
Surgery: 
      Prior to surgery, informed written consents to participate in this study were obtained. Panoramic x-rays were 
made to assess the height of the alveolar bone as well as proximity to vital structures in the edentulous planned 
surgical sites. The radiographs were also screened for any pathology. 
      Following anesthesia, two separate crestal incisions approximately 6mm in length were made and full 
thickness mucoperiosteal flaps were raised. Each subject received two TiO and two OS implants. Two 
osteotomies were prepared per site to allow placement of one implant of each surface (1 TiO and 1 OS). This 
paired surgical design permitted the retrieval of the first 2 implants (1 of each surface) at the earlier time point 
without disturbing the healing of the other 2 implants. Drilling was completed using a 2.0 mm twist osteotomy 
drill under profuse irrigation with sterile saline. Single use osteotomy drills were used on each subject. All 
implants were placed by a self-tapping procedure and primary stability at the time of implant placement was 
insured. A submerged implant installation technique was used and the mucosal tissues were closed primarily 
with 4-0 chromic gut sutures. 
Implants retrieval: 
      At 3 and 7 days following surgery, one surgical site was chosen at random, re-entered and the paired (One 
TiO and one OS) implants were removed by reverse threading. The implants were immediately rinsed in cold 
PBS and then placed into 1000 µl of Tri-reagent (Invitrogen, Carlsbad, CA). Cell lysates were snap frozen, and 
stored at -80°C until further use. Tissues were again reapproximated and closed with 4.0 chromic gut sutures.  
RNA isolation and microarray hybridization: 
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      Total RNA was isolated from the lysates using the standard Tri-reagent protocol and collected by ethanol 
precipitation. This was followed by purification using RNeasy MinElute Clean up kit (Qiagen, Valencia, CA, 
USA). RNA was assessed for quality and quantity using a bioanalyzer ( Agilent, Santa Clara, CA, USA) and 
nanodrop ND-1000 spectrophotometer (Nanodrop, Wilmington, DE) respectively. Samples were processed and 
hybridized to the Affymetrix Human Gene 1.1 ST Array at the UNC core facility following the manufacturer’s 
recommended protocol and reagents (Affymetrix, Santa Clara, CA). The Human Gene 1.1 ST Array Plate 
interrogates more than 27,000 well-annotated genes. The raw microarray data is available online at the NCBI-
GEO ((http://www.ncbi.nlm.nih.gov/geo/) database, accession number GSE41446. 
Microarray data analysis: 
      Data analysis was completed using GeneSpring software v.12.0 (Agilent Technologies, Santa Clara, CA). 2-
Way ANOVAs statistical analysis was applied to determine differentially expressed genes among the various 
parameters (implant surface type and time points). Further analysis included pairwise comparisons of each 
implant surface independently at the different time points (day 7 vs. day 3). A p-value of 0.05 was set as the 
threshold for statistical significance. Exported gene lists included significant genes; fold changes and p-values 
for comparisons. These lists of genes were then condensed into organized classes of related biology using the 
GO Ontology Browser function in the GeneSpring. Significant GO (p < 0.05) was corrected for multiple 
sampling using the method of Benjamini and the Hochberg false discovery rate method [49].  
Results: 
Microarray 
      2-Way ANOVA was applied to determine differentially expressed genes among the various parameters 
(implant surface type and time points). No genes were identified (p-value<0.05) to be significantly different 
when comparing the 2 implants surfaces at each time point. Next, pairwise comparisons were made to 
determine the time-course dependent effects on gene expression profiles at either surface (TiO, OS) 
independently (day 7 vs. day3). 6450 genes were found to be differentially expressed (Fold change (FC) >1.1; 
p-value ≤0.05) at OS; of these, 2495 were upregulated, and 3955 were downregulated. On the other hand, 
13,292 genes were found to be differentially expressed (FC>1.1; p≤0.05) at TiO; of these, 3262 were 
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upregulated and 10,030 were downregulated (Table 1). The identity of the top 35 genes differentially 
upregulated at OS implants surfaces (day 7 vs. day 3; p-value<0.05) with their fold regulation in OS and TiO is 
shown in table 2. Another table (table 3) was created to include list of top 35 differentially downregulated genes 
(p-value≤0.05) at Osseospeed (Day 7 vs. day3) with their fold regulation in OS and TiO.  
Identification of significant gene ontologies associated with the different implant surfaces  
      GO analysis was used to identify functional categories overrepresented in the gene lists of the differentially 
upregulated and downregulated genes between day 7 and day 3 (fold change ≥2; p ≤0.05) independently at both 
implants surfaces.  
GO terms upregulated at Osseospeed and TiOblast (day 7 compared with day 3) 
      The gene functional annotation identified at OS and TiO consisted of a large variety of processes. 97 terms 
satisfied p≤0.05 at OS and 216 terms satisfied p≤0.05 at TiO. Table 4 outlines the top 30 GO terms for both 
surfaces. Functionally relevant categories relevant to the extracellular region and matrix, collagen fibril 
organization and blood vessel development were clearly demonstrated at both surfaces. Gene lists of 
differentially expressed genes relevant to the extracellular matrix category, collagen fibril organization, 
ossification and blood vessel development are represented in Table 5. 
      In this study, a high number of genes encoding ECM components were upregulated including several 
collagens (COL1A1, COL1A2, COLA3A1, COL6A1, COL6A3, COL12A1), glycoproteins (SPARC, ECM1, 
CHI3L1, IBSP, GPNMB), and proteoglycans (DCN, BGN, LUM, GPC4). Increased levels of several genes 
involved in collagen biosynthesis, processing and post-translational modifications including PLOD1, PLOD2, 
PLOD3 and LOX were also identified. Differential upregulation of heat shock protein 47 (HSP47) and 
(procollagen C-endopeptidase enhancer) PCOLCE was also evident. In addition, we observed an upregulation 
of several matrix metallopeptidases (MMPs) including MMP2, MMP7, MMP8, MMP9, MMP12, MMP13 and 
MMP14. Upregulation of TIMP2, TIMP3 and A2M was also identified. Furthermore, several phenotypical 
markers characteristic of osteoclast/bone resorption activity including cathepsin K (CTSK), acid phosphatase 5, 
tartrate resistant (ACP5) were increased at both surfaces.  
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      In addition, when we analyzed the lists of the differentially upregulated genes on both surfaces, we 
identified a number of genes (table 6) that have been associated with the alternatively activated macrophage 
(M2) including the membrane receptors mannose receptor, C type 1 (MRC1), macrophage scavenger receptor 
1(MSR1), membrane-spanning 4-domains, subfamily A member 4 (MS4A4A), the solute carrier family 38, 
member 6 (SLC38A6), and the chemokines CCL18, CCL22. 
GO terms downregulated at Osseospeed, TiOBlast (day 7 compared with day 3) 
      Further functional annotation analysis of the differentially downregulated genes at both surfaces highlighted 
several categories in this domain. 97 terms satisfied p≤0.05 in both surfaces. The functional categories 
differentially regulated were the same for both surfaces. Table 7 outlines the top 30 terms. An 
overrepresentation of functional annotations associated with chemotaxis, immune response and inflammatory 
response was demonstrated.  Involved were several chemokines (CCL3, CCL4, CXCL1, CXCL2, CXCL5, 
CCL20), interleukins along with their associated receptors and kinases (IRAK2, IL1RAP, IL1B, IL1A, IL8), 
defensins (DEFA3|DEFA1|DEFA1B, DEFB4A), TREM1 and prostaglandin-endoperoxide synthase 2 (PTGS2).  
Discussion: 
      This study evaluated the global transcription regulation in implant adherent cells to either micro-roughened 
(TiO) or nanostructured (OS) titanium implants at an early phase of osseointegration (day 3 and 7) in human. 
Comparative analysis of gene expression profiles at these early time points did not reveal significant differences 
between both surfaces.  To further comprehend the early molecular events determining the process of 
osseointegration, analysis of the time course dependent changes (day 7 vs. day 3) on each surface was 
performed. 6450 genes were found to be differentially expressed at OS and 13,292 genes were found to be 
differentially expressed at TiO. A large number of genes upregulated at this early phase of osseointegration 
were related to the extracellular matrix and collagen fibril organization. The expression of several collagen 
encoding mRNAs including COL1A1, COL1A2, COL3A1, COL6A1, COL6A2 and COL12A1 was increased. 
Collagens comprise 90% of the organic content of bone [50]. Type I collagen constitutes the major type of 
collagen in bone [51] . Essential to collagen integrity and bone mechanical strength is regulation of 
fibrillogenesis by providing specific molecular bridges between collagen fibrils and other matrix components 
[52]. Type III and type XII collagen modulates the size of type I collagen and play a role in collagen fibril 
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formation [53,54]. Dysregulation of proper fibrillogenesis can ultimately affect bone strength and 
biomechanical properties. For instance, Col12a1 -/-   mice exhibits skeletal abnormalities including shorter, more 
slender long bones with decreased mechanical strength [54]. HSP47 is the molecular chaperone that assists in 
the folding and/or assembly of procollagen [55,56] and it was also upregulated. It is essential for the maturation 
of collagen. Fibrils of type I collagen secreted from hsp47-/- cells are abnormally thin and are more sensitive to 
protease digestion [57]. Collagens types I to III are secreted as procollagen precursors containing N and C 
propeptides that are cleaved to yield mature triple helical monomers that associate into fibrils. BMP1, also 
known as procollagen C proteinase, and related metalloproteinases cleave the C propeptides [58]. Attenuated 
BMP1 function compromises osteogenesis leading to bone fragility due to improper collagen fibrils maturation 
[59]. The activity of BMP1 is potentiated by a secreted glycoprotein, designated the procollagen C-
endopeptidase enhancer [PCOLCE/procollagen C-proteinase enhancer (PCPE)] [60]. An increased expression 
of PCOLCE was identified in the implant adherent cells implicating the role of collagen maturation in achieving 
implant integration. Other non-collagenous proteins involved in ECM assembly and cell matrix interaction were 
also differentially upregulated including various proteoglycans (eg. DCN, BGN, LUM, GPC4) and 
glycoproteins (e.g. SPARC, ECM1, IBSP). Several of the ECM related proteins differentially expressed are 
known to play a direct role in bone formation; lumican [61], SPARC [62], ECM protein1 [63,64] , periostin 
[65], biglycan [66], decorin [67] and IBSP [68]. Decorin, biglycan and lumican are secreted extracellular small 
leucine-rich proteoglycans (SLRPs) that modulate collagen matrix assembly and regulate fibrillogenesis 
[66,67]. An earlier report demonstrated the role of proteoglycans in the establishment of a bone-titanium 
integration where the addition of GAG degradation enzymes significantly reduced the interfacial strength of the 
titanium and the mineralized osteoblastic tissue culture [69]. Enhanced expression of several genes involved in 
the posttranslational modification of collagen was also observed. Included were the Lysyl hydroxylases 
(PLOD1, PLOD2, PLOD3) and the Lysyl oxidase (LOX). These genes encode for proteins involved in 
catalyzing the hydroxylation and the oxidative deamination of specific lysine and/or hydroxylysine residues in 
collagen respectively [70-73]. These posttranslational modifications greatly influence the pattern of collagen 
cross-linking. The organization, density and the amount of cross-linking of collagen determine the mechanical 
strength and ultimately, hierarchical tissue organization .In addition, the type and quantity of cross-linking are 
crucial for proper mineralization [74,75]. This study highlights the role of various ECM related genes during 
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implant healing that might be crucial in the biological and biomechanical establishment of the bone-implant 
interface. These not only provide the structural support and the scaffold for mineralization, but also contain 
reservoirs of cell signaling motifs that may guide subsequent cellular adhesion and behavior [16].  
      In addition, increased expression of various MMPs (MMP7, MMP8, MMP9, MMP13, MMP14) occurred. 
MMPs are zinc-dependent endoproteases, which have the capacity to degrade a variety of extracellular 
components. They are also involved in bone resorption and remodeling by osteoclasts [76]. Establishment of 
osseointegration is a dynamic process; where there is a delicate interplay between bone resorption in contact 
regions and bone formation in contact free regions [77]. Several genes implicated with the osteoclastogenic 
bone resorption were upregulated including CATK and ACP5. Recent histological data in human implicated a 
potential role of osteoclasts in modulating the process of osseointegration, where no new bone formation was 
observed in areas with no prior resorptive processes visible [78,79]. The recruitment and invasion of cells 
during vasculogenesis also involve proteolytic activities and degradation of the extracellular matrix [80]. This 
interrelationship is highlighted by gene deletions in mice demonstrating the essential role of MMPs in the onset 
of angiogenesis in the fracture healing and bone formation [81-83]. Indeed, our bioinformatics analysis revealed 
an overrepresentation of the functional biological processes related to blood vessel development in cells 
adherent to the implant surface.  The development of an elaborate vascular network maybe an important step for 
bone regeneration and successful integration of implants leading to turnover of necrotic bone that develops after 
implant placement. Precise regulation of MMP activity is crucial for preventing excessive ECM degradation 
that can hinder the formation of a functional bone-implant interface. Here, the array data identified differential 
expression of specific tissue inhibitors of metalloproteinases (TIMP2 and TIMP3) as well as the more broad-
spectrum tissue inhibitor (A2M), which suggests the presence of tight mechanisms associated with the early 
remodeling processes. In contrast to most MMPs, MMP-12 (macrophage metalloelastase) which has potent 
extracellular remodeling properties [84], has also been shown to cleave and inactivate human ELR+CXC 
chemokines consistent with a role in controlling the duration of the inflammatory cellular infiltrate of PMNs 
[85]. MMP-12 is mainly expressed by macrophages [86] and its activity is one of the mechanisms to dampen 
inflammation and promote resolution.   
      The osseointegration process is a consequence for the coordinated interplay of several cell types. Implant 
adherent macrophages and multinuclear cells are detected prior to bone formation at the surfaces of different 
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materials inserted in bone [35]. While macrophages have an established role in wound healing through the 
activity of secreted cytokine, their potential influence of macrophages in modulating implant-tissue integration 
has been briefly described. A previous in vivo report demonstrated the preferential accumulation of 
macrophages on rough implant surfaces, which was associated with more rapid bone-like tissue production [87]. 
Furthermore, Cooper and coworkers established utilizing the murine macrophage cell line the influence of 
surface roughness on BMP2 expression, which directly affects osteoblasts cell maturation and bone formation 
[88-90]. In cell culture model, Hamlet et al suggested the potential role for downregulation of a macrophage’s 
pro-inflammatory phenotype including cytokines and chemokines (eg. Tnfα, Ccl2, Ccl5 Il-1ß, Il1α) adjacent to 
nanoscale CaP-modified implants and chemically modified SLActive surfaces as a mechanism for the clinically 
proven superior osseointegration associated with these surface modifications [91,92]. Similarly in a human 
model, Bryington et al[48] demonstrated the influence of the presence of nanofeatures (OS) in mediating an 
immunomodulatory effect on macrophages by enhanced expression of IL-9 (a Th2-associated cytokine that 
reduces monocyte oxidative burst and TNF-α release) [93]) and IL-22 compared with micro-roughened surfaces 
(TiO). 
      The dynamic changes in the presence of polarized macrophages with pro-inflammatory (M1) and anti-
inflammatory (M2) properties may affect the early healing processes to achieve implant-tissue integration. The 
classical ‘M1’ activation of monocytes (eg. LPS- Th1 cytokines-INF γ, IL-1B) leads to the production of the 
pro-inflammatory cytokines such as IL-1 ß, IL-6 and TNF-α, whereas the alternative ‘M2’ macrophage 
activation (IL-4 activated or IL-13 activated-Th2 cytokines) exhibits an anti-inflammatory profile with the 
expression of IL-10. M2 macrophages are able to phagocytose without oxidant production [94] and their 
activation is associated with immunoregulation, matrix deposition and remodeling [95,96]. Omar et al [97] 
revealed surface specific signaling of human monocytes resulting in significantly greater expression of BMP2 
and RUNX2 of hMSCs cultured with conditioned media at oxidized surfaces compared with machined surfaces.  
They implicated a role for classical activation of monocytes (LPS activation) with osteoblast differentiation of 
hMSCs. Their in vivo analysis of LPS coated implants demonstrated an important role for signaling of 
osteoclasts but involving the classically activated monocytes. How alternatively activated macrophages are 
engaged was not directly considered in this previous study. In the present report, however, abundant 
upregulation of genes related to acquisition of M2 properties [98,99] [100] was identified. The data set included 
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the membrane receptors mannose receptor, C type 1 (MRC1), macrophage scavenger receptor 1(MSR1), 
membrane-spanning 4-domains, subfamily A member 4 (MS4A4A), the solute carrier family 38, member 6 
(SLC38A6), and the chemokines (CCL18, CCL22). Indirect and direct co-cultures of either M1 or M2 polarized 
human monocytes with hMSCs revealed their differential effects on the growth of hMSCs  [101] where M2 
macrophages and their associated cytokines supported the growth and proliferation of hMSCs, while M1 
macrophages and their associated cytokines were detrimental to the growth and survival of hMSC. Hence, the 
type of macrophage cells (M2 vs. M1) may potentially impact the early process of osseointegration by 
harnessing the host tissue response towards enhanced survival and function of hMSCs repair cells. M2 
macrophages release various chemokines including CCL18 [102], CCL22 [103] , the anti-inflammatory IL-10 
and TGF ß -1. CCL18 was suggested to play a role at the resolution stage of the inflammatory process as it 
upregulates IL-10, known for its capacity to inhibit production of Th1 cytokines. CCL18 can also induce an M2 
spectrum macrophage phenotype even in the absence of IL-4 [104]. CCL18 activated macrophages can remove 
cellular debris and apoptotic cells in the absence of a respiratory burst. The development of the bone-implant 
interface requires the colonization of the implant surface with MSCs/osteoprogenitors cells and their subsequent 
proliferation and differentiation. Homing of MSCs to the implant site is essential. CCL22 is amongst the 
chemokines that serve as a migratory cue that drive transendothelial migration of MSCs [105]. Consistent with 
the notion where M2 activation stands at the cross road between inflammation and resolution, our array data 
indentified downregulation of several chemokines (CCL3, CCL4, CXCL1, CXCL2, CXCL5, CCL20), 
interleukins along with their associated receptors and kinases (IRAK2, IL1RAP, IL1B, IL1A, IL8), defensins 
(DEFA3|DEFA1|DEFA1B, DEFB4A), TREM1 and prostaglandin-endoperoxide synthase 2 (PTGS2) [106-109]. 
Meanwhile, we also identified the differential upregulation of Chitinase 3-like 1 (CH13L1), also known as 
YKL-40. YKL-40 inhibits cellular responses induced by IL-1 and TNF-α [110] suggesting that the induction of 
YKL-40 feeds back to control local tissue responses. While a general picture of selection of M2 macrophages 
and diminished inflammation emerges in the context of the bone forming events at endosseous implants, further 
characterization of the roles of M2 macrophage is required. 
      Histomorphometric data using several animal models [26,111] demonstrates differential bone formation at 
the two surfaces annotated here (OS > TiO). Analysis of differential gene expression at this early time failed to 
identify significant differences between both surfaces. Moreover, upregulation of osteoblast differentiation 
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transcription factors was not demonstrated. In contrast, Bryington et al [48] were able to demonstrate a 
differential upregulation of OSX, a key transcription factor for osteoblast differentiation on the nanoscale 
featured implants compared with the microtopography TiOblast surface. A possible factor contributing to this 
difference is the age of the population included. In our study, the mean age was 60 years old as opposed to 36 
year old in Bryington et al study. MSCs are susceptible to age-related changes. MSCs from older donors have 
an overall decline in their differentiation potential [112-114]. This implicates that modulation of osteogenic 
gene expression might have been delayed in our aging population. Hence, further investigations using later time 
periods may be needed to identify key elements essential for modulating the osteoblast differentiation. In 
support of this speculation, a previous study [115] using a trephine model of the peri-implant tissue in the 
retromolar area has identified sequential inflammatory (days 4), angiogenic (days 7) and osteogenic (days14) 
responses involved in the process of osseointegration. These repair responses were evaluated with SLA, 
SLActive implants. In addition, while this study incorporated the use of Affymetrix microarray, Bryington et al 
[48] utilized qRT-PCR to identify differential gene expression in implant adherent cells. Differences in the 
sensitivity of the platforms used for assessing mRNA gene expression might have contributed to the differences 
in the results obtained [116].  
      Our explanted model with implant adherent cells provides important information critical to driving the 
process of osseointegration at the implant-bone interface. One limitation to this approach is the scarcity of the 
RNA quantity on human explanted implants in this population that did not allow further validation of our 
microarray data using qRT-PCR.  
Conclusions: 
      The present study investigated the global transcription regulation in implant adherent cells adherent to either 
a nanosurface or a moderately rough surface in a human model at early implantation times. In this study, novel 
biomolecular and cellular responses that underlie the process of osseointegration at this early phase were 
revealed. These genes exert a multitude of functions including ECM matrix organization, immune modulation, 
angiogenesis and skeletal remodeling. Numerous genes associated with the fibrillogenesis and cross-linking of 
the collagen matrix were identified. In addition, key markers for the alternatively activated ‘M2’ macrophage 
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were revealed. Further characterization of the roles of the genes identified is crucial to identifying potential 
targets for improving osseointegration. 
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Table 1: Number of genes differentially expressed (Day 7 vs. Day 3) 
 
 
 
 
 
* Upregulated (>1.1) and downregulated (<1.1) genes with p-value <0.05. FC; fold change 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison Differentially 
expressed genes * 
Upregulated 
genes* 
Downregulated 
genes* 
Differentially 
expressed (FC>2) 
OS 6450 2495 3955 163 
TiO 13292 3262 10,030 269 
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Table 2:List of top 35 differentially upregulated genes at OS (Day 7 vs. day3) with their fold regulation 
and p-value in OS and TiO. 
 
 
Gene 
symbol 
Gene description FC 
([OS-
Day7] vs 
[OS-
Day3]) 
p-
value  
FC  
([TiO-
Day7] vs 
[TiO-
Day3]) 
p-
value 
CTSK cathepsin K 8.21 0.008 8.66 0.002 
MMP12 matrix metallopeptidase 12 (macrophage 
elastase) 
8.10 0.015 11.73 0.003 
MMP9 matrix metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 
7.03 0.008 9.14 0.002 
MMP7 matrix metallopeptidase 7 (matrilysin, 
uterine) 
6.91 0.014 9.73 0.004 
TCTEX1D2|
TM4SF19/// 
TM4SF19 
Tctex1 domain containing 2 | transmembrane 
4 L six family member 19///transmembrane 4 
L six family member 19 
5.67 0.011 7.53 0.002 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 4.92 0.013 8.72 0.003 
LUM lumican 4.84 0.019 5.53 0.002 
COL6A3 collagen, type VI, alpha 3 4.50 0.013 4.79 0.002 
COL3A1 collagen, type III, alpha 1 4.50 0.014 4.84 0.002 
POSTN periostin, osteoblast specific factor 4.47 0.014 4.13 0.003 
COL1A1 collagen, type I, alpha 1 4.44 0.014 4.68 0.002 
DCN decorin 3.94 0.019 4.16 0.003 
CHIT1 chitinase 1 (chitotriosidase) 3.87 0.033 7.50 0.007 
ACP5 acid phosphatase 5, tartrate resistant 3.81 0.010 4.32 0.004 
GM2A GM2 ganglioside activator 3.77 0.013 4.86 0.002 
PNLIP| 
COL1A2/// 
COL1A2 
pancreatic lipase | collagen, type I, alpha 
2///collagen, type I, alpha 2 
3.75 0.015 3.73 0.002 
COL12A1 collagen, type XII, alpha 1 3.41 0.015 3.16 0.003 
TPM2 tropomyosin 2 (beta) 3.40 0.008 2.95 0.002 
SPARC secreted protein, acidic, cysteine-rich 
(osteonectin) 
3.35 0.014 4.21 0.002 
BGN biglycan 3.29 0.016 4.20 0.002 
LPL lipoprotein lipase 3.17 0.026 3.48 0.008 
GPNMB glycoprotein (transmembrane) nmb 3.07 0.021 3.77 0.003 
MSR1 macrophage scavenger receptor 1 3.05 0.022 2.78 0.006 
C1QB complement component 1, q subcomponent, 
B chain 
3.04 0.016 3.49 0.004 
MMP13 matrix metallopeptidase 13 (collagenase 3) 3.03 0.026 2.43 0.010 
COL6A1 collagen, type VI, alpha 1 3.00 0.013 3.01 0.002 
CDR1|YTHD
C2 
cerebellar degeneration-related protein 1, 
34kDa | YTH domain containing 2 
2.98 0.016 2.82 0.005 
HIST1H3B histone cluster 1, H3b 2.93 0.014 2.84 0.004 
C1QC complement component 1, q subcomponent, 
C chain 
2.87 0.023 1.55 NS 
LIPA lipase A, lysosomal acid, cholesterol esterase 2.84 0.024 2.68 NS 
CCL22 chemokine (C-C motif) ligand 22 2.82 0.020 5.76 
 
0.006  
 
 
BIRC5|EPR1 baculoviral IAP repeat-containing 5 | effector 
cell peptidase receptor 1 (non-protein 
2.70 0.013 2.05 
 
0.008 
	   137	  
coding)  
CCL18 chemokine (C-C motif) ligand 18 
(pulmonary and activation-regulated) 
2.70 0.027 2.56 0.005 
CKB creatine kinase, brain 2.67 0.025 2.17 0.017 
ATP1B1|NM
E7 
ATPase, Na+/K+ transporting, beta 1 
polypeptide | non-metastatic cells 7, protein 
expressed in (nucleoside-diphosphate kinase) 
2.67 0.018 2.50 0.007 
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Table 3:List of top 35 differentially downregulated genes at OS (Day 7 vs. day3) with their fold regulation 
and p-value in OS and TiO. 
 
Gene 
symbol 
Gene 
description 
FC 
([OS-
Day7] vs 
[OS-
Day3]) 
p-
value  
FC  
([TiO-
Day7] vs 
[TiO-
Day3]) 
p-
value 
DEFA3|DEFA
1|DEFA1B 
defensin, alpha 3, neutrophil-specific | 
defensin, alpha 1 | defensin, alpha 1B 
-3.03 0.016 -2.80 0.014 
SPRR2A|SPR
R2B 
small proline-rich protein 2A | small 
proline-rich protein 2B 
-2.90 0.040 -3.00 0.014 
SPRR2E small proline-rich protein 2E -2.75 0.037 -2.87 0.018 
IL1B interleukin 1, beta -2.60 0.019 -3.58 0.008 
KRT6C|KRT6
B|KRT6A 
keratin 6C | keratin 6B | keratin 6A -2.58 0.038 -2.27 0.017 
ALOX5AP arachidonate 5-lipoxygenase-activating 
protein 
-2.35 0.021 -3.00 0.005 
CXCL1 chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha) 
-2.24 0.022 -2.80 0.013 
LIPN lipase, family member N -2.23 0.036 -2.20 0.048 
S100A2 S100 calcium binding protein A2 -2.19 0.039 -2.41 0.025 
PTGS2 prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
-2.18 0.045 -2.20 NS 
CYTIP cytohesin 1 interacting protein -2.16 0.021 -4.67 NS 
TMEM154 transmembrane protein 154 -2.15 0.022 -2.06 0.045 
CSF3R colony stimulating factor 3 receptor 
(granulocyte) 
-2.12 0.032 -2.25 0.009 
IL1A interleukin 1, alpha -2.11 0.033 -2.92 0.009 
RGS2 regulator of G-protein signaling 2, 24kDa -2.11 0.022 -2.00 NS 
MIR222 microRNA 222 -2.06 0.027 -1.67 0.009 
RNU11 RNA, U11 small nuclear -2.02 0.025 -2.23 0.031 
SPRR1B small proline-rich protein 1B (cornifin) -1.99 0.039 -1.94 0.016 
NCF1|NCF1C|
NCF1B 
neutrophil cytosolic factor 1 | neutrophil 
cytosolic factor 1C pseudogene | neutrophil 
cytosolic factor 1B pseudogene 
-1.98 0.034 -1.95 0.020 
GPR97 G protein-coupled receptor 97 -1.98 0.029 -2.49 0.023 
SPRR2D|SPR
R2B///SPRR2
B|SPRR2F|SP
RR2D///SPRR
2A|SPRR2B///
SPRR2B 
small proline-rich protein 2D | small 
proline-rich protein 2B///small proline-rich 
protein 2B | small proline-rich protein 2F | 
small proline-rich protein 2D///small 
proline-rich protein 2A | small proline-rich 
protein 2B///small proline-rich protein 2B 
-1.97 0.041 -2.07 0.022 
FPR1 formyl peptide receptor 1 -1.96 0.031 -2.04 0.030 
IER3 immediate early response 3 -1.96 0.029 -2.27 0.030 
IL1R2 interleukin 1 receptor, type II -1.96 0.039 -1.74 ns 
FOS FBJ murine osteosarcoma viral oncogene 
homolog 
-1.96 0.012 -1.22 0.038 
SORL1 sortilin-related receptor, L(DLR class) A 
repeats-containing 
-1.95 0.034 -1.71 0.020 
IL1RAP interleukin 1 receptor accessory protein -1.92 0.036 -2.29 0.015 
KCNJ15 potassium inwardly-rectifying channel, -1.90 0.023 -2.00 0.021 
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subfamily J, member 15 
TREM1 triggering receptor expressed on myeloid 
cells 1 
-1.89 0.037 -2.59 0.017 
DUSP1 dual specificity phosphatase 1  -1.87 0.020 -1.58 ns 
ZFP36 zinc finger protein 36, C3H type, homolog 
(mouse)  
-1.87 0.032 -1.99 ns 
MIR223 microRNA 223  -1.85 0.030 -1.79 ns 
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Table 4: Top 30 GO terms for differentially upregulated genes at both surfaces (Day 7 vs. Day3). 98 
terms satisfied p <0.05 at OS; 216 terms satisfied p < 0.05 at TiO. 
 
 
GO Term - OS p-value  
(OS) 
Count in 
Selection 
(OS) 
GO Term - TiO p-value  
(TiO) 
Count in 
Selection 
(TiO) 
extracellular region part 3.59E-20 47 extracellular region part 2.89E-15 49 
proteinaceous 
extracellular matrix 
2.47E-16 27 proteinaceous 
extracellular matrix 
1.61E-13 28 
extracellular matrix 2.47E-16 28 extracellular matrix 1.61E-13 29 
extracellular region 2.67E-14 57 extracellular region 4.79E-10 62 
extracellular space 2.66E-10 30 extracellular space 7.65E-08 32 
Extracellular matrix 
organization 
2.66E-10 14 cytoplasmic part 7.65E-08 103 
extracellular structure 
organization 
2.66E-10 14 extracellular matrix 
part 
8.92E-08 14 
extracellular matrix part 8.31E-10 14 localization 1.05E-06 72 
collagen fibril 
organization 
3.59E-08 8 melanosome 2.17E-06 12 
collagen 8.29E-07 8 pigment granule 2.17E-06 12 
collagen metabolic 
process 
9.39E-06 7 collagen fibril 
organization 
1.82E-05 7 
multicellular 
organismal 
macromolecule 
metabolic process 
1.62E-05 7 establishment of 
localization 
2.89E-05 63 
multicellular 
organismal process 
4.21E-05 66 cell surface 3.00E-05 18 
multicellular 
organismal metabolic 
process 
4.21E-05 7 mitochondrial inner 
membrane 
3.65E-05 18 
fatty acid binding 4.25E-05 6 transport 3.93E-05 62 
pattern binding 1.09E-04 11 mitochondrial 
membrane 
4.23E-05 21 
polysaccharide binding 1.09E-04 11 mitochondrial envelope 8.55E-05 21 
lipid binding 1.81E-04 17 organelle inner 
membrane 
8.68E-05 18 
tissue remodeling 3.31E-04 7 anatomical structure 
development 
8.68E-05 59 
cellular component 
organization 
5.38E-04 43 regulation of plasma 
lipoprotein particle 
levels 
8.68E-05 7 
monocarboxylic acid 
binding 
7.23E-04 6 multicellular 
organismal process 
8.83E-05 83 
platelet-derived growth 
factor binding 
0.0018 4 blood vessel 
development 
8.94E-05 15 
carbohydrate binding 0.0018 14 vasculature 
development 
1.21E-04 15 
cellular component 
organization or 
biogenesis 
0.0019 43 collagen 1.30E-04 7 
extracellular matrix 
binding 
0.0021 5 extracellular matrix 
organization 
1.79E-04 10 
fibrillar collagen 0.0021 4 extracellular structure 
organization 
1.79E-04 10 
ossification 0.0026 8 system development 2.20E-04 52 
blood vessel 
development 
0.0026 11 mitochondrial 
membrane part 
2.29E-04 11 
glycosaminoglycan 0.0026 9 mitochondrial part 2.37E-04 24 
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glycosaminoglycan 
binding 
0.0026 9 mitochondrial part 2.37E-04 24 
collagen biosynthetic 
process 
0.0026 3 cholesterol transport 2.48E-04 7 
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Table 5: list of differentially expressed genes in the functional categories related to ECM and collagen 
fibril organization, blood vessel development, ossification and osteoclastogenesis. 
Extracellular matrix and collagen fibril organization 
Gene 
description 
Gene 
symbol 
FC [OS-D7 
vs OS-D3] 
p-value FC [TiO- 
D7 vs 
TiO-D3] 
p-value 
periostin, osteoblast specific 
factor 
POSTN 4.47 0.014 4.13 0.003 
chitinase 3-like 1 (cartilage 
glycoprotein-39) 
CHI3L1 4.92 0.013 8.72 0.003 
collagen, type I, alpha 1 COL1A1 4.44 0.014 4.68 0.002 
pancreatic lipase | collagen, 
type I, alpha 2///collagen, type 
I, alpha 2 
PNLIP|COL1A
2///COL1A2 
 
3.75 
0.015 3.73 0.002 
collagen, type III, alpha 1 COL3A1 4.50 0.014 4.84 0.002 
collagen, type VI, alpha 1 COL6A1 3.00 0.013 3.01 0.002 
collagen, type VI, alpha 3 COL6A3 4.50 0.013 4.80 0.002 
collagen, type XII, alpha 1 COL12A1 3.41 0.015 3.16 0.003 
coiled-coil domain containing 
80 
CCDC80 2.19 0.027 1.90 0.011 
decorin DCN 3.94 0.019 4.16 0.003 
extracellular matrix protein 1 ECM1 2.01 0.011 1.86 0.003 
glypican 4 GPC4 1.89 0.024 2.60 0.006 
annexin A2 ANXA2 2.18 0.015 2.34 0.003 
tenascin C TNC 2.05 0.028 2.38 0.005 
lectin, galactoside-binding, 
soluble, 1 
LGALS1 1.90 0.013 2.02 0.002 
lysyl oxidase LOX 2.07 0.027 1.87 0.020 
procollagen-lysine 1, 2-
oxoglutarate 5-dioxygenase 1 
PLOD1 1.77 0.013 1.90 0.002 
procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 2 
PLOD2 2.22 0.018 1.75 0.032 
procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 3 
PLOD3 1.45 0.021 1.53 0.006 
lipoprotein lipase LPL 3.17 0.026 3.48 0.008 
lumican LUM 4.84 0.019 5.53 0.002 
matrix metallopeptidase 2 
(gelatinase A, 72kDa 
gelatinase, 72kDa type IV 
collagenase) 
MMP2 1.87 0.029 1.81 0.008 
matrix metallopeptidase 7 
(matrilysin, uterine) 
MMP7 6.91 0.014 9.73 0.004 
matrix metallopeptidase 8 
(neutrophil collagenase) 
MMP8 2.46 0.018 3.24 0.008 
matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 
MMP9 7.03 0.008 9.14 0.002 
matrix metallopeptidase 12 
(macrophage elastase) 
MMP12 8.10 0.015 11.73 0.003 
matrix metallopeptidase 13 
(collagenase 3) 
MMP13 3.03 0.026 2.43 0.011 
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matrix metallopeptidase 14 
(membrane-inserted) 
MMP14 2.35 0.013 2.51 0.002 
 CD248 2.20 0.019 2.03 0.010 
biglycan BGN 3.29 0.016 4.20 0.002 
solute carrier family 1 (glial 
high affinity glutamate 
transporter), member 3 
SLC1A3 1.75 0.028 2.16 0.008 
secreted protein, acidic, 
cysteine-rich (osteonectin) 
SPARC 3.35 0.014 4.21 0.002 
transforming growth factor, 
beta-induced, 68kDa 
TGFBI 2.05 0.018 1.78 0.005 
TIMP metallopeptidase 
inhibitor 2 
TIMP2 2.09 0.013 2.11 0.002 
TIMP metallopeptidase 
inhibitor 3 
TIMP3 2.58 0.013 2.62 0.005 
alpha-2-macroglobulin A2M 2.49 0.020 2.87 0.006 
calreticulin CALR 1.72 0.024 2.02 0.005 
procollagen C-endopeptidase 
enhancer 
PCOLCE 2.50 0.017 2.12 0.006 
serpin peptidase inhibitor, 
clade H (heat shock protein 
47), member 1, (collagen 
binding protein 1)  
SERPINH1 2.12 0.015 1.98 0.005 
Ossification 
glycoprotein (transmembrane) 
nmb 
GPNMB 3.07 0.021 3.77 0.003 
collagen, type I, alpha 1 COL1A1 4.44 0.014 4.68 0.002 
extracellular matrix protein 1 ECM1 2.01 0.011 1.86 0.003 
integrin-binding sialoprotein IBSP 2.00 0.034 1.96 0.023 
ectonucleotide 
pyrophosphatase/phosphodiest
erase 1  
ENPP1 2.13 0.037 1.94 0.006 
Osteoclast-related genes 
cathepsin K CTSK 8.21 0.008 8.66 0.002 
acid phosphatase 5, tartrate 
resistant 
ACP5 3.81 0.009 4.32 0.004 
matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 
MMP9 7.03 0.008 9.14 0.002 
matrix metallopeptidase 14 
(membrane-inserted) 
Mmp14 2.35 0.013 2.51 0.002 
integrin, alpha V (vitronectin 
receptor, alpha polypeptide, 
antigen CD51) 
 1.99 0.016 2.03 0.003 
integrin, beta 3 (platelet 
glycoprotein IIIa, antigen 
CD61)  
ITGB3 1.83 0.047 1.84 0.017 
Blood vessel development  
collagen, type I, alpha 1 COL1A1 4.44 0.014 4.68 0.002 
pancreatic lipase | collagen, 
type I, alpha 2///collagen, type 
I, alpha 2 
PNLIP|COL1A
2///COL1A2 
 
3.75 
0.015 3.73 0.002 
collagen, type III, alpha 1 COL3A1 4.50 0.014 4.84 0.002 
endothelial PAS domain 
protein 1 
EPAS1 2.01 0.015 2.09 6.43E-04 
annexin A2 ANXA2 2.18 0.020 2.34 0.003 
apolipoprotein E | high 
mobility group AT-hook 
APOE|HMGA1
///HMGA1 
1.92 0.017 2.08 0.007 
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apolipoprotein E | high 
mobility group AT-hook 
1///high mobility group AT-
hook 1 
APOE|HMGA1
///HMGA1 
1.92 0.017 2.08 0.007 
apolipoprotein E | high 
mobility group AT-hook 1 
APOE|HMGA1 2.33 0.020 2.65 0.005 
interleukin 18 (interferon-
gamma-inducing factor) 
IL18 2.04 0.013 2.27 0.004 
integrin, alpha V (vitronectin 
receptor, alpha polypeptide, 
antigen CD51) 
ITGAV 1.99 0.016 2.03 0.003 
lysyl oxidase LOX 2.07 0.030 1.87 0.020 
matrix metallopeptidase 14 
(membrane-inserted) 
MMP14 2.35 0.013 2.51 0.002 
myosin IE MYO1E 2.05 0.023 2.15 0.009 
ATP synthase, H+ 
transporting, mitochondrial F1 
complex, beta polypeptide 
ATP5B 1.82 0.018 2.34 0.004 
tumor necrosis factor receptor 
superfamily, member 12A 
TNFRSF12A 1.89 0.015 2.28 0.004 
Thy-1 cell surface antigen THY1 2.50 0.022 2.51 0.005 
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Table 6: list of genes differentially expressed relevant to alternative activation of macrophages pathway 
(M2) 
Gene 
description 
Gene 
symbol 
FC [OS D7 vs 
D3] 
p-value FC [TiO D7 vs 
D3] 
p-value 
mannose receptor, C 
type 1 | mannose 
receptor, C type 1-like 1 
MRC1|MRC1L
1 
1.79 0.025 1.54 0.017 
macrophage scavenger 
receptor 1 
MSR1 3.05 0.022 2.78 0.006 
membrane-spanning 4-
domains, subfamily A, 
member 4 
MS4A4A 2.05 0.019 1.99 0.009 
chemokine (C-C motif) 
ligand 22 
CCL22 2.82 0.020  5.76 
 
 
0.006  
 
 
chemokine (C-C motif) 
ligand 18 (pulmonary 
and activation-regulated) 
CCL18 2.70 0.027 2.56 0.005 
solute carrier family 38, 
member 6 
SLC38A6 2.14 0.02205
3376 
2.78 0.002 
transforming growth 
factor, beta-induced, 
68kDa 
TGFBI 2.05 0.018 1.78 0.005 
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Table 7: Top 30 downregulated genes at both surfaces.  
GO ID GO Term P-value Count in 
Selection 
5051 chemotaxis 5.80E-16 20 
19177 taxis 5.80E-16 20 
5637 chemokine activity 4.18E-13 11 
19226 chemokine receptor binding 7.63E-13 11 
19080 response to chemical stimulus 1.06E-12 37 
18862 locomotion 5.74E-12 21 
3707 cytokine activity 1.16E-11 15 
5065 immune response 1.18E-11 23 
6918 response to external stimulus 1.55E-11 22 
6924 response to wounding 3.60E-11 20 
3708 cytokine receptor binding 5.20E-11 14 
5062 defense response 5.20E-11 22 
5064 inflammatory response 7.49E-11 16 
1699 immune system process  7.77E-11 26 
5061 response to stress 9.72E-11 33 
1024 G-protein coupled receptor binding 4.83E-09 11 
6920 response to biotic stimulus 2.38E-08 15 
3985 extracellular space 8.88E-08 19 
26637 response to other organism 8.88E-08 14 
3949 extracellular region 1.69E-06 29 
21158 extracellular region part 1.72E-06 20 
12798 keratinocyte differentiation 4.11E-06 7 
30186 cellular response to chemical stimulus 5.23E-06 15 
6928 response to bacterium 6.52E-06 10 
7201 epidermal cell differentiation 6.71E-06 7 
13861 keratinization 9.03E-06 6 
25864 response to stimulus 9.61E-06 48 
26635 multi-organism process 9.75E-06 17 
7176 tissue development 2.13E-05 16 
18995 regulation of cell proliferation 2.13E-05 17 
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